{"PMC3953438": [["IntroductionThere are at least 868 described zoonotic microbial pathogens, 33% of which are capable of human to human transmission [1].", [["human", "ORGANISM", 103, 108], ["human", "ORGANISM", 112, 117], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 112, 117], ["zoonotic microbial pathogens", "PROBLEM", 45, 73], ["zoonotic", "OBSERVATION_MODIFIER", 45, 53]]], ["Recent viral zoonoses have led to some of the most devastating and medically relevant outbreaks in modern history, including SARS coronavirus, pandemic influenza, and HIV/AIDS, highlighting the urgent need to understand how viruses adapt to infect new species.", [["viral zoonoses", "DISEASE", 7, 21], ["SARS coronavirus", "DISEASE", 125, 141], ["pandemic influenza", "DISEASE", 143, 161], ["HIV/AIDS", "DISEASE", 167, 175], ["SARS coronavirus", "ORGANISM", 125, 141], ["HIV", "SPECIES", 167, 170], ["SARS coronavirus", "SPECIES", 125, 141], ["HIV", "SPECIES", 167, 170], ["Recent viral zoonoses", "PROBLEM", 0, 21], ["SARS coronavirus", "PROBLEM", 125, 141], ["pandemic influenza", "PROBLEM", 143, 161], ["HIV/AIDS", "PROBLEM", 167, 175], ["viral zoonoses", "OBSERVATION", 7, 21]]], ["At a population level, factors influencing the transmission of zoonotic pathogens to humans include increasing population density, greater contact with wildlife, increased travel, and poor public health infrastructure [2], [3].", [["zoonotic pathogens", "DISEASE", 63, 81], ["humans", "ORGANISM", 85, 91], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["zoonotic pathogens", "PROBLEM", 63, 81], ["increasing population density", "PROBLEM", 100, 129], ["increased", "OBSERVATION_MODIFIER", 162, 171]]], ["However, these factors only allow the microbe increased access to new hosts; they do not directly enable it to adapt to and replicate in the new species.", [["new", "OBSERVATION_MODIFIER", 141, 144]]], ["Intermediate hosts, animals that are not the natural host of a virus but are still permissive or semi-permissive for viral replication, play a critical role in cross-species transmission.", [["a virus", "PROBLEM", 61, 68], ["viral replication", "PROBLEM", 117, 134]]], ["These hosts can facilitate increased contact between a virus and a new host, and drive adaptive changes that may improve virus replication (Reviewed in [4]).", [["a virus", "PROBLEM", 53, 60], ["a new host", "TREATMENT", 65, 75], ["adaptive changes", "TREATMENT", 87, 103]]], ["For example, spill-over of Nipah virus from fruit bats into pigs, the intermediate host, increased human exposure to the virus and resulted in eventual human outbreaks in Malaysia [5], [6].", [["Nipah virus", "DISEASE", 27, 38], ["Nipah virus", "ORGANISM", 27, 38], ["fruit bats", "ORGANISM", 44, 54], ["pigs", "ORGANISM", 60, 64], ["human", "ORGANISM", 99, 104], ["human", "ORGANISM", 152, 157], ["Nipah virus", "SPECIES", 27, 38], ["pigs", "SPECIES", 60, 64], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 152, 157], ["Nipah virus", "SPECIES", 27, 38], ["pigs", "SPECIES", 60, 64], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 152, 157], ["spill", "PROBLEM", 13, 18], ["Nipah virus", "PROBLEM", 27, 38], ["the virus", "PROBLEM", 117, 126], ["spill", "OBSERVATION", 13, 18], ["Nipah virus", "OBSERVATION", 27, 38], ["intermediate host", "OBSERVATION_MODIFIER", 70, 87]]], ["In another example, lentiviral adaptation through intermediate chimpanzee hosts led to both increased contact with humans, and adaptive genetic changes permitting the virus to inhibit the human versions of several host restriction factors (Reviewed in [7]).IntroductionAt a molecular level, the initial success of a virus after entry into a new host cell depends on its ability to overcome cellular host restriction factors.", [["cell", "ANATOMY", 350, 354], ["cellular", "ANATOMY", 390, 398], ["lentiviral", "ORGANISM", 20, 30], ["chimpanzee", "ORGANISM", 63, 73], ["humans", "ORGANISM", 115, 121], ["human", "ORGANISM", 188, 193], ["host cell", "CELL", 345, 354], ["cellular", "CELL", 390, 398], ["host restriction factors", "PROTEIN", 214, 238], ["cellular host restriction factors", "PROTEIN", 390, 423], ["humans", "SPECIES", 115, 121], ["human", "SPECIES", 188, 193], ["humans", "SPECIES", 115, 121], ["human", "SPECIES", 188, 193], ["lentiviral adaptation through intermediate chimpanzee hosts", "TREATMENT", 20, 79], ["adaptive genetic changes", "TREATMENT", 127, 151], ["the virus", "PROBLEM", 163, 172], ["a virus", "PROBLEM", 314, 321], ["a new host cell depends", "TREATMENT", 339, 362], ["cellular host restriction factors", "TREATMENT", 390, 423], ["new", "OBSERVATION_MODIFIER", 341, 344], ["host cell", "OBSERVATION", 345, 354], ["host restriction", "OBSERVATION", 399, 415]]], ["A subset of these proteins inhibits specific virus families, such as the restriction of retroviruses mediated by TRIM5\u03b1 [8].", [["retroviruses", "ORGANISM", 88, 100], ["TRIM5\u03b1 [8]", "GENE_OR_GENE_PRODUCT", 113, 123], ["TRIM5\u03b1", "PROTEIN", 113, 119], ["these proteins", "TREATMENT", 12, 26], ["specific virus families", "TREATMENT", 36, 59], ["the restriction of retroviruses", "TREATMENT", 69, 100]]], ["However, other restriction factors, including protein kinase R (PKR), block the replication of multiple virus families.", [["protein kinase R", "GENE_OR_GENE_PRODUCT", 46, 62], ["PKR", "GENE_OR_GENE_PRODUCT", 64, 67], ["restriction factors", "PROTEIN", 15, 34], ["protein kinase R", "PROTEIN", 46, 62], ["PKR", "PROTEIN", 64, 67], ["other restriction factors", "PROBLEM", 9, 34], ["protein kinase", "TEST", 46, 60], ["PKR", "TEST", 64, 67], ["multiple virus families", "TREATMENT", 95, 118]]], ["PKR is activated by binding to double-stranded RNA (dsRNA), a common byproduct of both RNA and DNA virus replication, followed by dimerization and autophosphorylation.", [["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["PKR", "PROTEIN", 0, 3], ["double-stranded RNA", "RNA", 31, 50], ["dsRNA", "RNA", 52, 57], ["PKR", "PROBLEM", 0, 3], ["double-stranded RNA (dsRNA", "TREATMENT", 31, 57], ["both RNA", "TREATMENT", 82, 90], ["DNA virus replication", "TREATMENT", 95, 116], ["stranded RNA", "OBSERVATION_MODIFIER", 38, 50], ["both RNA", "ANATOMY", 82, 90]]], ["Activated PKR then phosphorylates the \u03b1-subunit of eukaryotic initiation factor 2 (eIF2\u03b1), ultimately arresting translation initiation [9].", [["PKR", "GENE_OR_GENE_PRODUCT", 10, 13], ["eukaryotic initiation factor 2", "GENE_OR_GENE_PRODUCT", 51, 81], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 83, 88], ["PKR", "PROTEIN", 10, 13], ["\u03b1-subunit", "PROTEIN", 38, 47], ["eukaryotic initiation factor 2", "PROTEIN", 51, 81], ["eIF2\u03b1", "PROTEIN", 83, 88], ["Activated PKR", "TREATMENT", 0, 13], ["phosphorylates", "TREATMENT", 19, 33], ["eukaryotic initiation factor", "TREATMENT", 51, 79]]], ["In response to the broad and potent barrier to viral infection imposed by PKR, most virus families have evolved at least one mechanism to inhibit the PKR pathway [10].IntroductionThis conflict between host restriction factors and their viral antagonists results in an \u201carms race\u201d leading to rapid evolution of both sets of genes [11].", [["viral infection", "DISEASE", 47, 62], ["PKR", "GENE_OR_GENE_PRODUCT", 74, 77], ["PKR", "GENE_OR_GENE_PRODUCT", 150, 153], ["PKR", "PROTEIN", 74, 77], ["PKR", "PROTEIN", 150, 153], ["host restriction factors", "PROTEIN", 201, 225], ["viral infection", "PROBLEM", 47, 62], ["PKR", "PROBLEM", 74, 77], ["host restriction factors", "TREATMENT", 201, 225], ["their viral antagonists", "TEST", 230, 253], ["infection", "OBSERVATION", 53, 62]]], ["The extraordinarily high rate of positive selection (dN/dS) among primate PKR genes reflects the evolutionary pressure on PKR to evade virus antagonists [12], [13].", [["primate", "ORGANISM", 66, 73], ["PKR", "GENE_OR_GENE_PRODUCT", 74, 77], ["PKR", "GENE_OR_GENE_PRODUCT", 122, 125], ["primate PKR genes", "DNA", 66, 83], ["PKR", "PROTEIN", 122, 125], ["positive selection (dN/dS)", "TREATMENT", 33, 59], ["PKR", "TREATMENT", 122, 125], ["evade virus antagonists", "PROBLEM", 129, 152], ["extraordinarily", "OBSERVATION_MODIFIER", 4, 19], ["high", "OBSERVATION_MODIFIER", 20, 24], ["positive selection", "OBSERVATION", 33, 51], ["pressure", "OBSERVATION_MODIFIER", 110, 118]]], ["To productively infect new host species, virus antagonists must rapidly adapt to escape these differences in PKR.", [["PKR", "GENE_OR_GENE_PRODUCT", 109, 112], ["PKR", "PROTEIN", 109, 112], ["new host species", "PROBLEM", 23, 39], ["virus antagonists", "TREATMENT", 41, 58], ["PKR", "TEST", 109, 112], ["infect", "OBSERVATION_MODIFIER", 16, 22], ["new", "OBSERVATION_MODIFIER", 23, 26], ["host species", "OBSERVATION", 27, 39]]], ["In the current study, we modeled the process of viral adaptation through an intermediate, minimally permissive host.", [["the current study", "TEST", 3, 20], ["viral adaptation", "PROBLEM", 48, 64], ["viral adaptation", "OBSERVATION", 48, 64]]], ["We experimentally evolved a recombinant vaccinia virus expressing the rhesus cytomegalovirus PKR antagonist rhtrs1 in African green monkey cells expressing RhTRS1-resistant PKR.", [["cells", "ANATOMY", 139, 144], ["RhTRS1", "CHEMICAL", 156, 162], ["vaccinia virus", "ORGANISM", 40, 54], ["rhesus", "ORGANISM", 70, 76], ["cytomegalovirus", "ORGANISM", 77, 92], ["PKR", "GENE_OR_GENE_PRODUCT", 93, 96], ["rhtrs1", "GENE_OR_GENE_PRODUCT", 108, 114], ["green monkey cells", "CELL", 126, 144], ["RhTRS1", "GENE_OR_GENE_PRODUCT", 156, 162], ["PKR", "GENE_OR_GENE_PRODUCT", 173, 176], ["rhesus cytomegalovirus PKR antagonist rhtrs1", "PROTEIN", 70, 114], ["African green monkey cells", "CELL_TYPE", 118, 144], ["RhTRS1", "PROTEIN", 156, 162], ["PKR", "PROTEIN", 173, 176], ["rhesus cytomegalovirus", "SPECIES", 70, 92], ["vaccinia virus", "SPECIES", 40, 54], ["rhesus cytomegalovirus", "SPECIES", 70, 92], ["African green monkey", "SPECIES", 118, 138], ["a recombinant vaccinia virus", "TREATMENT", 26, 54], ["the rhesus cytomegalovirus PKR antagonist rhtrs1", "TREATMENT", 66, 114], ["RhTRS1", "TEST", 156, 162], ["resistant PKR", "PROBLEM", 163, 176], ["resistant PKR", "OBSERVATION", 163, 176]]], ["We demonstrate that amplification of the exogenous rhtrs1 locus was an early adaption that is sufficient to rescue virus replication in minimally-permissive AGM cells.", [["AGM cells", "ANATOMY", 157, 166], ["rhtrs1", "GENE_OR_GENE_PRODUCT", 51, 57], ["AGM cells", "CELL", 157, 166], ["exogenous rhtrs1 locus", "DNA", 41, 63], ["minimally-permissive AGM cells", "CELL_LINE", 136, 166], ["the exogenous rhtrs1 locus", "PROBLEM", 37, 63], ["rescue virus replication", "PROBLEM", 108, 132], ["AGM cells", "OBSERVATION", 157, 166]]], ["This amplification of the rhtrs1 locus was also sufficient to expand the species tropism of these viruses, enabling them to infect both human and rhesus cells substantially better than the initial virus.", [["cells", "ANATOMY", 153, 158], ["rhtrs1", "GENE_OR_GENE_PRODUCT", 26, 32], ["human", "ORGANISM", 136, 141], ["rhesus", "ORGANISM", 146, 152], ["cells", "CELL", 153, 158], ["rhtrs1 locus", "DNA", 26, 38], ["human and rhesus cells", "CELL_TYPE", 136, 158], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["the rhtrs1 locus", "PROBLEM", 22, 38], ["these viruses", "PROBLEM", 92, 105], ["viruses", "OBSERVATION", 98, 105]]], ["Importantly, rhtrs1 amplification did not occur when the initial virus was passaged through human fibroblasts, suggesting that amplification in AGM cells was a necessary intermediate step to expand the virus host range.", [["fibroblasts", "ANATOMY", 98, 109], ["AGM cells", "ANATOMY", 144, 153], ["rhtrs1", "GENE_OR_GENE_PRODUCT", 13, 19], ["human", "ORGANISM", 92, 97], ["fibroblasts", "CELL", 98, 109], ["AGM cells", "CELL", 144, 153], ["rhtrs1", "PROTEIN", 13, 19], ["human fibroblasts", "CELL_TYPE", 92, 109], ["AGM cells", "CELL_TYPE", 144, 153], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["the initial virus", "PROBLEM", 53, 70], ["human fibroblasts", "PROBLEM", 92, 109], ["amplification in AGM cells", "PROBLEM", 127, 153]]], ["Gene amplification is a universal mechanism of rapid adaptation occurring in eukaryotes [14], [15], prokaryotes [16], and viruses [17], [18], enabling diverse adaptations including evasion of host restriction factors (Reviewed in [19]).", [["host restriction factors", "PROTEIN", 192, 216], ["rapid adaptation", "PROBLEM", 47, 63], ["viruses", "TEST", 122, 129]]], ["Our results suggest that gene amplification in an intermediate host may be a risk factor for broad cross-species transmission independent of other adaptive events.Variable inhibition of African green monkey PKR by RhCMV TRS1 ::: ResultsThe rhesus cytomegalovirus (RhCMV) PKR inhibitor TRS1 (RhTRS1) can block PKR activation and rescue replication of a vaccinia virus mutant lacking the PKR inhibitor E3L (VV\u0394E3L+RhTRS1) in several African green monkey (Chlorocebus aethiops, AGM) cell lines [20].", [["AGM) cell lines", "ANATOMY", 475, 490], ["rhesus cytomegalovirus", "DISEASE", 240, 262], ["TRS1", "CHEMICAL", 285, 289], ["green monkey", "ORGANISM", 194, 206], ["PKR", "GENE_OR_GENE_PRODUCT", 207, 210], ["rhesus cytomegalovirus", "ORGANISM", 240, 262], ["RhCMV", "ORGANISM", 264, 269], ["PKR", "GENE_OR_GENE_PRODUCT", 271, 274], ["TRS1", "GENE_OR_GENE_PRODUCT", 285, 289], ["RhTRS1", "GENE_OR_GENE_PRODUCT", 291, 297], ["PKR", "GENE_OR_GENE_PRODUCT", 309, 312], ["vaccinia virus mutant", "ORGANISM", 352, 373], ["PKR", "GENE_OR_GENE_PRODUCT", 386, 389], ["E3L", "GENE_OR_GENE_PRODUCT", 400, 403], ["VV\u0394E3L+RhTRS1", "GENE_OR_GENE_PRODUCT", 405, 418], ["green monkey", "ORGANISM", 439, 451], ["Chlorocebus aethiops", "ORGANISM", 453, 473], ["AGM", "CELL", 475, 478], ["cell lines", "CELL", 480, 490], ["African green monkey PKR", "PROTEIN", 186, 210], ["RhCMV TRS1", "PROTEIN", 214, 224], ["rhesus cytomegalovirus (RhCMV) PKR inhibitor", "PROTEIN", 240, 284], ["TRS1", "PROTEIN", 285, 289], ["RhTRS1", "PROTEIN", 291, 297], ["PKR", "PROTEIN", 309, 312], ["PKR", "PROTEIN", 386, 389], ["E3L", "PROTEIN", 400, 403], ["VV\u0394E3L", "PROTEIN", 405, 411], ["RhTRS1", "PROTEIN", 412, 418], ["African green monkey (Chlorocebus aethiops, AGM) cell lines", "CELL_LINE", 431, 490], ["rhesus cytomegalovirus", "SPECIES", 240, 262], ["green monkey", "SPECIES", 439, 451], ["Chlorocebus aethiops", "SPECIES", 453, 473], ["African green monkey", "SPECIES", 186, 206], ["RhCMV", "SPECIES", 214, 219], ["rhesus cytomegalovirus", "SPECIES", 240, 262], ["RhCMV", "SPECIES", 264, 269], ["vaccinia virus", "SPECIES", 352, 366], ["African green monkey", "SPECIES", 431, 451], ["Chlorocebus aethiops", "SPECIES", 453, 473], ["gene amplification", "PROBLEM", 25, 43], ["The rhesus cytomegalovirus (RhCMV)", "TREATMENT", 236, 270], ["PKR inhibitor TRS1 (RhTRS1)", "TREATMENT", 271, 298], ["block PKR activation", "TREATMENT", 303, 323], ["rescue replication", "TREATMENT", 328, 346], ["a vaccinia virus", "TREATMENT", 350, 366], ["the PKR inhibitor", "TREATMENT", 382, 399], ["VV\u0394E3L+RhTRS1)", "TREATMENT", 405, 419], ["several African green monkey (Chlorocebus aethiops", "TREATMENT", 423, 473], ["cell lines", "TREATMENT", 480, 490], ["cell lines", "OBSERVATION", 480, 490]]], ["However, we discovered that a recombinant vaccinia virus expressing RhTRS1 and lacking both of the known vaccinia PKR antagonists, E3L and K3L, (VV\u0394E\u0394K+RhTRS1) produced 100 to 1000-fold less virus in AGM-derived PRO1190 cells relative to VV-\u03b2g (which contains both E3L and K3L) although it replicated almost as efficiently as VV-\u03b2g in AGM-derived BSC40 cells (Fig. 1A).", [["AGM-derived PRO1190 cells", "ANATOMY", 200, 225], ["AGM-derived BSC40 cells", "ANATOMY", 335, 358], ["vaccinia virus", "ORGANISM", 42, 56], ["RhTRS1", "GENE_OR_GENE_PRODUCT", 68, 74], ["vaccinia", "ORGANISM", 105, 113], ["PKR", "GENE_OR_GENE_PRODUCT", 114, 117], ["E3L", "GENE_OR_GENE_PRODUCT", 131, 134], ["K3L", "GENE_OR_GENE_PRODUCT", 139, 142], ["VV\u0394E\u0394K+RhTRS1", "GENE_OR_GENE_PRODUCT", 145, 158], ["AGM-derived PRO1190 cells", "CELL", 200, 225], ["VV-\u03b2g", "ORGANISM", 238, 243], ["E3L", "GENE_OR_GENE_PRODUCT", 265, 268], ["K3L", "GENE_OR_GENE_PRODUCT", 273, 276], ["VV-\u03b2g", "SIMPLE_CHEMICAL", 326, 331], ["AGM-derived BSC40 cells", "CELL", 335, 358], ["Fig. 1A", "CELL", 360, 367], ["RhTRS1", "PROTEIN", 68, 74], ["vaccinia PKR antagonists", "PROTEIN", 105, 129], ["E3L", "PROTEIN", 131, 134], ["K3L", "PROTEIN", 139, 142], ["VV\u0394E\u0394K", "PROTEIN", 145, 151], ["RhTRS1", "PROTEIN", 152, 158], ["AGM-derived PRO1190 cells", "CELL_LINE", 200, 225], ["\u03b2g", "PROTEIN", 241, 243], ["E3L", "PROTEIN", 265, 268], ["K3L", "PROTEIN", 273, 276], ["\u03b2g", "PROTEIN", 329, 331], ["AGM-derived BSC40 cells", "CELL_LINE", 335, 358], ["vaccinia virus", "SPECIES", 42, 56], ["VV-\u03b2g", "SPECIES", 238, 243], ["VV", "SPECIES", 326, 328], ["a recombinant vaccinia virus", "TREATMENT", 28, 56], ["vaccinia PKR antagonists", "TREATMENT", 105, 129], ["E3L", "TEST", 131, 134], ["K3L", "TEST", 139, 142], ["VV\u0394E\u0394K", "TEST", 145, 151], ["RhTRS1", "TEST", 152, 158], ["fold less virus in AGM", "PROBLEM", 181, 203], ["VV", "TEST", 238, 240], ["VV", "TEST", 326, 328], ["AGM", "TEST", 335, 338], ["vaccinia PKR", "OBSERVATION", 105, 117]]], ["Thus, RhTRS1 varies in its ability to support VV\u0394E\u0394K replication in different AGM cells.Variable inhibition of African green monkey PKR by RhCMV TRS1 ::: ResultsThis VV\u0394E\u0394K+RhTRS1 replication defect in PRO1190 cells may be due to incomplete inhibition of PKR in these cells by RhTRS1.", [["AGM cells", "ANATOMY", 78, 87], ["PRO1190 cells", "ANATOMY", 202, 215], ["cells", "ANATOMY", 268, 273], ["RhTRS1", "GENE_OR_GENE_PRODUCT", 6, 12], ["VV\u0394E\u0394K", "GENE_OR_GENE_PRODUCT", 46, 52], ["AGM cells", "CELL", 78, 87], ["green monkey", "ORGANISM", 119, 131], ["PKR", "GENE_OR_GENE_PRODUCT", 132, 135], ["VV\u0394E\u0394K+RhTRS1", "GENE_OR_GENE_PRODUCT", 166, 179], ["PRO1190 cells", "CELL", 202, 215], ["PKR", "GENE_OR_GENE_PRODUCT", 255, 258], ["cells", "CELL", 268, 273], ["RhTRS1", "GENE_OR_GENE_PRODUCT", 277, 283], ["RhTRS1", "PROTEIN", 6, 12], ["AGM cells", "CELL_TYPE", 78, 87], ["African green monkey PKR", "PROTEIN", 111, 135], ["RhCMV TRS1", "PROTEIN", 139, 149], ["PRO1190 cells", "CELL_LINE", 202, 215], ["PKR", "PROTEIN", 255, 258], ["RhTRS1", "PROTEIN", 277, 283], ["African green monkey", "SPECIES", 111, 131], ["RhCMV", "SPECIES", 139, 144], ["RhTRS1 varies", "PROBLEM", 6, 19], ["VV\u0394E\u0394K replication", "TREATMENT", 46, 64], ["ResultsThis", "TEST", 154, 165], ["VV\u0394E\u0394K", "TEST", 166, 172], ["RhTRS1 replication defect in PRO1190 cells", "PROBLEM", 173, 215], ["incomplete inhibition of PKR in these cells", "PROBLEM", 230, 273], ["AGM cells", "OBSERVATION", 78, 87], ["replication defect", "OBSERVATION", 180, 198], ["PRO1190 cells", "OBSERVATION", 202, 215], ["may be due to", "UNCERTAINTY", 216, 229], ["PKR", "OBSERVATION", 255, 258]]], ["To test this hypothesis, we generated PRO1190 cells stably expressing either a PKR-specific shRNA (PRO1190-PKR kd), which resulted in a 56% reduction of PKR expression, or a scrambled control shRNA (PRO1190-ctrl kd) (Fig. 1B).", [["PRO1190 cells", "ANATOMY", 38, 51], ["PRO", "CHEMICAL", 199, 202], ["PRO1190 cells", "CELL", 38, 51], ["PKR", "GENE_OR_GENE_PRODUCT", 79, 82], ["PRO1190-PKR kd", "GENE_OR_GENE_PRODUCT", 99, 113], ["PKR", "GENE_OR_GENE_PRODUCT", 153, 156], ["PRO1190 cells", "CELL_LINE", 38, 51], ["PKR", "PROTEIN", 79, 82], ["PRO1190", "PROTEIN", 99, 106], ["PKR kd", "PROTEIN", 107, 113], ["PKR", "PROTEIN", 153, 156], ["scrambled control shRNA", "DNA", 174, 197], ["ctrl kd", "PROTEIN", 207, 214], ["a PKR", "TEST", 77, 82], ["PKR expression", "PROBLEM", 153, 167], ["PKR expression", "OBSERVATION", 153, 167]]], ["Similarly, PKR-specific RT-qPCR demonstrated a 60% reduction in PKR mRNA from PRO1190-PKR kd cells relative to PRO1190-ctrl kd cells (2578 copies or 6503 copies PKR/ng total RNA respectively) but little difference between PRO1190 and PRO1190-ctrl kd cell PKR levels (Fig. S1).", [["1190-PKR kd cells", "ANATOMY", 81, 98], ["1190-ctrl kd cells", "ANATOMY", 114, 132], ["cell", "ANATOMY", 250, 254], ["PRO", "CHEMICAL", 234, 237], ["PRO", "CHEMICAL", 234, 237], ["PKR", "GENE_OR_GENE_PRODUCT", 11, 14], ["PKR", "GENE_OR_GENE_PRODUCT", 64, 67], ["PRO1190-PKR", "GENE_OR_GENE_PRODUCT", 78, 89], ["PKR", "GENE_OR_GENE_PRODUCT", 161, 164], ["kd cell PKR", "GENE_OR_GENE_PRODUCT", 247, 258], ["S1", "GENE_OR_GENE_PRODUCT", 272, 274], ["PKR", "PROTEIN", 11, 14], ["PKR mRNA", "RNA", 64, 72], ["PKR kd cells", "CELL_LINE", 86, 98], ["PRO1190-ctrl kd cells", "CELL_LINE", 111, 132], ["PKR", "PROTEIN", 161, 164], ["PKR", "PROTEIN", 255, 258], ["S1", "PROTEIN", 272, 274], ["PKR", "TEST", 11, 14], ["qPCR", "TEST", 27, 31], ["PKR mRNA", "TEST", 64, 72], ["PRO", "TEST", 78, 81], ["kd cells", "TEST", 90, 98], ["PRO", "TEST", 111, 114], ["ctrl kd cells", "TEST", 119, 132], ["PKR", "TEST", 161, 164], ["total RNA", "TEST", 168, 177], ["PRO", "TEST", 234, 237], ["PKR levels", "TEST", 255, 265]]], ["In PRO1190-PKR kd cells, VV\u0394E\u0394K+RhTRS1 replication was almost completely rescued to VV-\u03b2g levels (Fig. 1C).", [["PRO1190-PKR kd cells", "ANATOMY", 3, 23], ["VV\u0394E\u0394K+RhTRS1", "GENE_OR_GENE_PRODUCT", 25, 38], ["VV-\u03b2g", "GENE_OR_GENE_PRODUCT", 84, 89], ["PRO1190-PKR kd cells", "CELL_LINE", 3, 23], ["VV\u0394E\u0394K", "PROTEIN", 25, 31], ["RhTRS1", "PROTEIN", 32, 38], ["\u03b2g", "PROTEIN", 87, 89], ["kd cells", "TEST", 15, 23], ["VV\u0394E\u0394K", "TEST", 25, 31], ["RhTRS1 replication", "TREATMENT", 32, 50], ["VV", "TEST", 84, 86]]], ["We detected a similar increase in VV\u0394E\u0394K+RhTRS1 replication after transiently transfecting PRO1190 cells with a siRNA specific for PKR, but not a control siRNA (data not shown).", [["PRO1190 cells", "ANATOMY", 91, 104], ["VV\u0394E\u0394K+RhTRS1", "GENE_OR_GENE_PRODUCT", 34, 47], ["PRO1190 cells", "CELL", 91, 104], ["PKR", "GENE_OR_GENE_PRODUCT", 131, 134], ["VV\u0394E\u0394K", "PROTEIN", 34, 40], ["RhTRS1", "PROTEIN", 41, 47], ["PRO1190 cells", "CELL_LINE", 91, 104], ["PKR", "PROTEIN", 131, 134], ["VV\u0394E\u0394K+RhTRS1 replication", "TREATMENT", 34, 59], ["a siRNA", "TREATMENT", 110, 117], ["PKR", "PROBLEM", 131, 134], ["similar", "OBSERVATION_MODIFIER", 14, 21], ["increase", "OBSERVATION_MODIFIER", 22, 30]]], ["Sequence analysis of PRO1190 PKR identified three non-synonymous mutations relative to a previously reported AGM PKR (GenBank # EU733254) that is sensitive to RhTRS1 (Fig. S2, [20]).", [["PRO1190 PKR", "GENE_OR_GENE_PRODUCT", 21, 32], ["PKR", "GENE_OR_GENE_PRODUCT", 113, 116], ["GenBank # EU733254", "GENE_OR_GENE_PRODUCT", 118, 136], ["PRO1190 PKR", "PROTEIN", 21, 32], ["AGM PKR", "PROTEIN", 109, 116], ["RhTRS1", "PROTEIN", 159, 165], ["Sequence analysis", "TEST", 0, 17], ["PRO1190 PKR", "TEST", 21, 32], ["three non-synonymous mutations", "PROBLEM", 44, 74]]], ["Interestingly, one of these single nucleotide variants is heterozygous in PRO1190 cells, and changes a residue (T577M) that is evolving under positive selection in primates [12].", [["PRO1190 cells", "ANATOMY", 74, 87], ["nucleotide", "CHEMICAL", 35, 45], ["PRO1190 cells", "CELL", 74, 87], ["PRO1190 cells", "CELL_LINE", 74, 87], ["these single nucleotide variants", "PROBLEM", 22, 54], ["heterozygous in PRO1190 cells", "PROBLEM", 58, 87], ["a residue (T577M)", "PROBLEM", 101, 118], ["heterozygous", "OBSERVATION", 58, 70], ["PRO1190 cells", "OBSERVATION", 74, 87], ["positive selection", "OBSERVATION", 142, 160]]], ["Although additional studies will be needed to determine whether one or more of these PRO1190 PKR polymorphisms is responsible for increased resistance to RhTRS1, the results shown in Fig. 1 demonstrate that the block to VV\u0394E\u0394K+RhTRS1 replication in PRO1190 cells is mediated by PKR.", [["PRO1190 cells", "ANATOMY", 249, 262], ["PRO1190", "GENE_OR_GENE_PRODUCT", 85, 92], ["PKR", "GENE_OR_GENE_PRODUCT", 93, 96], ["RhTRS1", "GENE_OR_GENE_PRODUCT", 154, 160], ["VV\u0394E\u0394K", "GENE_OR_GENE_PRODUCT", 220, 226], ["RhTRS1", "GENE_OR_GENE_PRODUCT", 227, 233], ["PRO1190 cells", "CELL", 249, 262], ["PKR", "GENE_OR_GENE_PRODUCT", 278, 281], ["PRO1190", "PROTEIN", 85, 92], ["PKR", "PROTEIN", 93, 96], ["RhTRS1", "PROTEIN", 154, 160], ["VV\u0394E\u0394K", "PROTEIN", 220, 226], ["RhTRS1", "PROTEIN", 227, 233], ["PRO1190 cells", "CELL_LINE", 249, 262], ["PKR", "PROTEIN", 278, 281], ["additional studies", "TEST", 9, 27], ["increased resistance to RhTRS1", "PROBLEM", 130, 160], ["the block", "PROBLEM", 207, 216], ["VV\u0394E\u0394K", "TEST", 220, 226], ["RhTRS1 replication in PRO1190 cells", "TREATMENT", 227, 262]]]], "f2659bd84b8347a97b54698fbc1dea43ef10a85e": [["IntroductionThe ubiquitin-proteasome system (UPS) constitutes a major degradation pathway for intracellular proteins and plays important roles in virtually all cellular processes.", [["intracellular", "ANATOMY", 94, 107], ["cellular", "ANATOMY", 160, 168], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 107], ["cellular", "CELL", 160, 168], ["ubiquitin-proteasome system", "PROTEIN", 16, 43], ["UPS", "PROTEIN", 45, 48], ["intracellular proteins", "PROTEIN", 94, 116], ["The ubiquitin-proteasome system", "TREATMENT", 12, 43], ["intracellular proteins", "PROBLEM", 94, 116], ["cellular processes", "OBSERVATION", 160, 178]]], ["UPS-mediated proteolysis involves two essential steps: ubiquitination and proteasomal degradation.", [["proteasomal", "ANATOMY", 74, 85], ["UPS", "GENE_OR_GENE_PRODUCT", 0, 3], ["UPS", "PROTEIN", 0, 3], ["mediated proteolysis", "PROBLEM", 4, 24], ["proteasomal degradation", "PROBLEM", 74, 97], ["proteasomal degradation", "OBSERVATION", 74, 97]]], ["Ubiquitination tags the target proteins with a chain of the small protein molecule ubiquitin and the ubiquitin chain serves as a signal of the target proteins for degradation by the 26S proteasome [1] .", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 83, 92], ["26S", "GENE_OR_GENE_PRODUCT", 182, 185], ["small protein molecule", "PROTEIN", 60, 82], ["ubiquitin", "PROTEIN", 83, 92], ["ubiquitin chain", "PROTEIN", 101, 116], ["target proteins", "PROTEIN", 143, 158], ["26S proteasome", "PROTEIN", 182, 196], ["Ubiquitination tags", "TEST", 0, 19], ["the small protein molecule ubiquitin", "TREATMENT", 56, 92]]], ["The 26S proteasome is a multi-unit protein proteolytic machine composed of a cylinder-shaped core particle (i.e., the 20S proteasome) and the 19S regulatory particle (i.e., the 19S proteasome) at one or both ends of the 20S.", [["26S", "GENE_OR_GENE_PRODUCT", 4, 7], ["20S", "GENE_OR_GENE_PRODUCT", 118, 121], ["20S", "GENE_OR_GENE_PRODUCT", 220, 223], ["26S proteasome", "PROTEIN", 4, 18], ["multi-unit protein proteolytic machine", "PROTEIN", 24, 62], ["20S proteasome", "PROTEIN", 118, 132], ["19S regulatory particle", "PROTEIN", 142, 165], ["19S proteasome", "PROTEIN", 177, 191], ["20S", "PROTEIN", 220, 223], ["The 26S proteasome", "TREATMENT", 0, 18], ["a multi-unit protein proteolytic machine", "TREATMENT", 22, 62], ["a cylinder-shaped core particle", "TREATMENT", 75, 106], ["the 20S proteasome", "TREATMENT", 114, 132], ["the 19S regulatory particle", "TREATMENT", 138, 165], ["the 19S proteasome", "TREATMENT", 173, 191], ["26S proteasome", "OBSERVATION", 4, 18], ["particle", "OBSERVATION_MODIFIER", 157, 165]]], ["Proteasomal proteolytic enzymes reside, and peptide cleavage takes place, in the 20S proteasome.", [["20S", "GENE_OR_GENE_PRODUCT", 81, 84], ["Proteasomal proteolytic enzymes", "PROTEIN", 0, 31], ["20S proteasome", "PROTEIN", 81, 95], ["Proteasomal proteolytic enzymes", "TEST", 0, 31], ["peptide cleavage", "PROBLEM", 44, 60]]], ["The 19S serves to regulate protein degradation by the 20S proteasome.", [["19S", "GENE_OR_GENE_PRODUCT", 4, 7], ["20S", "GENE_OR_GENE_PRODUCT", 54, 57], ["19S", "PROTEIN", 4, 7], ["20S proteasome", "PROTEIN", 54, 68], ["protein degradation", "PROBLEM", 27, 46], ["the 20S proteasome", "TREATMENT", 50, 68], ["protein degradation", "OBSERVATION", 27, 46]]], ["The 19S proteasome consists of two distinct substructures known as the \"lid\" and the \"base\".", [["19S proteasome", "PROTEIN", 4, 18], ["The 19S proteasome", "TREATMENT", 0, 18], ["19S proteasome", "OBSERVATION", 4, 18], ["two distinct", "OBSERVATION_MODIFIER", 31, 43], ["substructures", "OBSERVATION", 44, 57], ["base", "ANATOMY_MODIFIER", 86, 90]]], ["The base of the 19S directly interacts with the \u03b1 (outer) ring of the 20S, responsible for unfolding the target protein and regulating the gating of the 20S.", [["19S", "GENE_OR_GENE_PRODUCT", 16, 19], ["20S", "GENE_OR_GENE_PRODUCT", 70, 73], ["20S", "GENE_OR_GENE_PRODUCT", 153, 156], ["19S", "PROTEIN", 16, 19], ["\u03b1 (outer) ring", "PROTEIN", 48, 62], ["20S", "PROTEIN", 70, 73], ["target protein", "PROTEIN", 105, 119], ["20S", "PROTEIN", 153, 156], ["the target protein", "TEST", 101, 119], ["the gating", "TEST", 135, 145], ["base", "ANATOMY_MODIFIER", 4, 8]]], ["The lid plays a critical role in recognizing and binding polyubiquitinated target proteins and the removal of ubiquitin from the target proteins for ubiquitin recycling [2] .", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 110, 119], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 149, 158], ["polyubiquitinated target proteins", "PROTEIN", 57, 90], ["ubiquitin", "PROTEIN", 110, 119], ["target proteins", "PROTEIN", 129, 144], ["the removal of ubiquitin", "TREATMENT", 95, 119], ["ubiquitin recycling", "TREATMENT", 149, 168]]], ["Besides the 19S, the 11S proteasome which is formed by heteropolymerization of PA28\u03b1 and PA28\u03b2 or by homopolymerization of PA28\u03b3, can also associate with the 20S to form hybrid proteasomes (11S-20S-19S) or 11S-associated 20S proteasome complexes [3] .", [["19S", "GENE_OR_GENE_PRODUCT", 12, 15], ["11S", "GENE_OR_GENE_PRODUCT", 21, 24], ["PA28\u03b1", "GENE_OR_GENE_PRODUCT", 79, 84], ["PA28\u03b2", "GENE_OR_GENE_PRODUCT", 89, 94], ["PA28\u03b3", "GENE_OR_GENE_PRODUCT", 123, 128], ["20S", "GENE_OR_GENE_PRODUCT", 158, 161], ["11S-20S-19S", "GENE_OR_GENE_PRODUCT", 190, 201], ["20S", "GENE_OR_GENE_PRODUCT", 221, 224], ["19S", "PROTEIN", 12, 15], ["11S proteasome", "PROTEIN", 21, 35], ["PA28\u03b1", "PROTEIN", 79, 84], ["PA28\u03b2", "PROTEIN", 89, 94], ["PA28\u03b3", "PROTEIN", 123, 128], ["20S", "PROTEIN", 158, 161], ["hybrid proteasomes", "PROTEIN", 170, 188], ["11S", "PROTEIN", 190, 193], ["20S", "PROTEIN", 194, 197], ["19S", "PROTEIN", 198, 201], ["11S", "PROTEIN", 206, 209], ["20S proteasome complexes", "PROTEIN", 221, 245], ["the 11S proteasome", "TREATMENT", 17, 35], ["PA28", "TEST", 79, 83], ["PA28", "TEST", 89, 93], ["PA28", "TEST", 123, 127], ["hybrid proteasomes", "PROBLEM", 170, 188], ["11S", "TEST", 206, 209], ["20S proteasome complexes", "PROBLEM", 221, 245]]], ["Upregulation of 11S proteasomes by PA28\u03b1 overexpression can facilitate the degradation of misfolded proteins by the UPS [4, 5] .", [["11S proteasomes", "GENE_OR_GENE_PRODUCT", 16, 31], ["PA28\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["11S proteasomes", "PROTEIN", 16, 31], ["PA28\u03b1", "PROTEIN", 35, 40], ["misfolded proteins", "PROTEIN", 90, 108], ["UPS", "PROTEIN", 116, 119], ["Upregulation of 11S proteasomes", "TREATMENT", 0, 31], ["misfolded proteins", "PROBLEM", 90, 108], ["11S proteasomes", "OBSERVATION_MODIFIER", 16, 31]]], ["UPS involvement in the pathogenesis of many forms of liver disease is well documented [6, 7] .", [["liver", "ANATOMY", 53, 58], ["liver disease", "DISEASE", 53, 66], ["UPS", "GENE_OR_GENE_PRODUCT", 0, 3], ["liver", "ORGAN", 53, 58], ["UPS", "PROTEIN", 0, 3], ["liver disease", "PROBLEM", 53, 66], ["liver", "ANATOMY", 53, 58], ["disease", "OBSERVATION", 59, 66]]], ["Accordingly, the UPS has been suggested as a therapeutic target for many liver diseases [8, 9] .", [["liver", "ANATOMY", 73, 78], ["liver diseases", "DISEASE", 73, 87], ["UPS", "GENE_OR_GENE_PRODUCT", 17, 20], ["liver", "ORGAN", 73, 78], ["UPS", "PROTEIN", 17, 20], ["many liver diseases", "PROBLEM", 68, 87], ["liver", "ANATOMY", 73, 78], ["diseases", "OBSERVATION", 79, 87]]], ["Hence, it is important to achieve a better understanding on the regulation of the UPS and the consequence of UPS dysfunction in the liver.IntroductionThe COP9 signalosome (CSN) consists of 8 unique protein subunits (CSN1 through CSN8) in mammalian cells.", [["liver", "ANATOMY", 132, 137], ["cells", "ANATOMY", 248, 253], ["UPS", "GENE_OR_GENE_PRODUCT", 82, 85], ["UPS", "GENE_OR_GENE_PRODUCT", 109, 112], ["liver", "ORGAN", 132, 137], ["COP9", "GENE_OR_GENE_PRODUCT", 154, 158], ["CSN", "GENE_OR_GENE_PRODUCT", 172, 175], ["CSN1", "GENE_OR_GENE_PRODUCT", 216, 220], ["CSN8", "GENE_OR_GENE_PRODUCT", 229, 233], ["mammalian cells", "CELL", 238, 253], ["UPS", "PROTEIN", 82, 85], ["COP9 signalosome", "PROTEIN", 154, 170], ["CSN", "PROTEIN", 172, 175], ["8 unique protein subunits", "PROTEIN", 189, 214], ["CSN1", "PROTEIN", 216, 220], ["CSN8", "PROTEIN", 229, 233], ["mammalian cells", "CELL_TYPE", 238, 253], ["UPS dysfunction in the liver", "PROBLEM", 109, 137], ["The COP9 signalosome", "TREATMENT", 150, 170], ["8 unique protein subunits", "TREATMENT", 189, 214], ["liver", "ANATOMY", 132, 137], ["mammalian cells", "OBSERVATION", 238, 253]]], ["It is an evolutionarily conserved multifunctional protein complex that is essential in plants and animals [10] .", [["evolutionarily conserved multifunctional protein complex", "PROTEIN", 9, 65], ["an evolutionarily conserved multifunctional protein complex", "PROBLEM", 6, 65], ["multifunctional", "OBSERVATION_MODIFIER", 34, 49], ["protein complex", "OBSERVATION", 50, 65]]], ["The CSN has an intrinsic metalloproteinase that removes the ubiquitin-like protein Nedd8 from cullins via a process known as deneddylation [11, 12] .", [["CSN", "GENE_OR_GENE_PRODUCT", 4, 7], ["Nedd8", "GENE_OR_GENE_PRODUCT", 83, 88], ["cullins", "GENE_OR_GENE_PRODUCT", 94, 101], ["CSN", "PROTEIN", 4, 7], ["metalloproteinase", "PROTEIN", 25, 42], ["ubiquitin-like protein", "PROTEIN", 60, 82], ["Nedd8", "PROTEIN", 83, 88], ["cullins", "PROTEIN", 94, 101], ["an intrinsic metalloproteinase", "PROBLEM", 12, 42], ["the ubiquitin", "TREATMENT", 56, 69], ["protein Nedd8", "TREATMENT", 75, 88], ["intrinsic", "OBSERVATION_MODIFIER", 15, 24], ["metalloproteinase", "OBSERVATION", 25, 42]]], ["CSN-mediated deneddylation is purported to regulate the assembly and catalytic dynamics of various cullin-RING ubiquitin ligases (CRLs) [13] [14] [15] , a large family of ubiquitin E3's that control the ubiquitination and degradation of many proteins.", [["CSN", "GENE_OR_GENE_PRODUCT", 0, 3], ["cullin", "GENE_OR_GENE_PRODUCT", 99, 105], ["CRLs) [13] [14] [15]", "SIMPLE_CHEMICAL", 130, 150], ["ubiquitin E3", "GENE_OR_GENE_PRODUCT", 171, 183], ["CSN", "PROTEIN", 0, 3], ["cullin-RING ubiquitin ligases", "PROTEIN", 99, 128], ["CRLs", "PROTEIN", 130, 134], ["ubiquitin E3", "PROTEIN", 171, 183], ["various cullin-RING ubiquitin ligases", "TREATMENT", 91, 128], ["ubiquitin E3's", "TREATMENT", 171, 185], ["the ubiquitination", "PROBLEM", 199, 217], ["many proteins", "PROBLEM", 237, 250]]], ["CSN subunit 8 (CSN8) is the smallest and the least conserved subunit of the CSN complex.", [["CSN subunit 8", "GENE_OR_GENE_PRODUCT", 0, 13], ["CSN8", "GENE_OR_GENE_PRODUCT", 15, 19], ["CSN", "GENE_OR_GENE_PRODUCT", 76, 79], ["CSN subunit 8", "PROTEIN", 0, 13], ["CSN8", "PROTEIN", 15, 19], ["CSN complex", "PROTEIN", 76, 87], ["smallest", "OBSERVATION_MODIFIER", 28, 36]]], ["Conditional knockout of the csn8 gene in mice has helped determine the essential role of Csn8/CSN in antigen-induced initiation of T cell proliferation [16] and in the postnatal cardiac development and heart function [17, 18] .", [["T cell", "ANATOMY", 131, 137], ["cardiac", "ANATOMY", 178, 185], ["heart", "ANATOMY", 202, 207], ["csn8", "GENE_OR_GENE_PRODUCT", 28, 32], ["mice", "ORGANISM", 41, 45], ["Csn8", "GENE_OR_GENE_PRODUCT", 89, 93], ["CSN", "GENE_OR_GENE_PRODUCT", 94, 97], ["antigen", "GENE_OR_GENE_PRODUCT", 101, 108], ["T cell", "CELL", 131, 137], ["cardiac", "ORGAN", 178, 185], ["heart", "ORGAN", 202, 207], ["csn8 gene", "DNA", 28, 37], ["Csn8", "PROTEIN", 89, 93], ["CSN", "PROTEIN", 94, 97], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["T cell proliferation", "TREATMENT", 131, 151], ["heart function", "TEST", 202, 216], ["cardiac", "ANATOMY", 178, 185], ["heart", "ANATOMY", 202, 207]]], ["Csn8 deficiency was shown to cause UPS impairment in the heart but this has not been examined in other organs [17] .IntroductionWe have previously reported that Csn8/CSN is essential to hepatocyte survival and effective proliferation in mice [19] .", [["heart", "ANATOMY", 57, 62], ["organs", "ANATOMY", 103, 109], ["hepatocyte", "ANATOMY", 186, 196], ["UPS impairment", "DISEASE", 35, 49], ["Csn8", "GENE_OR_GENE_PRODUCT", 0, 4], ["UPS", "GENE_OR_GENE_PRODUCT", 35, 38], ["heart", "ORGAN", 57, 62], ["organs", "ORGAN", 103, 109], ["Csn8", "GENE_OR_GENE_PRODUCT", 161, 165], ["CSN", "GENE_OR_GENE_PRODUCT", 166, 169], ["hepatocyte", "CELL", 186, 196], ["mice", "ORGANISM", 237, 241], ["Csn8", "PROTEIN", 0, 4], ["UPS", "PROTEIN", 35, 38], ["Csn8", "PROTEIN", 161, 165], ["CSN", "PROTEIN", 166, 169], ["mice", "SPECIES", 237, 241], ["mice", "SPECIES", 237, 241], ["Csn8 deficiency", "PROBLEM", 0, 15], ["UPS impairment in the heart", "PROBLEM", 35, 62], ["hepatocyte survival", "TREATMENT", 186, 205], ["impairment", "OBSERVATION", 39, 49], ["heart", "ANATOMY", 57, 62], ["hepatocyte", "ANATOMY", 186, 196]]], ["In livers deficient of Csn8, hepatocytes showed massive apoptosis, resulting in marked proliferation of the oval cells and cells of the biliary lineage, and extensive interstitial fibrosis.", [["livers", "ANATOMY", 3, 9], ["hepatocytes", "ANATOMY", 29, 40], ["oval cells", "ANATOMY", 108, 118], ["cells", "ANATOMY", 123, 128], ["biliary lineage", "ANATOMY", 136, 151], ["interstitial", "ANATOMY", 167, 179], ["fibrosis", "DISEASE", 180, 188], ["livers", "ORGAN", 3, 9], ["Csn8", "GENE_OR_GENE_PRODUCT", 23, 27], ["hepatocytes", "CELL", 29, 40], ["oval cells", "CELL", 108, 118], ["cells", "CELL", 123, 128], ["biliary lineage", "CELL", 136, 151], ["interstitial", "TISSUE", 167, 179], ["Csn8", "PROTEIN", 23, 27], ["hepatocytes", "CELL_TYPE", 29, 40], ["oval cells", "CELL_TYPE", 108, 118], ["biliary lineage", "CELL_TYPE", 136, 151], ["massive apoptosis", "PROBLEM", 48, 65], ["marked proliferation of the oval cells", "PROBLEM", 80, 118], ["extensive interstitial fibrosis", "PROBLEM", 157, 188], ["livers", "ANATOMY", 3, 9], ["hepatocytes", "ANATOMY", 29, 40], ["massive", "OBSERVATION_MODIFIER", 48, 55], ["apoptosis", "OBSERVATION", 56, 65], ["marked", "OBSERVATION_MODIFIER", 80, 86], ["proliferation", "OBSERVATION_MODIFIER", 87, 100], ["oval cells", "OBSERVATION", 108, 118], ["biliary", "ANATOMY", 136, 143], ["lineage", "ANATOMY_MODIFIER", 144, 151], ["extensive", "OBSERVATION_MODIFIER", 157, 166], ["interstitial", "ANATOMY_MODIFIER", 167, 179], ["fibrosis", "OBSERVATION", 180, 188]]], ["The liver pathology induced by hepatocyte-specific Csn8 knockout (HS-Csn8KO) recapitulates the sequalea of chronic hepatic injury such as viral hepatitis [19] .", [["liver", "ANATOMY", 4, 9], ["hepatocyte", "ANATOMY", 31, 41], ["hepatic", "ANATOMY", 115, 122], ["chronic hepatic injury", "DISEASE", 107, 129], ["viral hepatitis", "DISEASE", 138, 153], ["liver", "ORGAN", 4, 9], ["hepatocyte", "CELL", 31, 41], ["Csn8", "GENE_OR_GENE_PRODUCT", 51, 55], ["hepatic", "ORGAN", 115, 122], ["Csn8 knockout", "PROTEIN", 51, 64], ["The liver pathology", "TEST", 0, 19], ["hepatocyte", "TEST", 31, 41], ["chronic hepatic injury", "PROBLEM", 107, 129], ["viral hepatitis", "PROBLEM", 138, 153], ["liver", "ANATOMY", 4, 9], ["pathology", "OBSERVATION", 10, 19], ["hepatocyte", "ANATOMY", 31, 41], ["chronic", "OBSERVATION_MODIFIER", 107, 114], ["hepatic", "ANATOMY", 115, 122], ["injury", "OBSERVATION", 123, 129], ["viral hepatitis", "OBSERVATION", 138, 153]]], ["Hence, dissecting the molecular links between Csn8 deficiency and the resultant hepatocyte apoptosis will shine light on the pathogenesis of a large group of liver diseases.IntroductionHepatocyte apoptosis is a common mechanism of liver injury including hepatitis, liver fibrosis and cirrhosis.", [["hepatocyte", "ANATOMY", 80, 90], ["liver", "ANATOMY", 158, 163], ["Hepatocyte", "ANATOMY", 185, 195], ["liver", "ANATOMY", 231, 236], ["liver", "ANATOMY", 265, 270], ["liver diseases", "DISEASE", 158, 172], ["liver injury", "DISEASE", 231, 243], ["hepatitis", "DISEASE", 254, 263], ["liver fibrosis", "DISEASE", 265, 279], ["cirrhosis", "DISEASE", 284, 293], ["Csn8", "GENE_OR_GENE_PRODUCT", 46, 50], ["hepatocyte", "CELL", 80, 90], ["liver", "ORGAN", 158, 163], ["Hepatocyte", "CELL", 185, 195], ["liver", "ORGAN", 231, 236], ["liver", "ORGAN", 265, 270], ["Csn8", "PROTEIN", 46, 50], ["Csn8 deficiency", "PROBLEM", 46, 61], ["the resultant hepatocyte apoptosis", "PROBLEM", 66, 100], ["liver diseases", "PROBLEM", 158, 172], ["Hepatocyte apoptosis", "PROBLEM", 185, 205], ["liver injury", "PROBLEM", 231, 243], ["hepatitis", "PROBLEM", 254, 263], ["liver fibrosis", "PROBLEM", 265, 279], ["cirrhosis", "PROBLEM", 284, 293], ["Csn8 deficiency", "OBSERVATION", 46, 61], ["resultant", "OBSERVATION_MODIFIER", 70, 79], ["hepatocyte apoptosis", "OBSERVATION", 80, 100], ["large", "OBSERVATION_MODIFIER", 143, 148], ["liver", "ANATOMY", 158, 163], ["diseases", "OBSERVATION", 164, 172], ["Hepatocyte", "ANATOMY", 185, 195], ["apoptosis", "OBSERVATION", 196, 205], ["liver", "ANATOMY", 231, 236], ["injury", "OBSERVATION", 237, 243], ["hepatitis", "OBSERVATION", 254, 263], ["liver", "ANATOMY", 265, 270], ["fibrosis", "OBSERVATION", 271, 279], ["cirrhosis", "OBSERVATION", 284, 293]]], ["It appears that hepatocyte apoptosis can be induced via both the extrinsic and the intrinsic pathways [20] .", [["hepatocyte", "ANATOMY", 16, 26], ["hepatocyte", "CELL", 16, 26], ["hepatocyte apoptosis", "PROBLEM", 16, 36], ["hepatocyte apoptosis", "OBSERVATION", 16, 36]]], ["In the intrinsic pathway, mitochondria release several apoptosis-promoting factors in response to diverse death signals via sensor molecules, such as BH3-only proteins.", [["mitochondria", "ANATOMY", 26, 38], ["death", "DISEASE", 106, 111], ["mitochondria", "CELLULAR_COMPONENT", 26, 38], ["BH3", "GENE_OR_GENE_PRODUCT", 150, 153], ["apoptosis-promoting factors", "PROTEIN", 55, 82], ["sensor molecules", "PROTEIN", 124, 140], ["BH3", "PROTEIN", 150, 153], ["several apoptosis", "PROBLEM", 47, 64], ["diverse death signals via sensor molecules", "PROBLEM", 98, 140], ["several", "OBSERVATION_MODIFIER", 47, 54], ["apoptosis", "OBSERVATION_MODIFIER", 55, 64]]], ["Activation of pro-apoptotic proteins, such as Bax, can trigger a series of events that lead to the activation of caspases [21] , resulting in DNA fragmentation and cellular morphologic changes characteristic of apoptosis.", [["cellular", "ANATOMY", 164, 172], ["Bax", "GENE_OR_GENE_PRODUCT", 46, 49], ["caspases [21]", "GENE_OR_GENE_PRODUCT", 113, 126], ["DNA", "CELLULAR_COMPONENT", 142, 145], ["cellular", "CELL", 164, 172], ["pro-apoptotic proteins", "PROTEIN", 14, 36], ["Bax", "PROTEIN", 46, 49], ["caspases", "PROTEIN", 113, 121], ["Activation of pro-apoptotic proteins", "TREATMENT", 0, 36], ["Bax", "TREATMENT", 46, 49], ["caspases", "PROBLEM", 113, 121], ["DNA fragmentation", "PROBLEM", 142, 159], ["cellular morphologic changes", "PROBLEM", 164, 192], ["apoptosis", "PROBLEM", 211, 220], ["pro-apoptotic proteins", "OBSERVATION", 14, 36], ["DNA fragmentation", "OBSERVATION", 142, 159], ["cellular morphologic", "OBSERVATION", 164, 184], ["apoptosis", "OBSERVATION", 211, 220]]], ["Notably, the Bcl2 family proteins constitute a critical intracellular checkpoint in the mitochondrial pathway of apoptosis [22] .", [["intracellular", "ANATOMY", 56, 69], ["mitochondrial", "ANATOMY", 88, 101], ["Bcl2", "GENE_OR_GENE_PRODUCT", 13, 17], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 69], ["mitochondrial", "CELLULAR_COMPONENT", 88, 101], ["Bcl2 family proteins", "PROTEIN", 13, 33], ["a critical intracellular checkpoint", "TREATMENT", 45, 80], ["apoptosis", "PROBLEM", 113, 122], ["intracellular checkpoint", "OBSERVATION", 56, 80]]], ["The Bcl2 family consists of both anti-apoptotic and pro-apoptotic proteins.", [["Bcl2", "GENE_OR_GENE_PRODUCT", 4, 8], ["Bcl2 family", "PROTEIN", 4, 15], ["anti-apoptotic and pro-apoptotic proteins", "PROTEIN", 33, 74], ["pro-apoptotic proteins", "TREATMENT", 52, 74], ["pro-apoptotic proteins", "OBSERVATION", 52, 74]]], ["The anti-apoptotic members, including Bcl2, Bcl-xL and Mcl1, display sequence conservation through four Bcl2 homology domains (BH1 through BH4), whereas the pro-apoptotic members are composed of more fully conserved 'multidomain' proteins (e.g., Bax and Bak) possessing homology in BH1~BH3, as well as the BH3-only proteins (e.g., Bid, Bim, Bad) which harbor only the BH3 domain [22, 23] .", [["BH4", "CHEMICAL", 139, 142], ["BH4", "CHEMICAL", 139, 142], ["Bcl2", "GENE_OR_GENE_PRODUCT", 38, 42], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 44, 50], ["Mcl1", "GENE_OR_GENE_PRODUCT", 55, 59], ["Bcl2", "GENE_OR_GENE_PRODUCT", 104, 108], ["BH4", "GENE_OR_GENE_PRODUCT", 139, 142], ["Bax", "GENE_OR_GENE_PRODUCT", 246, 249], ["Bak", "GENE_OR_GENE_PRODUCT", 254, 257], ["BH1~BH3", "GENE_OR_GENE_PRODUCT", 282, 289], ["Bid", "GENE_OR_GENE_PRODUCT", 331, 334], ["Bim", "GENE_OR_GENE_PRODUCT", 336, 339], ["Bad", "GENE_OR_GENE_PRODUCT", 341, 344], ["anti-apoptotic members", "PROTEIN", 4, 26], ["Bcl2", "PROTEIN", 38, 42], ["Bcl", "PROTEIN", 44, 47], ["xL", "PROTEIN", 48, 50], ["Mcl1", "PROTEIN", 55, 59], ["Bcl2 homology domains", "PROTEIN", 104, 125], ["BH1", "PROTEIN", 127, 130], ["BH4", "PROTEIN", 139, 142], ["pro-apoptotic members", "PROTEIN", 157, 178], ["multidomain' proteins", "PROTEIN", 217, 238], ["Bax", "PROTEIN", 246, 249], ["Bak", "PROTEIN", 254, 257], ["BH1", "PROTEIN", 282, 285], ["BH3", "PROTEIN", 286, 289], ["BH3", "PROTEIN", 306, 309], ["Bid", "PROTEIN", 331, 334], ["Bim", "PROTEIN", 336, 339], ["Bad", "PROTEIN", 341, 344], ["BH3 domain", "PROTEIN", 368, 378], ["Bcl2", "TEST", 38, 42], ["Bcl", "TEST", 44, 47], ["Mcl1", "PROBLEM", 55, 59], ["the BH3", "TEST", 302, 309], ["the BH3 domain", "TEST", 364, 378]]], ["The BH3-only proteins can be further categorized into the 'activator' (e.g., Bim, tBid) and the \"sensitizer\" (e.g., Bad, Noxa) subgroups [24, 25] .", [["Bim", "GENE_OR_GENE_PRODUCT", 77, 80], ["Bid", "GENE_OR_GENE_PRODUCT", 83, 86], ["Bad", "GENE_OR_GENE_PRODUCT", 116, 119], ["Noxa", "GENE_OR_GENE_PRODUCT", 121, 125], ["BH3", "PROTEIN", 4, 7], ["Bim", "PROTEIN", 77, 80], ["tBid", "PROTEIN", 82, 86], ["Bad", "PROTEIN", 116, 119], ["Noxa", "PROTEIN", 121, 125], ["The BH3", "TREATMENT", 0, 7]]], ["In viable cells, the anti-apoptotic proteins, Bcl2 and Bcl-xL, bind to and repress the multidomain pro-apoptotic proteins Bax and Bak, and keep them in inactive monomers.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["Bcl2", "GENE_OR_GENE_PRODUCT", 46, 50], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 55, 61], ["Bax", "GENE_OR_GENE_PRODUCT", 122, 125], ["Bak", "GENE_OR_GENE_PRODUCT", 130, 133], ["anti-apoptotic proteins", "PROTEIN", 21, 44], ["Bcl2", "PROTEIN", 46, 50], ["Bcl-xL", "PROTEIN", 55, 61], ["multidomain pro-apoptotic proteins", "PROTEIN", 87, 121], ["Bax", "PROTEIN", 122, 125], ["Bak", "PROTEIN", 130, 133], ["the anti-apoptotic proteins", "TREATMENT", 17, 44], ["Bcl2", "TREATMENT", 46, 50], ["Bcl-xL", "TREATMENT", 55, 61], ["the multidomain pro-apoptotic proteins Bax", "TREATMENT", 83, 125], ["Bak", "TREATMENT", 130, 133], ["viable cells", "OBSERVATION", 3, 15]]], ["In response to cellular stresses, BH3-only proteins Bim and tBid can bind to Bcl2 or Bcl-xL, thereby neutralize their antiapoptotic effects, and relieve Bax or Bak from Bcl2-bound complexes [23] ; or alternatively Bim and tBid directly activate Bax and Bak [25, 26] , thereby initiating caspase activation and cell death.", [["cellular", "ANATOMY", 15, 23], ["cell", "ANATOMY", 310, 314], ["death", "DISEASE", 315, 320], ["cellular", "CELL", 15, 23], ["Bim", "GENE_OR_GENE_PRODUCT", 52, 55], ["tBid", "GENE_OR_GENE_PRODUCT", 60, 64], ["Bcl2", "GENE_OR_GENE_PRODUCT", 77, 81], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 85, 91], ["Bax", "GENE_OR_GENE_PRODUCT", 153, 156], ["Bak", "GENE_OR_GENE_PRODUCT", 160, 163], ["Bcl2", "GENE_OR_GENE_PRODUCT", 169, 173], ["Bim", "GENE_OR_GENE_PRODUCT", 214, 217], ["tBid", "GENE_OR_GENE_PRODUCT", 222, 226], ["Bax", "GENE_OR_GENE_PRODUCT", 245, 248], ["Bak", "GENE_OR_GENE_PRODUCT", 253, 256], ["25, 26]", "SIMPLE_CHEMICAL", 258, 265], ["caspase", "GENE_OR_GENE_PRODUCT", 287, 294], ["cell", "CELL", 310, 314], ["BH3", "PROTEIN", 34, 37], ["Bim", "PROTEIN", 52, 55], ["tBid", "PROTEIN", 60, 64], ["Bcl2", "PROTEIN", 77, 81], ["Bcl-xL", "PROTEIN", 85, 91], ["Bax", "PROTEIN", 153, 156], ["Bak", "PROTEIN", 160, 163], ["Bcl2", "PROTEIN", 169, 173], ["Bim", "PROTEIN", 214, 217], ["tBid", "PROTEIN", 222, 226], ["Bax", "PROTEIN", 245, 248], ["Bak", "PROTEIN", 253, 256], ["caspase", "PROTEIN", 287, 294], ["cellular stresses", "TEST", 15, 32], ["BH3", "TEST", 34, 37], ["tBid", "PROBLEM", 60, 64], ["Bcl2", "TEST", 77, 81], ["Bcl-xL", "TREATMENT", 85, 91], ["Bax", "PROBLEM", 153, 156], ["Bak", "PROBLEM", 160, 163], ["Bcl2", "TEST", 169, 173], ["Bak", "TEST", 253, 256], ["caspase activation", "TREATMENT", 287, 305], ["cell death", "PROBLEM", 310, 320], ["cellular stresses", "OBSERVATION", 15, 32], ["cell death", "OBSERVATION", 310, 320]]], ["Therefore, the interaction and the functional balance between pro-apoptotic and anti-apoptotic Bcl2 family proteins in a cell determine the fate of the cell [21] .IntroductionUsing a Cre-loxP-mediated HS-Csn8KO mouse model, we have uncovered in the present study that Csn8 deficiency leads to UPS derangement and functional impairment, which are associated with massive apoptosis.", [["cell", "ANATOMY", 121, 125], ["cell", "ANATOMY", 152, 156], ["functional impairment", "DISEASE", 313, 334], ["Bcl2", "GENE_OR_GENE_PRODUCT", 95, 99], ["cell", "CELL", 121, 125], ["cell", "CELL", 152, 156], ["Cre-loxP", "GENE_OR_GENE_PRODUCT", 183, 191], ["mouse", "ORGANISM", 211, 216], ["Csn8", "GENE_OR_GENE_PRODUCT", 268, 272], ["UPS", "GENE_OR_GENE_PRODUCT", 293, 296], ["pro-apoptotic and anti-apoptotic Bcl2 family proteins", "PROTEIN", 62, 115], ["Cre-loxP-mediated HS", "DNA", 183, 203], ["Csn8", "PROTEIN", 268, 272], ["mouse", "SPECIES", 211, 216], ["pro-apoptotic", "TREATMENT", 62, 75], ["anti-apoptotic Bcl2 family proteins", "TREATMENT", 80, 115], ["a Cre-loxP", "TEST", 181, 191], ["Csn8 deficiency", "PROBLEM", 268, 283], ["UPS derangement", "PROBLEM", 293, 308], ["functional impairment", "PROBLEM", 313, 334], ["massive apoptosis", "PROBLEM", 362, 379], ["massive", "OBSERVATION_MODIFIER", 362, 369], ["apoptosis", "OBSERVATION", 370, 379]]], ["We also presented the first evidence that the upregulation of pro-apoptotic protein Bim and its interaction with Bcl2 may have mediated the Bax-dependent activation of the intrinsic pathway of hepatocyte apoptosis in Csn8 deficient livers.Animal modelsHS-Csn8KO mice were generated with the use of the Cre-loxP system as previously described [19] .", [["hepatocyte", "ANATOMY", 193, 203], ["livers", "ANATOMY", 232, 238], ["Bim", "GENE_OR_GENE_PRODUCT", 84, 87], ["Bcl2", "GENE_OR_GENE_PRODUCT", 113, 117], ["hepatocyte", "CELL", 193, 203], ["Csn8", "GENE_OR_GENE_PRODUCT", 217, 221], ["livers", "ORGAN", 232, 238], ["Animal", "ORGANISM", 239, 245], ["modelsHS-Csn8KO mice", "ORGANISM", 246, 266], ["pro-apoptotic protein", "PROTEIN", 62, 83], ["Bim", "PROTEIN", 84, 87], ["Bcl2", "PROTEIN", 113, 117], ["Csn8", "PROTEIN", 217, 221], ["mice", "SPECIES", 262, 266], ["mice", "SPECIES", 262, 266], ["pro-apoptotic protein Bim", "PROBLEM", 62, 87], ["Bcl2", "TREATMENT", 113, 117], ["hepatocyte apoptosis", "PROBLEM", 193, 213], ["Animal modelsHS", "TEST", 239, 254], ["the Cre-loxP system", "TREATMENT", 298, 317], ["pro-apoptotic protein Bim", "OBSERVATION", 62, 87], ["hepatocyte apoptosis", "OBSERVATION", 193, 213], ["livers", "ANATOMY", 232, 238]]], ["Briefly, Csn8 flox/flox mice were cross-bred with the Cre transgenic mice (Alb-Cre) in which the Cre expression is controlled by an albumin promoter [27] .", [["Csn8", "GENE_OR_GENE_PRODUCT", 9, 13], ["flox", "GENE_OR_GENE_PRODUCT", 19, 23], ["Cre", "GENE_OR_GENE_PRODUCT", 54, 57], ["mice", "ORGANISM", 69, 73], ["Alb-Cre", "GENE_OR_GENE_PRODUCT", 75, 82], ["Cre", "GENE_OR_GENE_PRODUCT", 97, 100], ["albumin", "GENE_OR_GENE_PRODUCT", 132, 139], ["Csn8", "PROTEIN", 9, 13], ["Alb", "PROTEIN", 75, 78], ["Cre", "PROTEIN", 79, 82], ["albumin promoter", "DNA", 132, 148], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 69, 73], ["Csn8 flox/flox mice", "TREATMENT", 9, 28], ["the Cre transgenic mice (Alb-Cre", "TREATMENT", 50, 82], ["an albumin promoter", "TREATMENT", 129, 148]]], ["Ultimately, littermate mice with a genotype of either Csn8 flox /flox ::Alb-Cre(+) or Csn8 flox /flox ::Alb-Cre(-) were used in the present study as the HS-Csn8KO or the control (CTL) mice, respectively.Animal modelsThe generation and characterization of transgenic mice with ubiquitous overexpression of a surrogate UPS substrate GFPdgn were previously described [28] .", [["littermate mice", "ORGANISM", 12, 27], ["Csn8", "GENE_OR_GENE_PRODUCT", 54, 58], ["Alb-Cre(+)", "GENE_OR_GENE_PRODUCT", 72, 82], ["Csn8 flox", "GENE_OR_GENE_PRODUCT", 86, 95], ["Cre", "GENE_OR_GENE_PRODUCT", 108, 111], ["control (CTL) mice", "ORGANISM", 170, 188], ["mice", "ORGANISM", 266, 270], ["UPS", "GENE_OR_GENE_PRODUCT", 317, 320], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 331, 337], ["Csn8 flox", "PROTEIN", 54, 63], ["flox", "PROTEIN", 65, 69], ["Alb", "PROTEIN", 72, 75], ["Cre", "PROTEIN", 76, 79], ["Csn8 flox", "DNA", 86, 95], ["flox", "DNA", 97, 101], ["Alb-Cre", "DNA", 104, 111], ["HS-Csn8KO", "DNA", 153, 162], ["surrogate UPS substrate", "PROTEIN", 307, 330], ["GFPdgn", "PROTEIN", 331, 337], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 266, 270], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 266, 270], ["Alb", "TEST", 72, 75], ["Cre", "TEST", 76, 79], ["the HS", "TEST", 149, 155], ["a surrogate UPS substrate GFPdgn", "PROBLEM", 305, 337]]], ["GFPdgn is an enhanced green fluorescence protein (GFP) modified by carboxyl fusion of degron CL1 [28] .", [["GFPdgn", "CHEMICAL", 0, 6], ["carboxyl", "CHEMICAL", 67, 75], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 0, 6], ["green fluorescence protein", "GENE_OR_GENE_PRODUCT", 22, 48], ["GFP", "GENE_OR_GENE_PRODUCT", 50, 53], ["GFPdgn", "PROTEIN", 0, 6], ["enhanced green fluorescence protein", "PROTEIN", 13, 48], ["GFP", "PROTEIN", 50, 53], ["carboxyl fusion", "PROTEIN", 67, 82], ["CL1", "PROTEIN", 93, 96], ["an enhanced green fluorescence protein", "PROBLEM", 10, 48], ["carboxyl fusion of degron CL1", "TEST", 67, 96]]], ["Using a cross-breeding strategy similar to what we previously reported [17] , the GFPdgn transgene was introduced into the HS-Csn8KO and CTL background via cross-breeding, yielding the HR-Csn8KO-GFPdgn group and the CTL-GFPdgn group used in the present study.Animal modelsThe care and use of animals in this study was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of South Dakota. transferred to PVDF membranes.", [["PVDF membranes", "ANATOMY", 436, 450], ["PVDF", "CHEMICAL", 436, 440], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 82, 88], ["HS-Csn8KO", "CELL", 123, 132], ["membranes", "CELLULAR_COMPONENT", 441, 450], ["GFPdgn transgene", "DNA", 82, 98], ["HS", "DNA", 123, 125], ["Csn8KO", "DNA", 126, 132], ["Csn8KO", "PROTEIN", 188, 194], ["CTL", "CELL_TYPE", 216, 219], ["a cross-breeding strategy", "TREATMENT", 6, 31], ["the GFPdgn transgene", "TREATMENT", 78, 98], ["the HR", "TEST", 181, 187], ["Csn8KO", "TEST", 188, 194], ["the CTL", "TEST", 212, 219], ["the present study", "TEST", 241, 258], ["this study", "TEST", 303, 313], ["PVDF membranes", "OBSERVATION", 436, 450]]], ["Western blots were performed with following antibodies: Rpn2, Rpn8, Rpn10, Rpt5, PA28\u03b1, PA28\u03b2, PA28\u03b3, VHL (von Hippel-Lindau), HIF1\u03b1 (hypoxia inducible factor 1\u03b1), and Csn8 (Biomol), Bim and Bcl-xL (Chemicon), Bax and Bcl2 (BD Pharmingen Tech.), Nedd8 (Alexis), \u03b2-tubulin and ubiquitin (Sigma), CIS (cytokineinducible Src homology 2 domain-containing protein) and GFP (Santa Cruz Biotechnology), and 20S subunit \u03b25 (custom made).", [["Rpn2", "GENE_OR_GENE_PRODUCT", 56, 60], ["Rpn8", "GENE_OR_GENE_PRODUCT", 62, 66], ["Rpn10", "GENE_OR_GENE_PRODUCT", 68, 73], ["Rpt5", "GENE_OR_GENE_PRODUCT", 75, 79], ["PA28\u03b1", "GENE_OR_GENE_PRODUCT", 81, 86], ["PA28\u03b2", "GENE_OR_GENE_PRODUCT", 88, 93], ["PA28\u03b3", "GENE_OR_GENE_PRODUCT", 95, 100], ["HIF1\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["hypoxia inducible factor 1\u03b1", "GENE_OR_GENE_PRODUCT", 134, 161], ["Csn8", "GENE_OR_GENE_PRODUCT", 168, 172], ["Biomol", "GENE_OR_GENE_PRODUCT", 174, 180], ["Bim", "GENE_OR_GENE_PRODUCT", 183, 186], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 191, 197], ["Chemicon", "GENE_OR_GENE_PRODUCT", 199, 207], ["Bax", "GENE_OR_GENE_PRODUCT", 210, 213], ["Bcl2", "GENE_OR_GENE_PRODUCT", 218, 222], ["BD Pharmingen", "GENE_OR_GENE_PRODUCT", 224, 237], ["Nedd8", "GENE_OR_GENE_PRODUCT", 246, 251], ["Alexis", "GENE_OR_GENE_PRODUCT", 253, 259], ["\u03b2-tubulin", "GENE_OR_GENE_PRODUCT", 262, 271], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 276, 285], ["Sigma", "GENE_OR_GENE_PRODUCT", 287, 292], ["cytokineinducible Src homology 2 domain-containing protein", "GENE_OR_GENE_PRODUCT", 300, 358], ["GFP", "GENE_OR_GENE_PRODUCT", 364, 367], ["20S subunit \u03b25", "GENE_OR_GENE_PRODUCT", 400, 414], ["antibodies", "PROTEIN", 44, 54], ["Rpn2", "PROTEIN", 56, 60], ["Rpn8", "PROTEIN", 62, 66], ["Rpn10", "PROTEIN", 68, 73], ["Rpt5", "PROTEIN", 75, 79], ["PA28", "PROTEIN", 81, 85], ["\u03b1", "PROTEIN", 85, 86], ["PA28\u03b2", "PROTEIN", 88, 93], ["PA28\u03b3", "PROTEIN", 95, 100], ["VHL", "PROTEIN", 102, 105], ["von Hippel-Lindau", "PROTEIN", 107, 124], ["HIF1\u03b1", "PROTEIN", 127, 132], ["hypoxia inducible factor 1\u03b1", "PROTEIN", 134, 161], ["Csn8", "PROTEIN", 168, 172], ["Biomol", "PROTEIN", 174, 180], ["Bim", "PROTEIN", 183, 186], ["Bcl-xL", "PROTEIN", 191, 197], ["Chemicon", "PROTEIN", 199, 207], ["Bax", "PROTEIN", 210, 213], ["Bcl2", "PROTEIN", 218, 222], ["BD Pharmingen Tech", "PROTEIN", 224, 242], ["Nedd8", "PROTEIN", 246, 251], ["Alexis", "PROTEIN", 253, 259], ["\u03b2-tubulin", "PROTEIN", 262, 271], ["ubiquitin", "PROTEIN", 276, 285], ["Sigma", "PROTEIN", 287, 292], ["CIS", "PROTEIN", 295, 298], ["cytokineinducible Src homology 2 domain-containing protein", "PROTEIN", 300, 358], ["GFP", "PROTEIN", 364, 367], ["Santa Cruz Biotechnology", "PROTEIN", 369, 393], ["20S subunit \u03b25", "PROTEIN", 400, 414], ["Western blots", "TEST", 0, 13], ["Rpn8", "TEST", 62, 66], ["Rpn10", "TEST", 68, 73], ["Rpt5", "TEST", 75, 79], ["PA28", "TEST", 81, 85], ["PA28", "TEST", 88, 92], ["PA28", "TEST", 95, 99], ["VHL", "TEST", 102, 105], ["HIF1\u03b1 (hypoxia inducible factor", "PROBLEM", 127, 158], ["Csn8", "TEST", 168, 172], ["Bcl-xL", "TEST", 191, 197], ["Chemicon", "TEST", 199, 207], ["Bax", "TEST", 210, 213], ["Bcl2", "TEST", 218, 222], ["\u03b2-tubulin", "PROBLEM", 262, 271], ["CIS (cytokineinducible Src homology", "TREATMENT", 295, 330], ["Bcl-xL", "ANATOMY", 191, 197]]], ["Horseradish peroxidase-conjugated anti-mouse,rabbit, or -rat secondary antibodies (Santa Cruz) were used to probe the bound primary antibodies and detected using ECL advanced detection reagents (Amersham Pharmacia Biotech, Piscataway, NJ).", [["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["rabbit", "ORGANISM", 45, 51], ["rat", "ORGANISM", 57, 60], ["Horseradish peroxidase", "PROTEIN", 0, 22], ["conjugated anti-mouse,rabbit, or -rat secondary antibodies", "PROTEIN", 23, 81], ["Santa Cruz", "PROTEIN", 83, 93], ["primary antibodies", "PROTEIN", 124, 142], ["Horseradish", "SPECIES", 0, 11], ["anti-mouse", "SPECIES", 34, 44], ["rabbit", "SPECIES", 45, 51], ["rat", "SPECIES", 57, 60], ["Horseradish", "SPECIES", 0, 11], ["rabbit", "SPECIES", 45, 51], ["rat", "SPECIES", 57, 60], ["Horseradish peroxidase", "TEST", 0, 22], ["conjugated anti-mouse", "TREATMENT", 23, 44], ["ECL advanced detection reagents", "TREATMENT", 162, 193]]], ["A VersaDoc Model 3000 Imaging System (Bio-Rad Laboratories, Hercules, CA) was used to visualize and digitalize the western blot images.", [["Imaging System", "TEST", 22, 36], ["Bio-Rad Laboratories", "TEST", 38, 58], ["Hercules", "TEST", 60, 68], ["blot images", "TEST", 123, 134]]], ["The densitometry of the western blots was performed with the Quantity-One software (Bio-Rad).Animal modelsFor co-immunoprecipitation, the proteins (400\u00b5g) solubilized in RIPA lysis buffer were incubated respectively with primary antibody against Bim, Bcl2, or Bax (2\u00b5g/ml) at 4\u00b0C for 3 hours and precipitated with protein-A/G-Sepharose (Santa Cruz) at 4\u00b0C for 2 hours.", [["Bim", "GENE_OR_GENE_PRODUCT", 246, 249], ["Bcl2", "GENE_OR_GENE_PRODUCT", 251, 255], ["Bax", "GENE_OR_GENE_PRODUCT", 260, 263], ["G-Sepharose", "SIMPLE_CHEMICAL", 324, 335], ["primary antibody", "PROTEIN", 221, 237], ["Bim", "PROTEIN", 246, 249], ["Bcl2", "PROTEIN", 251, 255], ["Bax", "PROTEIN", 260, 263], ["Santa Cruz", "PROTEIN", 337, 347], ["the western blots", "TEST", 20, 37], ["co-immunoprecipitation", "TEST", 110, 132], ["the proteins", "TEST", 134, 146], ["RIPA lysis buffer", "TREATMENT", 170, 187], ["primary antibody", "TEST", 221, 237], ["Bcl2", "TEST", 251, 255], ["Bax", "TEST", 260, 263], ["protein", "TEST", 314, 321]]], ["After centrifugation, the pellets were washed with RIPA buffer for four times.", [["centrifugation", "TREATMENT", 6, 20], ["the pellets", "TREATMENT", 22, 33], ["RIPA buffer", "TREATMENT", 51, 62]]], ["The immunoprecipitates dissolved in SDS-sample buffer were analyzed by western blotting.TUNEL assayThe terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay was performed using the TUNEL Cell Death Detection Kit (Roche Diagnostics, Mannheim, Germany), as previously described [19] .", [["immunoprecipitates", "ANATOMY", 4, 22], ["Cell", "ANATOMY", 217, 221], ["dUTP", "CHEMICAL", 150, 154], ["dUTP", "CHEMICAL", 150, 154], ["terminal deoxynucleotidyl transferase", "GENE_OR_GENE_PRODUCT", 103, 140], ["dUTP", "SIMPLE_CHEMICAL", 150, 154], ["terminal deoxynucleotidyl transferase", "PROTEIN", 103, 140], ["The immunoprecipitates", "TREATMENT", 0, 22], ["SDS-sample buffer", "TREATMENT", 36, 53], ["TUNEL assay", "TEST", 88, 99], ["The terminal deoxynucleotidyl transferase", "TEST", 99, 140], ["dissolved", "OBSERVATION_MODIFIER", 23, 32], ["terminal", "OBSERVATION_MODIFIER", 103, 111], ["deoxynucleotidyl transferase", "OBSERVATION", 112, 140], ["dUTP nick", "OBSERVATION", 150, 159]]], ["The label solution only (without terminal transferase) instead of TUNEL reaction mixture was used as negative control.", [["terminal transferase", "PROTEIN", 33, 53], ["The label solution", "TREATMENT", 0, 18], ["terminal transferase)", "TREATMENT", 33, 54], ["TUNEL reaction mixture", "TREATMENT", 66, 88]]], ["At least 300 nuclei were counted from three different random fields in each liver, and data from 3 livers per group are presented.", [["nuclei", "ANATOMY", 13, 19], ["liver", "ANATOMY", 76, 81], ["livers", "ANATOMY", 99, 105], ["nuclei", "CELLULAR_COMPONENT", 13, 19], ["liver", "ORGAN", 76, 81], ["livers", "ORGAN", 99, 105], ["300 nuclei", "OBSERVATION_MODIFIER", 9, 19], ["liver", "ANATOMY", 76, 81], ["livers", "ANATOMY", 99, 105]]], ["TUNEL index was expressed as a ratio of the number of TUNEL positive nuclei and the total number of nuclei stained with DAPI.Fluorescence microscopyGFPdgn direct fluorescence of cryosections from paraformaldehyde fixed mouse livers, and the TUNEL or DAPI labeled fluorescence in cryosections were visualized using a Zeiss Axiovert 200M epi-fluorescence microscope (Carl Zeiss MicroImaging GmbH, Germany).ImmunohistochemistryTissue samples were collected from the right lobe of the liver, fixed in 10% formalin, and processed for paraffinembedding.", [["nuclei", "ANATOMY", 69, 75], ["nuclei", "ANATOMY", 100, 106], ["cryosections", "ANATOMY", 178, 190], ["livers", "ANATOMY", 225, 231], ["cryosections", "ANATOMY", 279, 291], ["ImmunohistochemistryTissue samples", "ANATOMY", 404, 438], ["right lobe", "ANATOMY", 463, 473], ["liver", "ANATOMY", 481, 486], ["DAPI", "CHEMICAL", 120, 124], ["paraformaldehyde", "CHEMICAL", 196, 212], ["DAPI", "CHEMICAL", 250, 254], ["formalin", "CHEMICAL", 501, 509], ["nuclei", "CELLULAR_COMPONENT", 69, 75], ["nuclei", "CELLULAR_COMPONENT", 100, 106], ["DAPI", "SIMPLE_CHEMICAL", 120, 124], ["paraformaldehyde", "SIMPLE_CHEMICAL", 196, 212], ["mouse", "ORGANISM", 219, 224], ["livers", "ORGAN", 225, 231], ["DAPI", "SIMPLE_CHEMICAL", 250, 254], ["cryosections", "MULTI-TISSUE_STRUCTURE", 279, 291], ["ImmunohistochemistryTissue samples", "CANCER", 404, 438], ["right lobe", "MULTI-TISSUE_STRUCTURE", 463, 473], ["liver", "ORGAN", 481, 486], ["formalin", "SIMPLE_CHEMICAL", 501, 509], ["mouse", "SPECIES", 219, 224], ["mouse", "SPECIES", 219, 224], ["TUNEL index", "TEST", 0, 11], ["TUNEL positive nuclei", "PROBLEM", 54, 75], ["DAPI", "TREATMENT", 120, 124], ["Fluorescence", "TEST", 125, 137], ["paraformaldehyde fixed mouse livers", "TREATMENT", 196, 231], ["the TUNEL", "TEST", 237, 246], ["DAPI labeled fluorescence", "TEST", 250, 275], ["ImmunohistochemistryTissue samples", "TEST", 404, 438], ["paraffinembedding", "PROBLEM", 529, 546], ["TUNEL", "OBSERVATION", 54, 59], ["positive nuclei", "OBSERVATION", 60, 75], ["total", "OBSERVATION_MODIFIER", 84, 89], ["nuclei stained", "OBSERVATION", 100, 114], ["livers", "ANATOMY", 225, 231], ["right", "ANATOMY_MODIFIER", 463, 468], ["lobe", "ANATOMY_MODIFIER", 469, 473], ["liver", "ANATOMY", 481, 486], ["fixed", "OBSERVATION_MODIFIER", 488, 493]]], ["Serial 5-\u03bcm paraffin sections were used for Csn8 immunohistochemistry as previously described [19] .", [["sections", "ANATOMY", 21, 29], ["paraffin sections", "CANCER", 12, 29], ["Csn8", "GENE_OR_GENE_PRODUCT", 44, 48], ["Csn8", "PROTEIN", 44, 48], ["Serial 5-\u03bcm paraffin sections", "TREATMENT", 0, 29], ["Csn8 immunohistochemistry", "TEST", 44, 69]]], ["Briefly, paraffin-embedded sections were de-paraffinized and rehydrated.", [["sections", "ANATOMY", 27, 35], ["paraffin", "CHEMICAL", 9, 17], ["sections", "MULTI-TISSUE_STRUCTURE", 27, 35]]], ["The slides were further incubated in 1N HCl for 8 minutes at 65\u00b0C and blocked with 0.3% H 2 O 2 for 20 minutes, washed in PBS, and blocked with 1% (w/v) bovine serum albumin (BSA) in PBS.", [["serum", "ANATOMY", 160, 165], ["1N HCl", "CHEMICAL", 37, 43], ["HCl", "CHEMICAL", 40, 43], ["H 2 O 2", "CHEMICAL", 88, 95], ["bovine", "ORGANISM", 153, 159], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["albumin", "SIMPLE_CHEMICAL", 166, 173], ["BSA", "SIMPLE_CHEMICAL", 175, 178], ["bovine", "SPECIES", 153, 159], ["The slides", "TEST", 0, 10], ["1N HCl", "TREATMENT", 37, 43], ["PBS", "TREATMENT", 122, 125], ["w/v) bovine serum albumin (BSA", "TREATMENT", 148, 178]]], ["The BSA-blocked slides were incubated with rabbit anti-Csn8 antibody for 1 hour at room temperature.", [["BSA", "SIMPLE_CHEMICAL", 4, 7], ["rabbit", "ORGANISM", 43, 49], ["anti-Csn8", "GENE_OR_GENE_PRODUCT", 50, 59], ["BSA", "PROTEIN", 4, 7], ["rabbit anti-Csn8 antibody", "PROTEIN", 43, 68], ["rabbit", "SPECIES", 43, 49], ["rabbit", "SPECIES", 43, 49], ["The BSA", "TEST", 0, 7], ["blocked slides", "PROBLEM", 8, 22], ["rabbit anti-Csn8 antibody", "TREATMENT", 43, 68]]], ["Biotinylated anti-rabbit secondary antibody was used at a 1:200 dilution and visualized with peroxidase reaction using the ABC Vectastain kit (Vector Laboratories, Burlingame, CA).Electron microscopyThis was performed essentially as previously described [18] .", [["peroxidase", "GENE_OR_GENE_PRODUCT", 93, 103], ["Vectastain", "GENE_OR_GENE_PRODUCT", 127, 137], ["Biotinylated anti-rabbit secondary antibody", "PROTEIN", 0, 43], ["peroxidase", "PROTEIN", 93, 103], ["ABC Vectastain kit", "PROTEIN", 123, 141], ["anti-rabbit", "SPECIES", 13, 24], ["anti-rabbit", "SPECIES", 13, 24], ["Biotinylated anti-rabbit secondary antibody", "TREATMENT", 0, 43], ["peroxidase reaction", "PROBLEM", 93, 112], ["the ABC", "TEST", 119, 126], ["Electron microscopy", "TEST", 180, 199]]], ["Mice were anesthetized with isoflurane and the tissue samples from the left and right lobes of livers were fixed in 3.5% glutaraldehyde in 100 mM cacodylate buffer (pH 7.3).", [["tissue samples", "ANATOMY", 47, 61], ["left", "ANATOMY", 71, 75], ["right lobes", "ANATOMY", 80, 91], ["livers", "ANATOMY", 95, 101], ["isoflurane", "CHEMICAL", 28, 38], ["glutaraldehyde", "CHEMICAL", 121, 135], ["isoflurane", "CHEMICAL", 28, 38], ["glutaraldehyde", "CHEMICAL", 121, 135], ["cacodylate", "CHEMICAL", 146, 156], ["Mice", "ORGANISM", 0, 4], ["isoflurane", "SIMPLE_CHEMICAL", 28, 38], ["tissue samples", "CANCER", 47, 61], ["right lobes", "MULTI-TISSUE_STRUCTURE", 80, 91], ["livers", "ORGAN", 95, 101], ["glutaraldehyde", "SIMPLE_CHEMICAL", 121, 135], ["Mice", "SPECIES", 0, 4], ["Mice", "SPECIES", 0, 4], ["isoflurane", "TREATMENT", 28, 38], ["the tissue samples", "TEST", 43, 61], ["pH", "TEST", 165, 167], ["left", "ANATOMY_MODIFIER", 71, 75], ["right", "ANATOMY_MODIFIER", 80, 85], ["lobes", "ANATOMY_MODIFIER", 86, 91], ["livers", "ANATOMY", 95, 101], ["fixed", "OBSERVATION_MODIFIER", 107, 112]]], ["At least 3 tissue samples from each lobe of the liver were chosen randomly for ultrastructural analysis.", [["tissue samples", "ANATOMY", 11, 25], ["lobe", "ANATOMY", 36, 40], ["liver", "ANATOMY", 48, 53], ["tissue samples", "CANCER", 11, 25], ["lobe", "ORGAN", 36, 40], ["liver", "ORGAN", 48, 53], ["ultrastructural analysis", "TEST", 79, 103], ["3 tissue", "OBSERVATION_MODIFIER", 9, 17], ["lobe", "ANATOMY_MODIFIER", 36, 40], ["liver", "ANATOMY", 48, 53]]], ["Two mice for each genotype were examined.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["each genotype", "TEST", 13, 26]]], ["Toluidine (Tol) blue stain of the semi-thin sections of resin-embedded tissue was performed and observed using bright-field light microscope to help orientate the tissue sample and select areas of interest for ultra-thin sectioning.", [["semi-thin sections", "ANATOMY", 34, 52], ["tissue", "ANATOMY", 71, 77], ["tissue sample", "ANATOMY", 163, 176], ["Toluidine", "CHEMICAL", 0, 9], ["Tol) blue", "CHEMICAL", 11, 20], ["Toluidine", "CHEMICAL", 0, 9], ["Tol) blue", "CHEMICAL", 11, 20], ["Toluidine", "SIMPLE_CHEMICAL", 0, 9], ["Tol", "SIMPLE_CHEMICAL", 11, 14], ["semi-thin sections", "MULTI-TISSUE_STRUCTURE", 34, 52], ["tissue", "TISSUE", 71, 77], ["tissue", "TISSUE", 163, 169], ["Toluidine", "TREATMENT", 0, 9], ["blue stain", "TEST", 16, 26], ["bright-field light microscope", "TREATMENT", 111, 140], ["the tissue sample", "TEST", 159, 176], ["ultra-thin sectioning", "TREATMENT", 210, 231]]], ["Ultrathin sections were picked up on nickel grids, dried and etched with a saturated solution of sodium m-periodate and 0.1N HCl.", [["sections", "ANATOMY", 10, 18], ["nickel", "CHEMICAL", 37, 43], ["sodium m-periodate", "CHEMICAL", 97, 115], ["N HCl", "CHEMICAL", 123, 128], ["nickel", "CHEMICAL", 37, 43], ["sodium m-periodate", "CHEMICAL", 97, 115], ["HCl", "CHEMICAL", 125, 128], ["sodium m-periodate", "SIMPLE_CHEMICAL", 97, 115], ["0.1N HCl", "SIMPLE_CHEMICAL", 120, 128], ["Ultrathin sections", "TEST", 0, 18], ["nickel grids", "TREATMENT", 37, 49], ["a saturated solution of sodium m-periodate", "TREATMENT", 73, 115]]], ["Thin sections were counterstained with uranyl acetate and lead citrate.", [["Thin sections", "ANATOMY", 0, 13], ["uranyl acetate", "CHEMICAL", 39, 53], ["lead citrate", "CHEMICAL", 58, 70], ["uranyl acetate", "CHEMICAL", 39, 53], ["citrate", "CHEMICAL", 63, 70], ["Thin sections", "CANCER", 0, 13], ["uranyl acetate", "SIMPLE_CHEMICAL", 39, 53], ["lead citrate", "SIMPLE_CHEMICAL", 58, 70], ["Thin sections", "TEST", 0, 13], ["uranyl acetate", "TREATMENT", 39, 53], ["lead citrate", "TREATMENT", 58, 70]]], ["The sections were viewed in a Zeiss, Omega 912 electron microscope at 100 kV.Statistical analysesAll quantitative data were presented as mean \u00b1 SD unless otherwise indicated and analyzed using Student t-test for unpaired two group comparison.", [["sections", "ANATOMY", 4, 12], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["Statistical analyses", "TEST", 77, 97], ["All quantitative data", "TEST", 97, 118], ["Student t-test", "TEST", 193, 207]]], ["A p-value <0.05 is considered statistically significant.Csn8 deficiency increases high molecular weight (HMW) Nedd8 and ubiquitin conjugates and leads to UPS derangement in mouse liversTo dissect the molecular link between Csn8 deficiency and the activation of apoptotic pathways, we examined changes in the UPS in HS-Csn8KO livers.", [["livers", "ANATOMY", 179, 185], ["HS-Csn8KO livers", "ANATOMY", 315, 331], ["Csn8", "CHEMICAL", 56, 60], ["Csn8", "GENE_OR_GENE_PRODUCT", 56, 60], ["high molecular weight (HMW) Nedd8", "GENE_OR_GENE_PRODUCT", 82, 115], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 120, 129], ["UPS", "GENE_OR_GENE_PRODUCT", 154, 157], ["mouse", "ORGANISM", 173, 178], ["livers", "ORGAN", 179, 185], ["Csn8", "GENE_OR_GENE_PRODUCT", 223, 227], ["UPS", "GENE_OR_GENE_PRODUCT", 308, 311], ["livers", "ORGAN", 325, 331], ["Csn8", "PROTEIN", 56, 60], ["high molecular weight (HMW) Nedd8", "PROTEIN", 82, 115], ["UPS", "PROTEIN", 154, 157], ["Csn8", "PROTEIN", 223, 227], ["UPS", "PROTEIN", 308, 311], ["mouse", "SPECIES", 173, 178], ["mouse", "SPECIES", 173, 178], ["A p-value", "TEST", 0, 9], ["Csn8 deficiency", "PROBLEM", 56, 71], ["Nedd8 and ubiquitin conjugates", "TREATMENT", 110, 140], ["UPS derangement in mouse livers", "PROBLEM", 154, 185], ["Csn8 deficiency", "PROBLEM", 223, 238], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["livers", "ANATOMY", 179, 185], ["Csn8 deficiency", "OBSERVATION", 223, 238], ["livers", "ANATOMY", 325, 331]]], ["Significantly increases in the mono-neddylated form of cullins have been reported in HS-Csn8KO livers [19] , confirming that CSN-mediated cullin deneddylation in hepatocytes requires Csn8.", [["HS-Csn8KO livers", "ANATOMY", 85, 101], ["hepatocytes", "ANATOMY", 162, 173], ["cullins", "GENE_OR_GENE_PRODUCT", 55, 62], ["CSN", "GENE_OR_GENE_PRODUCT", 125, 128], ["cullin", "GENE_OR_GENE_PRODUCT", 138, 144], ["hepatocytes", "CELL", 162, 173], ["Csn8", "GENE_OR_GENE_PRODUCT", 183, 187], ["cullins", "PROTEIN", 55, 62], ["CSN", "PROTEIN", 125, 128], ["cullin", "PROTEIN", 138, 144], ["hepatocytes", "CELL_TYPE", 162, 173], ["Csn8", "PROTEIN", 183, 187], ["mediated cullin deneddylation in hepatocytes", "PROBLEM", 129, 173], ["increases", "OBSERVATION_MODIFIER", 14, 23], ["cullin", "OBSERVATION", 138, 144], ["hepatocytes", "ANATOMY", 162, 173]]], ["CSN-mediated cullin deneddylation is purported to prevent self-ubiquitination and destabilization of CRLs.", [["CSN", "GENE_OR_GENE_PRODUCT", 0, 3], ["cullin", "GENE_OR_GENE_PRODUCT", 13, 19], ["CRLs", "GENE_OR_GENE_PRODUCT", 101, 105], ["CSN", "PROTEIN", 0, 3], ["cullin", "PROTEIN", 13, 19], ["CRLs", "PROTEIN", 101, 105], ["mediated cullin deneddylation", "TREATMENT", 4, 33], ["self-ubiquitination", "PROBLEM", 58, 77], ["destabilization of CRLs", "PROBLEM", 82, 105], ["cullin deneddylation", "OBSERVATION", 13, 33], ["ubiquitination", "OBSERVATION", 63, 77]]], ["Consistent with this postulate, we detected in HS-Csn8KO livers significant decreases in CIS (cytokine-inducible Src homology 2 domain-containing protein) and VHL (p<0.01, Figure 1A ).", [["HS-Csn8KO livers", "ANATOMY", 47, 63], ["CIS", "GENE_OR_GENE_PRODUCT", 89, 92], ["cytokine-inducible Src homology 2 domain-containing protein", "GENE_OR_GENE_PRODUCT", 94, 153], ["CIS", "PROTEIN", 89, 92], ["cytokine", "PROTEIN", 94, 102], ["Src homology 2 domain-containing protein", "PROTEIN", 113, 153], ["VHL", "PROTEIN", 159, 162], ["HS", "TEST", 47, 49], ["significant decreases in CIS", "PROBLEM", 64, 92], ["cytokine", "TEST", 94, 102], ["Src homology", "TEST", 113, 125], ["protein", "TEST", 146, 153], ["VHL", "TEST", 159, 162], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["decreases", "OBSERVATION_MODIFIER", 76, 85]]], ["CIS and VHL serve as the receptor protein for Bim-EL and HIF1\u03b1 in the Elongin B/C-Cullin2-CIS and the Elongin B/C-Cullin2-VHL ligases that target Bim-EL and HIF1\u03b1 for degradation, respectively [29, 30] .", [["Bim-EL", "GENE_OR_GENE_PRODUCT", 46, 52], ["HIF1\u03b1", "GENE_OR_GENE_PRODUCT", 57, 62], ["Elongin B", "GENE_OR_GENE_PRODUCT", 70, 79], ["C", "GENE_OR_GENE_PRODUCT", 80, 81], ["Elongin B", "GENE_OR_GENE_PRODUCT", 102, 111], ["C", "GENE_OR_GENE_PRODUCT", 112, 113], ["Bim-EL", "GENE_OR_GENE_PRODUCT", 146, 152], ["HIF1\u03b1", "GENE_OR_GENE_PRODUCT", 157, 162], ["CIS", "PROTEIN", 0, 3], ["VHL", "PROTEIN", 8, 11], ["Bim", "PROTEIN", 46, 49], ["EL", "PROTEIN", 50, 52], ["HIF1\u03b1", "PROTEIN", 57, 62], ["Elongin B", "PROTEIN", 70, 79], ["C", "PROTEIN", 80, 81], ["Cullin2", "PROTEIN", 82, 89], ["CIS", "PROTEIN", 90, 93], ["Elongin B/C-Cullin2-VHL ligases", "PROTEIN", 102, 133], ["Bim", "PROTEIN", 146, 149], ["EL", "PROTEIN", 150, 152], ["HIF1\u03b1", "PROTEIN", 157, 162], ["CIS", "TEST", 0, 3], ["the receptor protein", "TEST", 21, 41], ["Bim", "TEST", 46, 49], ["HIF1\u03b1", "TEST", 57, 62], ["the Elongin B/C", "TEST", 66, 81], ["Cullin2", "TEST", 82, 89], ["CIS", "TEST", 90, 93], ["the Elongin B/C", "TEST", 98, 113], ["Cullin2", "TEST", 114, 121], ["VHL ligases", "TREATMENT", 122, 133]]], ["In agreement with the decrease of CIS, the extra-long form of Bim (Bim-EL) protein which is a known substrate of CIS [29] , was significantly increased in HS-Csn8KO livers compared with the CTL (p<0.01).", [["HS-Csn8KO livers", "ANATOMY", 155, 171], ["CTL", "ANATOMY", 190, 193], ["CIS", "GENE_OR_GENE_PRODUCT", 34, 37], ["Bim", "GENE_OR_GENE_PRODUCT", 62, 65], ["Bim-EL)", "GENE_OR_GENE_PRODUCT", 67, 74], ["CIS [29]", "GENE_OR_GENE_PRODUCT", 113, 121], ["livers", "ORGAN", 165, 171], ["CIS", "PROTEIN", 34, 37], ["Bim", "PROTEIN", 62, 65], ["Bim", "PROTEIN", 67, 70], ["EL", "PROTEIN", 71, 73], ["CIS", "PROTEIN", 113, 116], ["CTL", "CELL_TYPE", 190, 193], ["the decrease of CIS", "PROBLEM", 18, 37], ["Bim (Bim-EL) protein", "TEST", 62, 82], ["a known substrate of CIS", "PROBLEM", 92, 116], ["HS", "TEST", 155, 157], ["the CTL", "TEST", 186, 193], ["increased", "OBSERVATION_MODIFIER", 142, 151], ["livers", "ANATOMY", 165, 171]]], ["By contrast, the protein level of HIF1\u03b1, a substrate of VHL [31] , showed no discernible increase (p>0.05, Figure 1A ).Csn8 deficiency increases high molecular weight (HMW) Nedd8 and ubiquitin conjugates and leads to UPS derangement in mouse liversWe previously observed marked increases in the mononeddylated form of cullins in HS-Csn8KO livers [19] ; here we report that HMW nedd8 conjugates were significantly higher in HS-Csn8KO liver than the CTL at 4 weeks of age (p<0.01, Figure 1B, 1C) .", [["livers", "ANATOMY", 242, 248], ["HS-Csn8KO livers", "ANATOMY", 329, 345], ["HS-Csn8KO liver", "ANATOMY", 423, 438], ["Csn8", "CHEMICAL", 119, 123], ["HIF1\u03b1", "GENE_OR_GENE_PRODUCT", 34, 39], ["Csn8", "GENE_OR_GENE_PRODUCT", 119, 123], ["high molecular weight (HMW) Nedd8", "GENE_OR_GENE_PRODUCT", 145, 178], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 183, 192], ["UPS", "GENE_OR_GENE_PRODUCT", 217, 220], ["mouse", "ORGANISM", 236, 241], ["livers", "ORGAN", 242, 248], ["cullins", "GENE_OR_GENE_PRODUCT", 318, 325], ["HMW", "GENE_OR_GENE_PRODUCT", 373, 376], ["nedd8", "GENE_OR_GENE_PRODUCT", 377, 382], ["liver", "ORGAN", 433, 438], ["HIF1\u03b1", "PROTEIN", 34, 39], ["VHL", "PROTEIN", 56, 59], ["Csn8", "PROTEIN", 119, 123], ["high molecular weight (HMW) Nedd8", "PROTEIN", 145, 178], ["UPS", "PROTEIN", 217, 220], ["cullins", "PROTEIN", 318, 325], ["CTL", "CELL_TYPE", 448, 451], ["mouse", "SPECIES", 236, 241], ["mouse", "SPECIES", 236, 241], ["the protein level", "TEST", 13, 30], ["HIF1\u03b1", "TEST", 34, 39], ["VHL", "TEST", 56, 59], ["discernible increase", "PROBLEM", 77, 97], ["Csn8 deficiency", "PROBLEM", 119, 134], ["Nedd8 and ubiquitin conjugates", "TREATMENT", 173, 203], ["UPS derangement in mouse livers", "PROBLEM", 217, 248], ["HMW nedd8 conjugates", "TEST", 373, 393], ["no", "UNCERTAINTY", 74, 76], ["discernible", "OBSERVATION_MODIFIER", 77, 88], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["livers", "ANATOMY", 242, 248], ["marked", "OBSERVATION_MODIFIER", 271, 277], ["increases", "OBSERVATION_MODIFIER", 278, 287], ["livers", "ANATOMY", 339, 345], ["liver", "ANATOMY", 433, 438]]], ["Interestingly, the abundance of HMW ubiquitin conjugates were also remarkably greater in HS-Csn8KO livers than in the CTL (p<0.01, Figure 1D ).Csn8 deficiency increases high molecular weight (HMW) Nedd8 and ubiquitin conjugates and leads to UPS derangement in mouse liversThe CSN holo-complex shares morphology and subunit domain structure similarities with the lid of the 19S proteasome; hence, it has been proposed that the CSN may serve as an alternative \"lid\" for the 19S proteasome to compete with the lid of the 19S proteasome in binding the base of the 19S.", [["HS-Csn8KO livers", "ANATOMY", 89, 105], ["CTL", "ANATOMY", 118, 121], ["livers", "ANATOMY", 266, 272], ["Csn8", "CHEMICAL", 143, 147], ["HMW ubiquitin", "GENE_OR_GENE_PRODUCT", 32, 45], ["livers", "ORGAN", 99, 105], ["Csn8", "GENE_OR_GENE_PRODUCT", 143, 147], ["high molecular weight (HMW) Nedd8", "GENE_OR_GENE_PRODUCT", 169, 202], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 207, 216], ["UPS", "GENE_OR_GENE_PRODUCT", 241, 244], ["mouse", "ORGANISM", 260, 265], ["livers", "ORGAN", 266, 272], ["CSN", "GENE_OR_GENE_PRODUCT", 276, 279], ["CSN", "GENE_OR_GENE_PRODUCT", 426, 429], ["19S proteasome", "GENE_OR_GENE_PRODUCT", 472, 486], ["19S proteasome", "GENE_OR_GENE_PRODUCT", 518, 532], ["CTL", "CELL_TYPE", 118, 121], ["Csn8", "PROTEIN", 143, 147], ["high molecular weight (HMW) Nedd8", "PROTEIN", 169, 202], ["UPS", "PROTEIN", 241, 244], ["CSN holo-complex", "PROTEIN", 276, 292], ["19S proteasome", "PROTEIN", 373, 387], ["CSN", "PROTEIN", 426, 429], ["19S proteasome", "PROTEIN", 472, 486], ["19S proteasome", "PROTEIN", 518, 532], ["19S", "PROTEIN", 560, 563], ["mouse", "SPECIES", 260, 265], ["mouse", "SPECIES", 260, 265], ["HMW ubiquitin conjugates", "PROBLEM", 32, 56], ["the CTL", "TEST", 114, 121], ["Csn8 deficiency", "PROBLEM", 143, 158], ["Nedd8 and ubiquitin conjugates", "TREATMENT", 197, 227], ["UPS derangement in mouse livers", "PROBLEM", 241, 272], ["the 19S proteasome", "TREATMENT", 369, 387], ["the 19S proteasome", "TREATMENT", 468, 486], ["ubiquitin conjugates", "OBSERVATION", 36, 56], ["livers", "ANATOMY", 99, 105], ["livers", "ANATOMY", 266, 272], ["19S proteasome", "OBSERVATION", 373, 387], ["base", "ANATOMY_MODIFIER", 548, 552]]], ["Csn8 deficiency is known to reduce the abundance of CSN holocomplex in mice [16, 17] .", [["Csn8", "CHEMICAL", 0, 4], ["Csn8", "GENE_OR_GENE_PRODUCT", 0, 4], ["CSN", "GENE_OR_GENE_PRODUCT", 52, 55], ["mice", "ORGANISM", 71, 75], ["Csn8", "PROTEIN", 0, 4], ["CSN", "PROTEIN", 52, 55], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["Csn8 deficiency", "PROBLEM", 0, 15]]], ["Therefore, we examined the subunit protein levels of the 19S proteasome in HS-Csn8KO mouse livers.", [["livers", "ANATOMY", 91, 97], ["19S", "GENE_OR_GENE_PRODUCT", 57, 60], ["mouse", "ORGANISM", 85, 90], ["livers", "ORGAN", 91, 97], ["19S proteasome", "PROTEIN", 57, 71], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 85, 90], ["the subunit protein levels", "TEST", 23, 49], ["livers", "ANATOMY", 91, 97]]], ["Csn8 deficiency show no discernible effect on the protein levels of Rpn2, Rpn8, and Rpn10, three 19S lid subunits.", [["Csn8", "GENE_OR_GENE_PRODUCT", 0, 4], ["Rpn2", "GENE_OR_GENE_PRODUCT", 68, 72], ["Rpn8", "GENE_OR_GENE_PRODUCT", 74, 78], ["Rpn10", "GENE_OR_GENE_PRODUCT", 84, 89], ["19S lid subunits", "GENE_OR_GENE_PRODUCT", 97, 113], ["Csn8", "PROTEIN", 0, 4], ["Rpn2", "PROTEIN", 68, 72], ["Rpn8", "PROTEIN", 74, 78], ["Rpn10", "PROTEIN", 84, 89], ["19S lid subunits", "PROTEIN", 97, 113], ["Csn8 deficiency", "PROBLEM", 0, 15], ["discernible effect", "PROBLEM", 24, 42], ["the protein levels", "TEST", 46, 64], ["Rpn2", "TEST", 68, 72], ["Rpn8", "TEST", 74, 78], ["Rpn10", "TEST", 84, 89], ["no", "UNCERTAINTY", 21, 23], ["discernible", "OBSERVATION_MODIFIER", 24, 35], ["effect", "OBSERVATION_MODIFIER", 36, 42], ["19S lid", "OBSERVATION", 97, 104]]], ["Interestingly, the level of a 19S base subunit Rpt5 was significantly lower in HS-Csn8KO liver than the CTL (p<0.01, Figure 2A , 2B).", [["HS-Csn8KO liver", "ANATOMY", 79, 94], ["Rpt5", "GENE_OR_GENE_PRODUCT", 47, 51], ["liver", "ORGAN", 89, 94], ["19S base subunit", "PROTEIN", 30, 46], ["Rpt5", "PROTEIN", 47, 51], ["CTL", "CELL_TYPE", 104, 107], ["a 19S base subunit Rpt5", "TEST", 28, 51], ["HS", "TEST", 79, 81], ["the CTL", "TEST", 100, 107], ["liver", "ANATOMY", 89, 94]]], ["HS-Csn8KO showed no discernible effect on the protein level of 20S subunit \u03b25.", [["HS-Csn8KO", "GENE_OR_GENE_PRODUCT", 0, 9], ["20S subunit \u03b25", "GENE_OR_GENE_PRODUCT", 63, 77], ["HS-Csn8KO", "DNA", 0, 9], ["20S subunit \u03b25", "PROTEIN", 63, 77], ["HS", "TEST", 0, 2], ["Csn8KO", "TEST", 3, 9], ["discernible effect", "PROBLEM", 20, 38], ["the protein level", "TEST", 42, 59], ["no", "UNCERTAINTY", 17, 19], ["discernible", "OBSERVATION_MODIFIER", 20, 31], ["effect", "OBSERVATION", 32, 38]]], ["Strikingly, all three subunits (PA28-\u03b1, -\u03b2, -\u03b3) of the 11S proteasome showed greater protein expression in HS-Csn8KO livers than in the CTL (p<0.05, 0.01; Figure 2C , 2D).Csn8 deficiency impairs UPS proteolytic function in the liverProteolysis via the UPS plays important roles in a variety of basic cellular processes.", [["HS-Csn8KO livers", "ANATOMY", 107, 123], ["CTL", "ANATOMY", 136, 139], ["liver", "ANATOMY", 227, 232], ["cellular", "ANATOMY", 300, 308], ["PA28-\u03b1", "GENE_OR_GENE_PRODUCT", 32, 38], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 40, 42], ["-\u03b3", "GENE_OR_GENE_PRODUCT", 44, 46], ["11S", "GENE_OR_GENE_PRODUCT", 55, 58], ["Csn8", "GENE_OR_GENE_PRODUCT", 171, 175], ["UPS", "GENE_OR_GENE_PRODUCT", 195, 198], ["liver", "ORGAN", 227, 232], ["UPS", "GENE_OR_GENE_PRODUCT", 252, 255], ["cellular", "CELL", 300, 308], ["PA28", "PROTEIN", 32, 36], ["\u03b1", "PROTEIN", 37, 38], ["-\u03b2", "PROTEIN", 40, 42], ["-\u03b3", "PROTEIN", 44, 46], ["11S proteasome", "PROTEIN", 55, 69], ["CTL", "CELL_TYPE", 136, 139], ["Csn8", "PROTEIN", 171, 175], ["UPS", "PROTEIN", 195, 198], ["UPS", "PROTEIN", 252, 255], ["PA28", "TEST", 32, 36], ["the 11S proteasome", "TEST", 51, 69], ["HS", "TEST", 107, 109], ["the CTL", "TEST", 132, 139], ["Csn8 deficiency", "PROBLEM", 171, 186], ["proteolytic function in the liver", "PROBLEM", 199, 232], ["Proteolysis", "PROBLEM", 232, 243], ["greater", "OBSERVATION_MODIFIER", 77, 84], ["protein expression", "OBSERVATION", 85, 103], ["livers", "ANATOMY", 117, 123], ["proteolytic function", "OBSERVATION", 199, 219], ["liver", "ANATOMY", 227, 232], ["cellular processes", "OBSERVATION", 300, 318]]], ["The CSN may act as a UPS regulator by cullin neddylation of CRLs and potential association with the 19S proteasome [32, 33] .", [["CSN", "GENE_OR_GENE_PRODUCT", 4, 7], ["UPS", "GENE_OR_GENE_PRODUCT", 21, 24], ["cullin", "GENE_OR_GENE_PRODUCT", 38, 44], ["CRLs", "GENE_OR_GENE_PRODUCT", 60, 64], ["CSN", "PROTEIN", 4, 7], ["UPS regulator", "PROTEIN", 21, 34], ["cullin", "PROTEIN", 38, 44], ["CRLs", "PROTEIN", 60, 64], ["19S proteasome", "PROTEIN", 100, 114]]], ["To investigate UPS proteolytic function in intact animals, we previously established a transgenic mouse model that ubiquitously overexpresses GFPdgn, a modified green fluorescence protein (GFP) with its carboxyl fusion of degron CL1.", [["carboxyl", "CHEMICAL", 203, 211], ["UPS", "GENE_OR_GENE_PRODUCT", 15, 18], ["mouse", "ORGANISM", 98, 103], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 142, 148], ["green fluorescence protein", "GENE_OR_GENE_PRODUCT", 161, 187], ["GFP", "GENE_OR_GENE_PRODUCT", 189, 192], ["degron CL1", "GENE_OR_GENE_PRODUCT", 222, 232], ["UPS", "PROTEIN", 15, 18], ["GFPdgn", "PROTEIN", 142, 148], ["modified green fluorescence protein", "PROTEIN", 152, 187], ["GFP", "PROTEIN", 189, 192], ["carboxyl fusion", "PROTEIN", 203, 218], ["degron CL1", "PROTEIN", 222, 232], ["mouse", "SPECIES", 98, 103], ["mouse", "SPECIES", 98, 103], ["a modified green fluorescence protein (GFP", "TREATMENT", 150, 192], ["its carboxyl fusion of degron CL1", "TREATMENT", 199, 232], ["carboxyl fusion", "OBSERVATION", 203, 218], ["degron CL1", "OBSERVATION", 222, 232]]], ["GFPdgn, which is similar to GFP u [34] , has proven to be a surrogate substrate of the UPS [28] .", [["GFPdgn", "CHEMICAL", 0, 6], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 0, 6], ["GFP u [34]", "GENE_OR_GENE_PRODUCT", 28, 38], ["GFPdgn", "PROTEIN", 0, 6], ["GFP u", "TEST", 28, 33]]], ["GFPdgn protein levels inversely correlate to UPS proteolytic function in the cell [35, 36] .", [["cell", "ANATOMY", 77, 81], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 0, 6], ["UPS", "GENE_OR_GENE_PRODUCT", 45, 48], ["cell", "CELL", 77, 81], ["GFPdgn", "PROTEIN", 0, 6], ["UPS", "PROTEIN", 45, 48], ["GFPdgn protein levels", "TEST", 0, 21], ["proteolytic function", "TEST", 49, 69]]], ["Therefore, we introduced GFPdgn into the CTL and HS-Csn8KO mice via crossbreeding, to explore the in vivo impact of hepatic Csn8 deficiency on UPS-mediated proteolysis in the liver.", [["hepatic", "ANATOMY", 116, 123], ["liver", "ANATOMY", 175, 180], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 25, 31], ["CTL", "CELL", 41, 44], ["HS-Csn8KO mice", "ORGANISM", 49, 63], ["hepatic", "ORGAN", 116, 123], ["Csn8", "GENE_OR_GENE_PRODUCT", 124, 128], ["UPS", "GENE_OR_GENE_PRODUCT", 143, 146], ["liver", "ORGAN", 175, 180], ["GFPdgn", "PROTEIN", 25, 31], ["CTL", "CELL_TYPE", 41, 44], ["hepatic Csn8", "PROTEIN", 116, 128], ["UPS", "PROTEIN", 143, 146], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["HS", "TEST", 49, 51], ["hepatic Csn8 deficiency", "PROBLEM", 116, 139], ["mediated proteolysis in the liver", "PROBLEM", 147, 180], ["hepatic", "ANATOMY", 116, 123], ["Csn8 deficiency", "OBSERVATION", 124, 139], ["proteolysis", "OBSERVATION", 156, 167], ["liver", "ANATOMY", 175, 180]]], ["HS-Csn8KO increased significantly hepatic GFPdgn protein levels (p<0.01; Figure 3A , 3B).", [["hepatic", "ANATOMY", 34, 41], ["HS-Csn8KO", "GENE_OR_GENE_PRODUCT", 0, 9], ["hepatic", "ORGAN", 34, 41], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 42, 48], ["HS-Csn8KO", "DNA", 0, 9], ["hepatic GFPdgn", "PROTEIN", 34, 48], ["HS", "TEST", 0, 2], ["hepatic GFPdgn protein levels", "TEST", 34, 63], ["hepatic", "ANATOMY", 34, 41]]], ["The accumulation of GFPdgn was further confirmed by the increased intensity of GFP direct fluorescence in HS-Csn8KO mouse livers ( Figure 3C ).", [["livers", "ANATOMY", 122, 128], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 20, 26], ["GFP", "GENE_OR_GENE_PRODUCT", 79, 82], ["mouse", "ORGANISM", 116, 121], ["livers", "ORGAN", 122, 128], ["GFPdgn", "PROTEIN", 20, 26], ["GFP", "PROTEIN", 79, 82], ["mouse", "SPECIES", 116, 121], ["mouse", "SPECIES", 116, 121], ["The accumulation of GFPdgn", "PROBLEM", 0, 26], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["intensity", "OBSERVATION_MODIFIER", 66, 75], ["livers", "ANATOMY", 122, 128]]], ["These results compellingly demonstrate that Csn8 deficiency in liver leads to severe impairment of UPS-mediated proteolysis.", [["liver", "ANATOMY", 63, 68], ["Csn8", "CHEMICAL", 44, 48], ["Csn8", "GENE_OR_GENE_PRODUCT", 44, 48], ["liver", "ORGAN", 63, 68], ["UPS", "GENE_OR_GENE_PRODUCT", 99, 102], ["Csn8", "PROTEIN", 44, 48], ["UPS", "PROTEIN", 99, 102], ["Csn8 deficiency in liver", "PROBLEM", 44, 68], ["severe impairment of UPS-mediated proteolysis", "PROBLEM", 78, 123], ["deficiency", "OBSERVATION", 49, 59], ["liver", "ANATOMY", 63, 68], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["impairment", "OBSERVATION", 85, 95], ["proteolysis", "OBSERVATION", 112, 123]]], ["Meanwhile, the quantitative western blot analyses confirmed a dramatic decline in the protein level of subunit Rpt5 of the 19S proteasome in HS-Csn8KO-GFPdgn livers ( Figure 3D, 3E) , indicating that UPS malfunction resulted from Csn8 deficiency in the liver is closely associated with the down regulation of a key subunit of the base of 19S proteasomes.Morphological characterization of HS-Csn8KO liversConsistent with protein accumulation resulting from impaired UPS function in HS-Csn8KO livers, immunohistochemistry examination revealed that Csn8-negative hepatocytes displayed striking enlargement in cell size and nuclear size, compared with those in the littermate CTL at 6 weeks of age ( Figure 4A ).", [["HS-Csn8KO-GFPdgn livers", "ANATOMY", 141, 164], ["liver", "ANATOMY", 253, 258], ["HS-Csn8KO livers", "ANATOMY", 388, 404], ["HS-Csn8KO livers", "ANATOMY", 481, 497], ["hepatocytes", "ANATOMY", 560, 571], ["cell", "ANATOMY", 606, 610], ["nuclear", "ANATOMY", 620, 627], ["Csn8", "CHEMICAL", 230, 234], ["Rpt5", "GENE_OR_GENE_PRODUCT", 111, 115], ["19S", "GENE_OR_GENE_PRODUCT", 123, 126], ["UPS", "GENE_OR_GENE_PRODUCT", 200, 203], ["Csn8", "GENE_OR_GENE_PRODUCT", 230, 234], ["liver", "ORGAN", 253, 258], ["19S proteasomes", "GENE_OR_GENE_PRODUCT", 338, 353], ["UPS", "GENE_OR_GENE_PRODUCT", 465, 468], ["livers", "ORGAN", 491, 497], ["Csn8", "GENE_OR_GENE_PRODUCT", 546, 550], ["hepatocytes", "CELL", 560, 571], ["cell", "CELL", 606, 610], ["nuclear", "CELLULAR_COMPONENT", 620, 627], ["subunit Rpt5", "PROTEIN", 103, 115], ["19S proteasome", "PROTEIN", 123, 137], ["UPS", "PROTEIN", 200, 203], ["Csn8", "PROTEIN", 230, 234], ["19S proteasomes", "PROTEIN", 338, 353], ["HS", "DNA", 388, 390], ["UPS", "PROTEIN", 465, 468], ["Csn8", "PROTEIN", 546, 550], ["negative hepatocytes", "CELL_TYPE", 551, 571], ["littermate CTL", "CELL_TYPE", 661, 675], ["the quantitative western blot analyses", "TEST", 11, 49], ["a dramatic decline", "PROBLEM", 60, 78], ["the protein level", "TEST", 82, 99], ["HS", "TEST", 141, 143], ["Csn8KO", "TEST", 144, 150], ["UPS malfunction", "PROBLEM", 200, 215], ["Csn8 deficiency in the liver", "PROBLEM", 230, 258], ["Morphological characterization", "TEST", 354, 384], ["HS", "TEST", 388, 390], ["protein accumulation", "PROBLEM", 420, 440], ["impaired UPS function", "PROBLEM", 456, 477], ["immunohistochemistry examination", "TEST", 499, 531], ["Csn8", "TEST", 546, 550], ["striking enlargement in cell size", "PROBLEM", 582, 615], ["dramatic", "OBSERVATION_MODIFIER", 62, 70], ["decline", "OBSERVATION_MODIFIER", 71, 78], ["livers", "ANATOMY", 158, 164], ["Csn8 deficiency", "OBSERVATION", 230, 245], ["liver", "ANATOMY", 253, 258], ["base", "ANATOMY_MODIFIER", 330, 334], ["19S proteasomes", "OBSERVATION", 338, 353], ["livers", "ANATOMY", 398, 404], ["protein accumulation", "OBSERVATION", 420, 440], ["impaired", "OBSERVATION_MODIFIER", 456, 464], ["UPS function", "OBSERVATION", 465, 477], ["livers", "ANATOMY", 491, 497], ["hepatocytes", "ANATOMY", 560, 571], ["striking", "OBSERVATION_MODIFIER", 582, 590], ["enlargement", "OBSERVATION", 591, 602], ["cell", "OBSERVATION_MODIFIER", 606, 610], ["size", "OBSERVATION_MODIFIER", 611, 615], ["nuclear", "OBSERVATION_MODIFIER", 620, 627], ["size", "OBSERVATION_MODIFIER", 628, 632]]], ["Toluidine blue stain of the semi-thin sections of resin-embedded liver tissue samples of 4-week-old mice revealed a large number of greenish granules or puncta in the cytoplasm of hepatocytes of HS-Csn8KO but not CTL livers ( Figure 4B ).Morphological characterization of HS-Csn8KO liversTransmission electron microscopy (TEM) of the liver tissue from 4-week-old CTL mice revealed that hepatocytes were enriched with mitochondria which were frequently associated with rough endoplasmic reticulum.", [["semi-thin sections", "ANATOMY", 28, 46], ["liver tissue samples", "ANATOMY", 65, 85], ["greenish granules", "ANATOMY", 132, 149], ["puncta", "ANATOMY", 153, 159], ["cytoplasm", "ANATOMY", 167, 176], ["hepatocytes", "ANATOMY", 180, 191], ["HS-Csn8KO", "ANATOMY", 195, 204], ["livers", "ANATOMY", 217, 223], ["HS-Csn8KO livers", "ANATOMY", 272, 288], ["liver tissue", "ANATOMY", 334, 346], ["hepatocytes", "ANATOMY", 386, 397], ["mitochondria", "ANATOMY", 417, 429], ["endoplasmic reticulum", "ANATOMY", 474, 495], ["Toluidine blue", "CHEMICAL", 0, 14], ["Toluidine blue", "CHEMICAL", 0, 14], ["Toluidine", "SIMPLE_CHEMICAL", 0, 9], ["semi-thin sections", "MULTI-TISSUE_STRUCTURE", 28, 46], ["liver tissue samples", "TISSUE", 65, 85], ["mice", "ORGANISM", 100, 104], ["granules", "ORGANISM_SUBSTANCE", 141, 149], ["puncta", "CELLULAR_COMPONENT", 153, 159], ["cytoplasm", "ORGANISM_SUBSTANCE", 167, 176], ["hepatocytes", "CELL", 180, 191], ["HS-Csn8KO", "CELL", 195, 204], ["CTL", "CELL", 213, 216], ["livers", "ORGAN", 217, 223], ["liver tissue", "TISSUE", 334, 346], ["CTL", "ORGANISM", 363, 366], ["mice", "ORGANISM", 367, 371], ["hepatocytes", "CELL", 386, 397], ["mitochondria", "CELLULAR_COMPONENT", 417, 429], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 474, 495], ["hepatocytes", "CELL_TYPE", 180, 191], ["HS", "DNA", 272, 274], ["hepatocytes", "CELL_TYPE", 386, 397], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 367, 371], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 367, 371], ["Toluidine blue stain", "TEST", 0, 20], ["greenish granules", "PROBLEM", 132, 149], ["puncta", "PROBLEM", 153, 159], ["Morphological characterization", "TEST", 238, 268], ["HS", "TEST", 272, 274], ["Transmission electron microscopy", "TEST", 288, 320], ["the liver tissue", "TEST", 330, 346], ["rough endoplasmic reticulum", "PROBLEM", 468, 495], ["liver", "ANATOMY", 65, 70], ["large", "OBSERVATION_MODIFIER", 116, 121], ["number", "OBSERVATION_MODIFIER", 122, 128], ["greenish granules", "OBSERVATION", 132, 149], ["puncta", "OBSERVATION", 153, 159], ["hepatocytes", "ANATOMY", 180, 191], ["livers", "ANATOMY", 217, 223], ["livers", "ANATOMY", 282, 288], ["liver", "ANATOMY", 334, 339], ["hepatocytes", "ANATOMY", 386, 397], ["endoplasmic reticulum", "OBSERVATION", 474, 495]]], ["The hepatocyte in CTL livers usually contained a centrally located sphere-shaped nucleus which displayed a smooth outline profile and a diameter of approximately 2\u00b5m.", [["hepatocyte", "ANATOMY", 4, 14], ["CTL livers", "ANATOMY", 18, 28], ["nucleus", "ANATOMY", 81, 88], ["hepatocyte", "CELL", 4, 14], ["livers", "ORGAN", 22, 28], ["nucleus", "CELLULAR_COMPONENT", 81, 88], ["The hepatocyte in CTL livers", "TEST", 0, 28], ["a centrally located sphere-shaped nucleus", "PROBLEM", 47, 88], ["hepatocyte", "ANATOMY", 4, 14], ["CTL", "ANATOMY_MODIFIER", 18, 21], ["livers", "ANATOMY", 22, 28], ["centrally", "OBSERVATION_MODIFIER", 49, 58], ["sphere", "OBSERVATION_MODIFIER", 67, 73], ["shaped nucleus", "OBSERVATION", 74, 88], ["smooth", "OBSERVATION_MODIFIER", 107, 113], ["outline", "OBSERVATION_MODIFIER", 114, 121], ["profile", "OBSERVATION_MODIFIER", 122, 129], ["diameter", "OBSERVATION_MODIFIER", 136, 144], ["approximately", "OBSERVATION_MODIFIER", 148, 161], ["2\u00b5m", "OBSERVATION_MODIFIER", 162, 165]]], ["Electron-lucent or -dense vacuoles and autophagosomes were rare in the hepatocytes of CTL livers ( Figure 5A , 5C).", [["vacuoles", "ANATOMY", 26, 34], ["autophagosomes", "ANATOMY", 39, 53], ["hepatocytes", "ANATOMY", 71, 82], ["CTL livers", "ANATOMY", 86, 96], ["dense vacuoles", "CELLULAR_COMPONENT", 20, 34], ["autophagosomes", "CELLULAR_COMPONENT", 39, 53], ["hepatocytes", "CELL", 71, 82], ["livers", "ORGAN", 90, 96], ["hepatocytes", "CELL_TYPE", 71, 82], ["Electron", "TEST", 0, 8], ["lucent or -dense vacuoles", "PROBLEM", 9, 34], ["autophagosomes", "PROBLEM", 39, 53], ["lucent", "OBSERVATION_MODIFIER", 9, 15], ["dense", "OBSERVATION_MODIFIER", 20, 25], ["vacuoles", "OBSERVATION", 26, 34], ["autophagosomes", "OBSERVATION", 39, 53], ["rare", "OBSERVATION_MODIFIER", 59, 63], ["hepatocytes", "ANATOMY", 71, 82], ["CTL livers", "OBSERVATION", 86, 96]]], ["In HS-Csn8KO mice, however, the nucleus of hepatocytes was markedly enlarged and lost its normal spherical shape.", [["nucleus", "ANATOMY", 32, 39], ["hepatocytes", "ANATOMY", 43, 54], ["HS-Csn8KO mice", "ORGANISM", 3, 17], ["nucleus", "CELLULAR_COMPONENT", 32, 39], ["hepatocytes", "CELL", 43, 54], ["hepatocytes", "CELL_TYPE", 43, 54], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["markedly enlarged", "PROBLEM", 59, 76], ["nucleus", "ANATOMY_MODIFIER", 32, 39], ["hepatocytes", "ANATOMY", 43, 54], ["markedly", "OBSERVATION_MODIFIER", 59, 67], ["enlarged", "OBSERVATION", 68, 76], ["normal", "OBSERVATION_MODIFIER", 90, 96], ["spherical", "OBSERVATION_MODIFIER", 97, 106], ["shape", "OBSERVATION_MODIFIER", 107, 112]]], ["The outline of the nuclear envelop became rather rough and cytoplasmic invaginations resulting cytoplasmic inclusions were sometimes seen in the nuclear territory ( Figure 5B ).", [["nuclear", "ANATOMY", 19, 26], ["cytoplasmic invaginations", "ANATOMY", 59, 84], ["cytoplasmic", "ANATOMY", 95, 106], ["nuclear territory", "ANATOMY", 145, 162], ["nuclear", "CELLULAR_COMPONENT", 19, 26], ["cytoplasmic invaginations", "CELLULAR_COMPONENT", 59, 84], ["cytoplasmic", "ORGANISM_SUBSTANCE", 95, 106], ["cytoplasmic invaginations", "PROBLEM", 59, 84], ["cytoplasmic inclusions", "PROBLEM", 95, 117], ["cytoplasmic", "OBSERVATION_MODIFIER", 59, 70], ["invaginations", "OBSERVATION_MODIFIER", 71, 84], ["cytoplasmic inclusions", "OBSERVATION", 95, 117], ["nuclear territory", "ANATOMY", 145, 162]]], ["In HS-Csn8KO livers, a prominent feature is the presence of a large number of electron-lucent vacuoles of various sizes (diameter ranging from 0.2\u00b5m to 0.8\u00b5m) in the majority of hepatocytes.", [["HS-Csn8KO livers", "ANATOMY", 3, 19], ["vacuoles", "ANATOMY", 94, 102], ["hepatocytes", "ANATOMY", 178, 189], ["livers", "ORGAN", 13, 19], ["vacuoles", "CELLULAR_COMPONENT", 94, 102], ["hepatocytes", "CELL", 178, 189], ["hepatocytes", "CELL_TYPE", 178, 189], ["diameter", "TEST", 121, 129], ["livers", "ANATOMY", 13, 19], ["prominent", "OBSERVATION_MODIFIER", 23, 32], ["large", "OBSERVATION_MODIFIER", 62, 67], ["number", "OBSERVATION_MODIFIER", 68, 74], ["lucent", "OBSERVATION_MODIFIER", 87, 93], ["vacuoles", "OBSERVATION", 94, 102], ["various", "OBSERVATION_MODIFIER", 106, 113], ["sizes", "OBSERVATION_MODIFIER", 114, 119], ["diameter", "OBSERVATION_MODIFIER", 121, 129], ["majority", "ANATOMY_MODIFIER", 166, 174], ["hepatocytes", "ANATOMY", 178, 189]]], ["Electron dense vacuoles with a diameter of approximately 0.2\u00b5m were also more frequently observed in HS-Csn8KO than in CTL hepatocytes.", [["vacuoles", "ANATOMY", 15, 23], ["CTL hepatocytes", "ANATOMY", 119, 134], ["vacuoles", "CELLULAR_COMPONENT", 15, 23], ["HS-Csn8KO", "GENE_OR_GENE_PRODUCT", 101, 110], ["CTL hepatocytes", "CELL", 119, 134], ["Csn8KO", "CELL_LINE", 104, 110], ["CTL hepatocytes", "CELL_TYPE", 119, 134], ["Electron dense vacuoles", "PROBLEM", 0, 23], ["HS", "TEST", 101, 103], ["dense", "OBSERVATION_MODIFIER", 9, 14], ["vacuoles", "OBSERVATION", 15, 23], ["diameter", "OBSERVATION_MODIFIER", 31, 39], ["hepatocytes", "ANATOMY", 123, 134]]], ["Large inclusion body-like (IBL) structures full of homogenous dense fine granules were present in a subpopulation of hepatocytes in HS-Csn8KO livers.", [["body", "ANATOMY", 16, 20], ["fine granules", "ANATOMY", 68, 81], ["hepatocytes", "ANATOMY", 117, 128], ["HS-Csn8KO livers", "ANATOMY", 132, 148], ["granules", "ORGANISM_SUBSTANCE", 73, 81], ["hepatocytes", "CELL", 117, 128], ["livers", "ORGAN", 142, 148], ["hepatocytes", "CELL_TYPE", 117, 128], ["Large inclusion body-like (IBL) structures", "PROBLEM", 0, 42], ["homogenous dense fine granules", "PROBLEM", 51, 81], ["inclusion body", "OBSERVATION", 6, 20], ["homogenous", "OBSERVATION_MODIFIER", 51, 61], ["dense", "OBSERVATION_MODIFIER", 62, 67], ["fine", "OBSERVATION_MODIFIER", 68, 72], ["granules", "OBSERVATION", 73, 81], ["subpopulation", "OBSERVATION_MODIFIER", 100, 113], ["hepatocytes", "ANATOMY", 117, 128], ["livers", "ANATOMY", 142, 148]]], ["Some of the IBL structures appeared to be membrane-bound ( Figure 5D ) but others were not ( Figure 5E) ; both often showed a clear boundary from their surroundings.", [["membrane", "ANATOMY", 42, 50], ["IBL", "GENE_OR_GENE_PRODUCT", 12, 15], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["IBL", "PROTEIN", 12, 15], ["the IBL structures", "PROBLEM", 8, 26], ["IBL", "OBSERVATION", 12, 15], ["clear", "OBSERVATION", 126, 131]]], ["In addition, multi-layered myelin-like structures ( Figure 5B ) and autophagosome-like structures of various stages ( Figure 5F ) were also observed in HS-Csn8KO hepatocytes.", [["myelin-like structures", "ANATOMY", 27, 49], ["autophagosome-like structures", "ANATOMY", 68, 97], ["HS-Csn8KO hepatocytes", "ANATOMY", 152, 173], ["autophagosome", "CELLULAR_COMPONENT", 68, 81], ["HS-Csn8KO hepatocytes", "CELL", 152, 173], ["HS-Csn8KO hepatocytes", "CELL_LINE", 152, 173], ["multi-layered myelin-like structures ( Figure 5B )", "PROBLEM", 13, 63], ["autophagosome-like structures of various stages", "PROBLEM", 68, 115], ["multi-layered", "OBSERVATION_MODIFIER", 13, 26], ["myelin", "OBSERVATION", 27, 33], ["various stages", "OBSERVATION_MODIFIER", 101, 115], ["hepatocytes", "ANATOMY", 162, 173]]], ["TEM feature of apoptosis was also observed in HS-Csn8KO livers (data not shown).Temporal changes in apoptosis in HS-Csn8KO mouse liversWe have previously reported massive apoptosis in the liver of HS-Csn8KO mice at 4 weeks of age [19] .", [["HS-Csn8KO livers", "ANATOMY", 46, 62], ["livers", "ANATOMY", 129, 135], ["liver", "ANATOMY", 188, 193], ["livers", "ORGAN", 56, 62], ["mouse", "ORGANISM", 123, 128], ["livers", "ORGAN", 129, 135], ["liver", "ORGAN", 188, 193], ["mice", "ORGANISM", 207, 211], ["mouse", "SPECIES", 123, 128], ["mice", "SPECIES", 207, 211], ["mouse", "SPECIES", 123, 128], ["apoptosis", "PROBLEM", 15, 24], ["Temporal changes in apoptosis in HS", "PROBLEM", 80, 115], ["massive apoptosis", "PROBLEM", 163, 180], ["apoptosis", "OBSERVATION", 15, 24], ["livers", "ANATOMY", 56, 62], ["apoptosis", "OBSERVATION", 100, 109], ["livers", "ANATOMY", 129, 135], ["massive", "OBSERVATION_MODIFIER", 163, 170], ["apoptosis", "OBSERVATION", 171, 180], ["liver", "ANATOMY", 188, 193]]], ["Our previous characterization of this HS-Csn8KO mouse model has revealed that the depletion of Csn8 protein starts in between postnatal week 1 and 2 and a significant decrease of Csn8 protein is evidenced at week 2 [19] .", [["HS", "GENE_OR_GENE_PRODUCT", 38, 40], ["mouse", "ORGANISM", 48, 53], ["Csn8", "GENE_OR_GENE_PRODUCT", 95, 99], ["Csn8", "GENE_OR_GENE_PRODUCT", 179, 183], ["Csn8 protein", "PROTEIN", 95, 107], ["Csn8 protein", "PROTEIN", 179, 191], ["mouse", "SPECIES", 48, 53], ["mouse", "SPECIES", 48, 53], ["this HS", "TEST", 33, 40], ["the depletion of Csn8 protein", "PROBLEM", 78, 107], ["a significant decrease of Csn8 protein", "PROBLEM", 153, 191], ["depletion", "OBSERVATION", 82, 91], ["significant", "OBSERVATION_MODIFIER", 155, 166], ["decrease", "OBSERVATION_MODIFIER", 167, 175]]], ["Hence, we characterized in the present study the time course of hepatocyte apoptosis in HS-Csn8KO mice during the first 6 weeks after birth.", [["hepatocyte", "ANATOMY", 64, 74], ["hepatocyte", "CELL", 64, 74], ["mice", "ORGANISM", 98, 102], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["hepatocyte apoptosis", "PROBLEM", 64, 84], ["hepatocyte", "ANATOMY", 64, 74], ["apoptosis", "OBSERVATION", 75, 84]]], ["We observed that hepatocyte apoptosis, as revealed TUNEL assays, was significantly increased at week 2, peaked at week 3, and remained at a significantly increased level at 4 and 6 weeks Notably, we have previously observed cardiomyocyte massive necrosis in cardiomyocyte-restricted Csn8KO mice produced using the same Csn8-floxed allele [17] ; however, the same in vivo Evans blue dye permeability assay as we used in cardiac Csn8KO mice [17] , showed no discernible increases in hepatocyte membrane permeability in the HS-Csn8KO mice atIncreased expression of the Bcl2 family members in HS-Csb8KO liversIn the regulation of apoptosis, the Bcl2 family proteins play a critical role in response to specific stress signals either to promote or to inhibit cell death.", [["hepatocyte", "ANATOMY", 17, 27], ["cardiomyocyte", "ANATOMY", 224, 237], ["cardiomyocyte", "ANATOMY", 258, 271], ["cardiac", "ANATOMY", 419, 426], ["hepatocyte membrane", "ANATOMY", 481, 500], ["HS-Csb8KO livers", "ANATOMY", 589, 605], ["cell", "ANATOMY", 754, 758], ["necrosis", "DISEASE", 246, 254], ["death", "DISEASE", 759, 764], ["hepatocyte", "CELL", 17, 27], ["cardiomyocyte", "CELL", 224, 237], ["cardiomyocyte", "CELL", 258, 271], ["Csn8KO", "ORGANISM", 283, 289], ["mice", "ORGANISM", 290, 294], ["Csn8", "GENE_OR_GENE_PRODUCT", 319, 323], ["Evans blue dye", "SIMPLE_CHEMICAL", 371, 385], ["mice", "ORGANISM", 434, 438], ["hepatocyte membrane", "CELLULAR_COMPONENT", 481, 500], ["mice", "ORGANISM", 531, 535], ["Bcl2", "GENE_OR_GENE_PRODUCT", 566, 570], ["Bcl2", "GENE_OR_GENE_PRODUCT", 641, 645], ["cell", "CELL", 754, 758], ["Csn8", "PROTEIN", 319, 323], ["Bcl2 family members", "PROTEIN", 566, 585], ["Bcl2 family proteins", "PROTEIN", 641, 661], ["mice", "SPECIES", 290, 294], ["mice", "SPECIES", 434, 438], ["mice", "SPECIES", 531, 535], ["mice", "SPECIES", 531, 535], ["hepatocyte apoptosis", "TEST", 17, 37], ["TUNEL assays", "TEST", 51, 63], ["cardiomyocyte massive necrosis", "PROBLEM", 224, 254], ["cardiomyocyte", "TEST", 258, 271], ["discernible increases in hepatocyte membrane permeability", "PROBLEM", 456, 513], ["apoptosis", "PROBLEM", 626, 635], ["cell death", "PROBLEM", 754, 764], ["hepatocyte", "ANATOMY", 17, 27], ["apoptosis", "OBSERVATION", 28, 37], ["TUNEL assays", "OBSERVATION", 51, 63], ["significantly", "OBSERVATION_MODIFIER", 69, 82], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["cardiomyocyte", "ANATOMY", 224, 237], ["massive", "OBSERVATION_MODIFIER", 238, 245], ["necrosis", "OBSERVATION", 246, 254], ["cardiomyocyte", "ANATOMY", 258, 271], ["no discernible", "UNCERTAINTY", 453, 467], ["increases", "OBSERVATION_MODIFIER", 468, 477], ["hepatocyte membrane permeability", "OBSERVATION", 481, 513], ["livers", "ANATOMY", 599, 605], ["apoptosis", "OBSERVATION", 626, 635]]], ["Thus, we examined the expression of pro-apoptotic Bcl2 family proteins in HS-Csn8KO livers.", [["HS-Csn8KO livers", "ANATOMY", 74, 90], ["Bcl2", "GENE_OR_GENE_PRODUCT", 50, 54], ["pro-apoptotic Bcl2 family proteins", "PROTEIN", 36, 70], ["livers", "ANATOMY", 84, 90]]], ["We found that the protein levels of BH3-only protein Bim-EL and Bim-L were significantly upregulated ( Figure 7A , 7B) and the multi-domain pro-apoptotic protein Bax was also expressed at a higher level compared with that in the CTL group ( Figure 7A, 7C) .", [["CTL", "ANATOMY", 229, 232], ["BH3", "GENE_OR_GENE_PRODUCT", 36, 39], ["Bim-EL", "GENE_OR_GENE_PRODUCT", 53, 59], ["Bim-L", "GENE_OR_GENE_PRODUCT", 64, 69], ["Bax", "GENE_OR_GENE_PRODUCT", 162, 165], ["BH3", "PROTEIN", 36, 39], ["Bim", "PROTEIN", 53, 56], ["EL", "PROTEIN", 57, 59], ["Bim", "PROTEIN", 64, 67], ["L", "PROTEIN", 68, 69], ["multi-domain pro-apoptotic protein", "PROTEIN", 127, 161], ["Bax", "PROTEIN", 162, 165], ["the protein levels", "TEST", 14, 32], ["BH3", "TEST", 36, 39], ["protein Bim", "TEST", 45, 56], ["Bim", "TEST", 64, 67], ["Figure 7A", "TEST", 103, 112], ["the multi-domain pro-apoptotic protein Bax", "TEST", 123, 165], ["protein Bax", "OBSERVATION", 154, 165]]], ["Likewise, the protein abundance of antiapoptotic family members Bcl2 and Bcl-XL was elevated in HS-Csn8KO livers ( Figure 7A, 7D) .", [["HS-Csn8KO livers", "ANATOMY", 96, 112], ["Bcl2", "GENE_OR_GENE_PRODUCT", 64, 68], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 73, 79], ["antiapoptotic family members", "PROTEIN", 35, 63], ["Bcl2", "PROTEIN", 64, 68], ["Bcl", "PROTEIN", 73, 76], ["Bcl2", "TEST", 64, 68], ["Bcl", "TEST", 73, 76], ["elevated", "PROBLEM", 84, 92], ["livers", "ANATOMY", 106, 112]]], ["These findings imply that disequilibrium or altered interaction between the pro-apoptotic and anti-apoptotic proteins of the Bcl2 family might be involved in Csn8 deficiency-induced hepatocyte apoptosis, prompting us to examine their interactions (see below, Figure 8 ).Increased interaction between Bim-EL and Bcl2 in HS-Csn8KO liversActivation and polymerization of Bax and/or Bad constitute a critical step in the mitochondrial pathway of apoptosis.", [["hepatocyte", "ANATOMY", 182, 192], ["HS-Csn8KO livers", "ANATOMY", 319, 335], ["mitochondrial", "ANATOMY", 417, 430], ["Bcl2", "GENE_OR_GENE_PRODUCT", 125, 129], ["Csn8", "GENE_OR_GENE_PRODUCT", 158, 162], ["hepatocyte", "CELL", 182, 192], ["Bim-EL", "GENE_OR_GENE_PRODUCT", 300, 306], ["Bcl2", "GENE_OR_GENE_PRODUCT", 311, 315], ["Bax", "GENE_OR_GENE_PRODUCT", 368, 371], ["Bad", "GENE_OR_GENE_PRODUCT", 379, 382], ["mitochondrial", "CELLULAR_COMPONENT", 417, 430], ["pro-apoptotic and anti-apoptotic proteins", "PROTEIN", 76, 117], ["Bcl2 family", "PROTEIN", 125, 136], ["Csn8", "PROTEIN", 158, 162], ["Bim", "PROTEIN", 300, 303], ["EL", "PROTEIN", 304, 306], ["Bcl2", "PROTEIN", 311, 315], ["Bax", "PROTEIN", 368, 371], ["Bad", "PROTEIN", 379, 382], ["disequilibrium", "PROBLEM", 26, 40], ["altered interaction", "PROBLEM", 44, 63], ["Csn8 deficiency", "PROBLEM", 158, 173], ["hepatocyte apoptosis", "PROBLEM", 182, 202], ["Increased interaction", "PROBLEM", 270, 291], ["Bax", "TREATMENT", 368, 371], ["apoptosis", "PROBLEM", 442, 451], ["hepatocyte apoptosis", "OBSERVATION", 182, 202], ["livers", "ANATOMY", 329, 335], ["apoptosis", "OBSERVATION", 442, 451]]], ["The mechanism by which BH3-only protein Bim activates Bax remains a matter of active debate.", [["BH3", "GENE_OR_GENE_PRODUCT", 23, 26], ["Bim", "GENE_OR_GENE_PRODUCT", 40, 43], ["Bax", "GENE_OR_GENE_PRODUCT", 54, 57], ["BH3", "PROTEIN", 23, 26], ["Bim", "PROTEIN", 40, 43], ["Bax", "PROTEIN", 54, 57], ["BH3", "TEST", 23, 26]]], ["One possibility is the neutralization of anti-apoptotic Bcl2 family members that releases Bax from the anti-apoptotic complex and the other is for Bim to bind directly and activate Bax [23] [24] [25] .", [["Bcl2", "GENE_OR_GENE_PRODUCT", 56, 60], ["Bax", "GENE_OR_GENE_PRODUCT", 90, 93], ["Bim", "GENE_OR_GENE_PRODUCT", 147, 150], ["Bax", "GENE_OR_GENE_PRODUCT", 181, 184], ["anti-apoptotic Bcl2 family members", "PROTEIN", 41, 75], ["Bax", "PROTEIN", 90, 93], ["anti-apoptotic complex", "PROTEIN", 103, 125], ["Bim", "PROTEIN", 147, 150]]], ["To gain insight into the mechanism of BH3-only protein Bim-induced apoptosis and its interactions with other Bcl2 family members, we performed reciprocal immunoprecipitation experiments to determine whether Bim directly or indirectly activates Bax.", [["BH3", "GENE_OR_GENE_PRODUCT", 38, 41], ["Bim-", "GENE_OR_GENE_PRODUCT", 55, 59], ["Bcl2", "GENE_OR_GENE_PRODUCT", 109, 113], ["Bim", "GENE_OR_GENE_PRODUCT", 207, 210], ["Bax", "GENE_OR_GENE_PRODUCT", 244, 247], ["BH3", "PROTEIN", 38, 41], ["protein Bim-", "PROTEIN", 47, 59], ["Bcl2 family members", "PROTEIN", 109, 128], ["Bim", "PROTEIN", 207, 210], ["Bax", "PROTEIN", 244, 247], ["BH3", "TEST", 38, 41], ["protein Bim-induced apoptosis", "PROBLEM", 47, 76], ["reciprocal immunoprecipitation experiments", "TREATMENT", 143, 185]]], ["First, we used the Bim antibody to pull down Bim proteins from the crude protein extracts of HS-Csn8KO livers.", [["extracts", "ANATOMY", 81, 89], ["livers", "ANATOMY", 103, 109], ["Bim", "GENE_OR_GENE_PRODUCT", 19, 22], ["Bim", "GENE_OR_GENE_PRODUCT", 45, 48], ["extracts", "ORGANISM_SUBSTANCE", 81, 89], ["livers", "ORGAN", 103, 109], ["Bim antibody", "PROTEIN", 19, 31], ["Bim proteins", "PROTEIN", 45, 57], ["the Bim antibody", "TREATMENT", 15, 31], ["Bim proteins", "TREATMENT", 45, 57], ["livers", "ANATOMY", 103, 109]]], ["The immunoprecipitated Bim-containing protein complexes were then probed with antibodies against Bcl2, Bcl-XL, or Bax by western blotting, respectively.", [["Bcl2", "GENE_OR_GENE_PRODUCT", 97, 101], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 103, 109], ["Bax", "GENE_OR_GENE_PRODUCT", 114, 117], ["immunoprecipitated Bim-containing protein complexes", "PROTEIN", 4, 55], ["Bcl2", "PROTEIN", 97, 101], ["Bcl", "PROTEIN", 103, 106], ["Bax", "PROTEIN", 114, 117], ["The immunoprecipitated Bim-containing protein complexes", "PROBLEM", 0, 55], ["antibodies", "TEST", 78, 88], ["Bcl2", "TEST", 97, 101], ["Bcl", "TEST", 103, 106], ["Bax", "TREATMENT", 114, 117], ["protein complexes", "OBSERVATION", 38, 55]]], ["As shown in Figure 8A and 8B, anti-apoptotic protein Bcl2 but not Bcl-xL was coimmunoprecipitated with Bim, indicating that Bim preferentially binds to Bcl2 in HS-Csn8KO hepatocytes.", [["HS-Csn8KO hepatocytes", "ANATOMY", 160, 181], ["Bcl2", "GENE_OR_GENE_PRODUCT", 53, 57], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 66, 72], ["Bim", "GENE_OR_GENE_PRODUCT", 103, 106], ["Bim", "GENE_OR_GENE_PRODUCT", 124, 127], ["Bcl2", "GENE_OR_GENE_PRODUCT", 152, 156], ["HS-Csn8KO hepatocytes", "CELL", 160, 181], ["Figure 8A and 8B", "PROTEIN", 12, 28], ["anti-apoptotic protein", "PROTEIN", 30, 52], ["Bcl2", "PROTEIN", 53, 57], ["Bcl-xL", "PROTEIN", 66, 72], ["Bim", "PROTEIN", 103, 106], ["Bim", "PROTEIN", 124, 127], ["Bcl2", "PROTEIN", 152, 156], ["HS-Csn8KO hepatocytes", "CELL_LINE", 160, 181], ["anti-apoptotic protein Bcl2", "TEST", 30, 57], ["Bcl-xL", "PROBLEM", 66, 72], ["Bim", "PROBLEM", 103, 106], ["Bcl2 in HS", "TEST", 152, 162], ["hepatocytes", "ANATOMY", 170, 181]]], ["No Bax was detected in the Bim-precipitated complexes, which indicates that Bim does not bind directly to Bax in this case.", [["Bax", "GENE_OR_GENE_PRODUCT", 3, 6], ["Bim", "GENE_OR_GENE_PRODUCT", 76, 79], ["Bax", "GENE_OR_GENE_PRODUCT", 106, 109], ["Bax", "PROTEIN", 3, 6], ["Bim-precipitated complexes", "PROTEIN", 27, 53], ["Bim", "PROTEIN", 76, 79], ["Bax", "PROTEIN", 106, 109], ["Bax", "PROBLEM", 3, 6], ["Bax", "OBSERVATION", 3, 6]]], ["Second, the antibody against Bcl2 was used to pull down the respective protein complexes, which were then immunobloted for Bim and Bax ( Figure 8C and 8D) .", [["Bcl2", "GENE_OR_GENE_PRODUCT", 29, 33], ["Bim", "GENE_OR_GENE_PRODUCT", 123, 126], ["Bax", "GENE_OR_GENE_PRODUCT", 131, 134], ["Bcl2", "PROTEIN", 29, 33], ["protein complexes", "PROTEIN", 71, 88], ["Bim", "PROTEIN", 123, 126], ["Bax", "PROTEIN", 131, 134], ["the antibody", "TEST", 8, 20], ["Bcl2", "TEST", 29, 33], ["Bim", "PROBLEM", 123, 126], ["Bax", "TEST", 131, 134]]], ["The results showed that Bim-EL not Bax was co-immunoprecipitated with Bcl2, which further confirmed that Bim most likely activates indirectly Bax via binding and engaging anti-apoptotic protein Bcl2.", [["Bim", "GENE_OR_GENE_PRODUCT", 24, 27], ["Bax", "GENE_OR_GENE_PRODUCT", 35, 38], ["Bcl2", "GENE_OR_GENE_PRODUCT", 70, 74], ["Bim", "GENE_OR_GENE_PRODUCT", 105, 108], ["Bax", "GENE_OR_GENE_PRODUCT", 142, 145], ["Bcl2", "GENE_OR_GENE_PRODUCT", 194, 198], ["Bim", "PROTEIN", 24, 27], ["EL", "PROTEIN", 28, 30], ["Bax", "PROTEIN", 35, 38], ["Bcl2", "PROTEIN", 70, 74], ["Bim", "PROTEIN", 105, 108], ["Bax", "PROTEIN", 142, 145], ["anti-apoptotic protein", "PROTEIN", 171, 193], ["Bcl2", "PROTEIN", 194, 198], ["Bcl2", "PROBLEM", 70, 74], ["Bim", "PROBLEM", 105, 108], ["engaging anti-apoptotic protein Bcl2", "TREATMENT", 162, 198], ["protein Bcl2", "OBSERVATION", 186, 198]]], ["Lastly, we also employed Bax antibodies for immunoprecipitation.", [["Bax", "GENE_OR_GENE_PRODUCT", 25, 28], ["Bax antibodies", "PROTEIN", 25, 39], ["Bax antibodies", "TREATMENT", 25, 39], ["immunoprecipitation", "PROBLEM", 44, 63]]], ["Bim was nearly undetectable in Bax-containing protein complexes from Csn8KO livers ( Figure 8E ).", [["Csn8KO livers", "ANATOMY", 69, 82], ["Bim", "GENE_OR_GENE_PRODUCT", 0, 3], ["livers", "ORGAN", 76, 82], ["Bim", "PROTEIN", 0, 3], ["Bax-containing protein complexes", "PROTEIN", 31, 63], ["undetectable", "OBSERVATION_MODIFIER", 15, 27], ["protein complexes", "OBSERVATION", 46, 63], ["livers", "ANATOMY", 76, 82]]], ["Thus, our results do not support a direct interaction between Bim and Bax, but rather suggest the exclusive binding of Bim with Bcl2 for the indirect activation of pro-apoptotic protein Bax to trigger apoptosis in HS-Csn8KO livers.DiscussionA growing body of evidence indicates that the CSN is involved in the regulation of a variety of cellular processes including development [37] [38] [39] , cell cycle progression [40, 41] , DNA damage checkpoint [42] , and immune responses [16, 43, 44] .", [["HS-Csn8KO livers", "ANATOMY", 214, 230], ["cellular", "ANATOMY", 337, 345], ["cell", "ANATOMY", 395, 399], ["Bim", "GENE_OR_GENE_PRODUCT", 62, 65], ["Bax", "GENE_OR_GENE_PRODUCT", 70, 73], ["Bim", "GENE_OR_GENE_PRODUCT", 119, 122], ["Bcl2", "GENE_OR_GENE_PRODUCT", 128, 132], ["Bax", "GENE_OR_GENE_PRODUCT", 186, 189], ["livers", "ORGAN", 224, 230], ["CSN", "GENE_OR_GENE_PRODUCT", 287, 290], ["cellular", "CELL", 337, 345], ["cell", "CELL", 395, 399], ["DNA", "CELLULAR_COMPONENT", 429, 432], ["Bim", "PROTEIN", 62, 65], ["Bax", "PROTEIN", 70, 73], ["Bim", "PROTEIN", 119, 122], ["Bcl2", "PROTEIN", 128, 132], ["pro-apoptotic protein", "PROTEIN", 164, 185], ["Bax", "PROTEIN", 186, 189], ["CSN", "PROTEIN", 287, 290], ["Bim and Bax", "TREATMENT", 62, 73], ["Bcl2", "TREATMENT", 128, 132], ["pro-apoptotic protein Bax", "TREATMENT", 164, 189], ["apoptosis", "PROBLEM", 201, 210], ["cell cycle progression", "TEST", 395, 417], ["DNA damage checkpoint", "TEST", 429, 450], ["immune responses", "TEST", 462, 478], ["livers", "ANATOMY", 224, 230]]], ["The most studied functions of the CSN are its roles in the regulation of ubiquitination via its deneddylation activity toward CRLs.", [["CSN", "GENE_OR_GENE_PRODUCT", 34, 37], ["CRLs", "GENE_OR_GENE_PRODUCT", 126, 130], ["CSN", "PROTEIN", 34, 37], ["CRLs", "PROTEIN", 126, 130]]], ["Previous studies with cardiomyocyte-or hepatocyte-restricted Csn8KO in mice have revealed that Csn8 is essential for the cell survival and the functioning of the heart and livers [17] [18] [19] .", [["cardiomyocyte", "ANATOMY", 22, 35], ["hepatocyte", "ANATOMY", 39, 49], ["cell", "ANATOMY", 121, 125], ["heart", "ANATOMY", 162, 167], ["livers", "ANATOMY", 172, 178], ["cardiomyocyte", "CELL", 22, 35], ["hepatocyte", "CELL", 39, 49], ["Csn8KO", "GENE_OR_GENE_PRODUCT", 61, 67], ["mice", "ORGANISM", 71, 75], ["Csn8", "GENE_OR_GENE_PRODUCT", 95, 99], ["cell", "CELL", 121, 125], ["heart", "ORGAN", 162, 167], ["livers", "ORGAN", 172, 178], ["Csn8KO", "PROTEIN", 61, 67], ["Csn8", "PROTEIN", 95, 99], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["Previous studies", "TEST", 0, 16], ["cardiomyocyte", "TEST", 22, 35], ["hepatocyte", "TEST", 39, 49], ["the cell survival", "TREATMENT", 117, 134], ["cardiomyocyte", "ANATOMY", 22, 35], ["hepatocyte", "ANATOMY", 39, 49], ["cell survival", "OBSERVATION", 121, 134], ["heart", "ANATOMY", 162, 167], ["livers", "ANATOMY", 172, 178]]], ["Csn8 is required for UPS function in the perinatal heart (a post-mitotic organ) but this has not been examined in a mitotic organ.", [["heart", "ANATOMY", 51, 56], ["organ", "ANATOMY", 73, 78], ["organ", "ANATOMY", 124, 129], ["Csn8", "GENE_OR_GENE_PRODUCT", 0, 4], ["UPS", "GENE_OR_GENE_PRODUCT", 21, 24], ["heart", "ORGAN", 51, 56], ["organ", "ORGAN", 73, 78], ["organ", "ORGAN", 124, 129], ["Csn8", "PROTEIN", 0, 4], ["UPS", "PROTEIN", 21, 24], ["UPS function", "TEST", 21, 33], ["perinatal heart", "ANATOMY", 41, 56], ["post-mitotic organ", "OBSERVATION", 60, 78]]], ["In the present study, we investigated the effect of HS-Csn8KO on UPS function in livers and explored the potential molecular pathway through which hepatocyte apoptosis is activated by Csn8 deficiency.", [["livers", "ANATOMY", 81, 87], ["hepatocyte", "ANATOMY", 147, 157], ["Csn8", "CHEMICAL", 184, 188], ["HS-Csn8KO", "GENE_OR_GENE_PRODUCT", 52, 61], ["UPS", "GENE_OR_GENE_PRODUCT", 65, 68], ["livers", "ORGAN", 81, 87], ["hepatocyte", "CELL", 147, 157], ["Csn8", "GENE_OR_GENE_PRODUCT", 184, 188], ["Csn8KO", "PROTEIN", 55, 61], ["UPS", "PROTEIN", 65, 68], ["Csn8", "PROTEIN", 184, 188], ["HS", "TEST", 52, 54], ["hepatocyte apoptosis", "PROBLEM", 147, 167], ["Csn8 deficiency", "PROBLEM", 184, 199], ["livers", "ANATOMY", 81, 87], ["hepatocyte", "ANATOMY", 147, 157], ["apoptosis", "OBSERVATION", 158, 167]]], ["Our results reveal that the conditional targeting of the csn8 gene in hepatocytes perturbs the UPS and leads to the impairment of UPS proteolytic function.", [["hepatocytes", "ANATOMY", 70, 81], ["csn8", "GENE_OR_GENE_PRODUCT", 57, 61], ["hepatocytes", "CELL", 70, 81], ["UPS", "GENE_OR_GENE_PRODUCT", 95, 98], ["UPS", "GENE_OR_GENE_PRODUCT", 130, 133], ["csn8 gene", "DNA", 57, 66], ["hepatocytes", "CELL_TYPE", 70, 81], ["UPS", "PROTEIN", 95, 98], ["UPS", "PROTEIN", 130, 133], ["hepatocytes", "ANATOMY", 70, 81]]], ["Our data further suggest that the UPS impairment is associated with increased hepatocyte apoptosis and the latter is likely activated via a Bim-mediated proapoptotic signaling pathway.", [["hepatocyte", "ANATOMY", 78, 88], ["UPS impairment", "DISEASE", 34, 48], ["UPS", "GENE_OR_GENE_PRODUCT", 34, 37], ["hepatocyte", "CELL", 78, 88], ["UPS", "PROTEIN", 34, 37], ["Our data", "TEST", 0, 8], ["the UPS impairment", "PROBLEM", 30, 48], ["increased hepatocyte apoptosis", "PROBLEM", 68, 98], ["a Bim-mediated proapoptotic signaling pathway", "TREATMENT", 138, 183], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["hepatocyte apoptosis", "OBSERVATION", 78, 98]]], ["Liver CSN8 KnockoutCsn8 deficiency causes UPS derangementPrevious studies have demonstrated that Csn8 is required for the formation of the CSN holocomplex and the bona fide cullin deneddylation activity of the CSN in mammals [16, 17, 19] .", [["Liver", "ANATOMY", 0, 5], ["CSN holocomplex", "ANATOMY", 139, 154], ["UPS derangement", "DISEASE", 42, 57], ["Liver", "ORGAN", 0, 5], ["Csn8", "GENE_OR_GENE_PRODUCT", 97, 101], ["CSN", "GENE_OR_GENE_PRODUCT", 139, 142], ["cullin", "GENE_OR_GENE_PRODUCT", 173, 179], ["CSN", "GENE_OR_GENE_PRODUCT", 210, 213], ["CSN8", "PROTEIN", 6, 10], ["Csn8", "PROTEIN", 97, 101], ["CSN holocomplex", "PROTEIN", 139, 154], ["cullin", "PROTEIN", 173, 179], ["CSN", "PROTEIN", 210, 213], ["KnockoutCsn8 deficiency", "PROBLEM", 11, 34], ["UPS derangement", "PROBLEM", 42, 57], ["Previous studies", "TEST", 57, 73], ["KnockoutCsn8 deficiency", "OBSERVATION", 11, 34], ["cullin deneddylation", "OBSERVATION", 173, 193]]], ["CSN regulation of CRLs has long been believed to depend on CSN deneddylase activity but additional mechanisms independent of deneddylation were also suggested by recent reports [14, 45] .", [["CSN", "GENE_OR_GENE_PRODUCT", 0, 3], ["CRLs", "GENE_OR_GENE_PRODUCT", 18, 22], ["CSN", "GENE_OR_GENE_PRODUCT", 59, 62], ["CSN", "PROTEIN", 0, 3], ["CRLs", "PROTEIN", 18, 22], ["CSN", "PROTEIN", 59, 62]]], ["Consistent with a role of the CSN in preventing self-destruction of the components of CRLs, we observed in HS-Csn8KO livers significant decreases in CIS and VHL, two SOCS (suppressor of cytokine signaling)-box-containing substrate receptors of CRLs.", [["CRLs", "ANATOMY", 86, 90], ["CSN", "GENE_OR_GENE_PRODUCT", 30, 33], ["CRLs", "GENE_OR_GENE_PRODUCT", 86, 90], ["SOCS", "GENE_OR_GENE_PRODUCT", 166, 170], ["CRLs", "GENE_OR_GENE_PRODUCT", 244, 248], ["CSN", "PROTEIN", 30, 33], ["CRLs", "PROTEIN", 86, 90], ["CIS", "PROTEIN", 149, 152], ["VHL", "PROTEIN", 157, 160], ["SOCS (suppressor of cytokine signaling)-box-containing substrate receptors", "PROTEIN", 166, 240], ["CRLs", "PROTEIN", 244, 248], ["self-destruction of the components of CRLs", "PROBLEM", 48, 90], ["significant decreases in CIS", "PROBLEM", 124, 152], ["VHL", "PROBLEM", 157, 160], ["cytokine signaling", "TREATMENT", 186, 204], ["livers", "ANATOMY", 117, 123], ["significant", "OBSERVATION_MODIFIER", 124, 135], ["decreases", "OBSERVATION_MODIFIER", 136, 145]]], ["The CIS down-regulation was accompanied by increases of its substrate Bim-EL but decreased VHL was not associated with an increase of HIF1\u03b1, a known substrate of VHL ( Figure 1A) .", [["VHL", "DISEASE", 91, 94], ["CIS", "GENE_OR_GENE_PRODUCT", 4, 7], ["Bim-EL", "GENE_OR_GENE_PRODUCT", 70, 76], ["HIF1\u03b1", "GENE_OR_GENE_PRODUCT", 134, 139], ["VHL ( Figure 1A", "GENE_OR_GENE_PRODUCT", 162, 177], ["CIS", "PROTEIN", 4, 7], ["Bim", "PROTEIN", 70, 73], ["EL", "PROTEIN", 74, 76], ["VHL", "PROTEIN", 91, 94], ["HIF1\u03b1", "PROTEIN", 134, 139], ["VHL", "DNA", 162, 165], ["The CIS down", "TEST", 0, 12], ["decreased VHL", "PROBLEM", 81, 94], ["an increase of HIF1\u03b1", "PROBLEM", 119, 139], ["increases", "OBSERVATION_MODIFIER", 43, 52], ["VHL", "OBSERVATION", 91, 94], ["increase", "OBSERVATION_MODIFIER", 122, 130]]], ["Interestingly, some other examined substrate receptor proteins (e.g., \u03b2-TrCP, Skp2) did not show significant changes although their bona fide substrates (e.g., \u03b2-catenin for \u03b2+-TrCP and p27 for Skp2) were significantly increased (data not shown).", [["\u03b2-TrCP", "GENE_OR_GENE_PRODUCT", 70, 76], ["Skp2", "GENE_OR_GENE_PRODUCT", 78, 82], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 160, 169], ["\u03b2+-TrCP", "GENE_OR_GENE_PRODUCT", 174, 181], ["p27", "GENE_OR_GENE_PRODUCT", 186, 189], ["Skp2", "GENE_OR_GENE_PRODUCT", 194, 198], ["substrate receptor proteins", "PROTEIN", 35, 62], ["\u03b2-TrCP", "PROTEIN", 70, 76], ["Skp2", "PROTEIN", 78, 82], ["bona fide substrates", "PROTEIN", 132, 152], ["\u03b2-catenin", "PROTEIN", 160, 169], ["\u03b2", "PROTEIN", 174, 175], ["TrCP", "PROTEIN", 177, 181], ["p27", "PROTEIN", 186, 189], ["Skp2", "PROTEIN", 194, 198], ["substrate receptor proteins", "TEST", 35, 62], ["TrCP", "TEST", 72, 76], ["Skp2", "TEST", 78, 82], ["significant changes", "PROBLEM", 97, 116], ["\u03b2-catenin", "TEST", 160, 169], ["TrCP", "TEST", 177, 181], ["Skp2", "TEST", 194, 198]]], ["These in vivo data support the notion that the CSN differentially regulates the stability and activity of CRLs.Csn8 deficiency causes UPS derangementRecent data demonstrate that not only cullins but also a number of other proteins, such as p53, epidermal growth factor (EGF) receptor, ribosomal protein L11, etc., can also be modified by Nedd8 [46] .", [["Csn8", "CHEMICAL", 111, 115], ["UPS derangement", "DISEASE", 134, 149], ["CSN", "GENE_OR_GENE_PRODUCT", 47, 50], ["CRLs", "GENE_OR_GENE_PRODUCT", 106, 110], ["Csn8", "GENE_OR_GENE_PRODUCT", 111, 115], ["cullins", "GENE_OR_GENE_PRODUCT", 187, 194], ["p53", "GENE_OR_GENE_PRODUCT", 240, 243], ["epidermal growth factor (EGF) receptor", "GENE_OR_GENE_PRODUCT", 245, 283], ["ribosomal protein L11", "GENE_OR_GENE_PRODUCT", 285, 306], ["CSN", "PROTEIN", 47, 50], ["CRLs", "PROTEIN", 106, 110], ["Csn8", "PROTEIN", 111, 115], ["cullins", "PROTEIN", 187, 194], ["p53", "PROTEIN", 240, 243], ["epidermal growth factor (EGF) receptor", "PROTEIN", 245, 283], ["ribosomal protein L11", "PROTEIN", 285, 306], ["Csn8 deficiency", "PROBLEM", 111, 126], ["UPS derangement", "PROBLEM", 134, 149], ["Recent data", "TEST", 149, 160], ["other proteins", "PROBLEM", 216, 230], ["epidermal growth factor (EGF) receptor", "PROBLEM", 245, 283], ["ribosomal protein L11", "TREATMENT", 285, 306], ["stability", "OBSERVATION_MODIFIER", 80, 89]]], ["In the present study, our examination of Nedd8 conjugates reveals a remarkable increase of HMW Nedd8-conjugated proteins in HS-Csn8KO livers ( Figure 1B, 1C) .", [["HS-Csn8KO livers", "ANATOMY", 124, 140], ["Nedd8 conjugates", "SIMPLE_CHEMICAL", 41, 57], ["Nedd8", "GENE_OR_GENE_PRODUCT", 95, 100], ["Nedd8 conjugates", "PROTEIN", 41, 57], ["HMW Nedd8", "PROTEIN", 91, 100], ["conjugated proteins", "PROTEIN", 101, 120], ["the present study", "TEST", 3, 20], ["our examination", "TEST", 22, 37], ["Nedd8 conjugates", "TEST", 41, 57], ["HS", "TEST", 124, 126], ["increase", "OBSERVATION_MODIFIER", 79, 87], ["livers", "ANATOMY", 134, 140]]], ["These increased HMW Nedd8 conjugates are likely neddylated forms of non-cullin proteins because immunoblotting shows that they are negative for cullin1 through cullin4 that we have examined.", [["HMW", "GENE_OR_GENE_PRODUCT", 16, 19], ["Nedd8", "GENE_OR_GENE_PRODUCT", 20, 25], ["non-cullin", "GENE_OR_GENE_PRODUCT", 68, 78], ["cullin1", "GENE_OR_GENE_PRODUCT", 144, 151], ["cullin4", "GENE_OR_GENE_PRODUCT", 160, 167], ["HMW Nedd8", "PROTEIN", 16, 25], ["non-cullin proteins", "PROTEIN", 68, 87], ["cullin1", "PROTEIN", 144, 151], ["cullin4", "PROTEIN", 160, 167], ["These increased HMW Nedd8 conjugates", "TREATMENT", 0, 36], ["non-cullin proteins", "PROBLEM", 68, 87], ["immunoblotting", "TEST", 96, 110]]], ["These new findings imply that the CSN may also be responsible for deneddylation of target proteins other than cullins.", [["CSN", "GENE_OR_GENE_PRODUCT", 34, 37], ["cullins", "GENE_OR_GENE_PRODUCT", 110, 117], ["CSN", "PROTEIN", 34, 37], ["target proteins", "PROTEIN", 83, 98], ["cullins", "PROTEIN", 110, 117], ["target proteins", "PROBLEM", 83, 98], ["cullins", "TEST", 110, 117], ["may also be responsible for", "UNCERTAINTY", 38, 65]]], ["It will be interesting to identify the HMW neddylated proteins accumulated in HS-Csn8KO mouse livers.Csn8 deficiency causes UPS derangementCRLs are a large family of ubiquitin ligases and are by estimate responsible for ~20% of ubiquitination in the cell [47] .", [["livers", "ANATOMY", 94, 100], ["cell", "ANATOMY", 250, 254], ["Csn8", "CHEMICAL", 101, 105], ["HMW", "GENE_OR_GENE_PRODUCT", 39, 42], ["mouse", "ORGANISM", 88, 93], ["livers", "ORGAN", 94, 100], ["Csn8", "GENE_OR_GENE_PRODUCT", 101, 105], ["UPS derangementCRLs", "GENE_OR_GENE_PRODUCT", 124, 143], ["cell", "CELL", 250, 254], ["HMW neddylated proteins", "PROTEIN", 39, 62], ["Csn8", "PROTEIN", 101, 105], ["UPS", "PROTEIN", 124, 127], ["ubiquitin ligases", "PROTEIN", 166, 183], ["mouse", "SPECIES", 88, 93], ["mouse", "SPECIES", 88, 93], ["Csn8 deficiency", "PROBLEM", 101, 116], ["UPS derangementCRLs", "PROBLEM", 124, 143], ["ubiquitin ligases", "PROBLEM", 166, 183], ["livers", "ANATOMY", 94, 100], ["ubiquitin ligases", "OBSERVATION", 166, 183]]], ["It is reasonable to expect that defects in the CSN impair CRLs and thereby lead to an appreciable decrease in global ubiquitination.", [["CSN", "ANATOMY", 47, 50], ["CSN", "GENE_OR_GENE_PRODUCT", 47, 50], ["CRLs", "GENE_OR_GENE_PRODUCT", 58, 62], ["CSN", "PROTEIN", 47, 50], ["CRLs", "PROTEIN", 58, 62], ["defects in the CSN impair CRLs", "PROBLEM", 32, 62], ["an appreciable decrease in global ubiquitination", "PROBLEM", 83, 131], ["defects", "OBSERVATION", 32, 39], ["appreciable", "OBSERVATION_MODIFIER", 86, 97], ["decrease", "OBSERVATION_MODIFIER", 98, 106], ["global ubiquitination", "OBSERVATION", 110, 131]]], ["Similar to what was observed in the heart with cardiomyocyte-restricted Csn8KO, we detected remarkable increases in the HMW ubiquitin conjugates in HS-Csn8KO livers ( Figure 1D ).", [["heart", "ANATOMY", 36, 41], ["cardiomyocyte", "ANATOMY", 47, 60], ["HS-Csn8KO livers", "ANATOMY", 148, 164], ["heart", "ORGAN", 36, 41], ["cardiomyocyte", "CELL", 47, 60], ["Csn8KO", "GENE_OR_GENE_PRODUCT", 72, 78], ["Csn8KO", "PROTEIN", 72, 78], ["HMW ubiquitin conjugates", "PROTEIN", 120, 144], ["heart", "ANATOMY", 36, 41], ["cardiomyocyte", "ANATOMY", 47, 60], ["remarkable", "OBSERVATION_MODIFIER", 92, 102], ["increases", "OBSERVATION_MODIFIER", 103, 112], ["livers", "ANATOMY", 158, 164]]], ["This suggests that the removal of ubiquitinated proteins by the 26S proteasome is likely also impaired by Csn8 deficiency.", [["26S", "GENE_OR_GENE_PRODUCT", 64, 67], ["Csn8", "GENE_OR_GENE_PRODUCT", 106, 110], ["ubiquitinated proteins", "PROTEIN", 34, 56], ["26S proteasome", "PROTEIN", 64, 78], ["Csn8", "PROTEIN", 106, 110], ["the removal of ubiquitinated proteins", "TREATMENT", 19, 56], ["the 26S proteasome", "TREATMENT", 60, 78], ["Csn8 deficiency", "PROBLEM", 106, 121], ["ubiquitinated proteins", "OBSERVATION", 34, 56], ["likely also", "UNCERTAINTY", 82, 93], ["Csn8 deficiency", "OBSERVATION", 106, 121]]], ["Consistent with decreased proteasomal function, the surrogate UPS substrate GFPdgn, when overexpressed in the HS-Csn8KO, was also significantly accumulated ( Figure 3A ~ 3C) .", [["proteasomal", "ANATOMY", 26, 37], ["UPS", "GENE_OR_GENE_PRODUCT", 62, 65], ["GFPdgn", "GENE_OR_GENE_PRODUCT", 76, 82], ["HS-Csn8KO", "GENE_OR_GENE_PRODUCT", 110, 119], ["surrogate UPS substrate", "PROTEIN", 52, 75], ["GFPdgn", "PROTEIN", 76, 82], ["HS", "DNA", 110, 112], ["Csn8KO", "DNA", 113, 119], ["decreased proteasomal function", "PROBLEM", 16, 46], ["decreased", "OBSERVATION_MODIFIER", 16, 25], ["proteasomal function", "OBSERVATION", 26, 46]]], ["The marked reduction of the protein levels of Rpt5 (a critical subunit of the 19S base) in HS-Csn8KO livers (Figures 2A, 3D, 3E ) may have contributed to the proteasomal impairment because Rpt5 has been elegantly shown to play an indispensable role in 26S proteasome assembly [48, 49] .", [["HS-Csn8KO livers", "ANATOMY", 91, 107], ["proteasomal", "ANATOMY", 158, 169], ["Rpt5", "CHEMICAL", 189, 193], ["Rpt5", "GENE_OR_GENE_PRODUCT", 46, 50], ["Rpt5", "GENE_OR_GENE_PRODUCT", 189, 193], ["26S", "GENE_OR_GENE_PRODUCT", 252, 255], ["Rpt5", "PROTEIN", 46, 50], ["19S base", "PROTEIN", 78, 86], ["Rpt5", "PROTEIN", 189, 193], ["26S proteasome", "PROTEIN", 252, 266], ["The marked reduction of the protein levels of Rpt5", "PROBLEM", 0, 50], ["HS", "TEST", 91, 93], ["the proteasomal impairment", "PROBLEM", 154, 180], ["marked", "OBSERVATION_MODIFIER", 4, 10], ["reduction", "OBSERVATION_MODIFIER", 11, 20], ["protein levels", "OBSERVATION", 28, 42], ["livers", "ANATOMY", 101, 107]]], ["The mechanism for Rpt5 down-regulation is unclear and does not appear to be attributable to an increased caspase activity in HS-Csn8KO livers.", [["HS-Csn8KO livers", "ANATOMY", 125, 141], ["Rpt5", "GENE_OR_GENE_PRODUCT", 18, 22], ["caspase", "GENE_OR_GENE_PRODUCT", 105, 112], ["livers", "ORGAN", 135, 141], ["Rpt5", "PROTEIN", 18, 22], ["caspase", "PROTEIN", 105, 112], ["Rpt5", "TEST", 18, 22], ["an increased caspase activity", "PROBLEM", 92, 121], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["caspase activity", "OBSERVATION", 105, 121], ["livers", "ANATOMY", 135, 141]]], ["Activated caspase 3 can cleave Rpt5, Rpn2, and Rpn10 of the 19S proteasome during apoptosis [50] .", [["caspase 3", "GENE_OR_GENE_PRODUCT", 10, 19], ["Rpt5", "GENE_OR_GENE_PRODUCT", 31, 35], ["Rpn2", "GENE_OR_GENE_PRODUCT", 37, 41], ["Rpn10", "GENE_OR_GENE_PRODUCT", 47, 52], ["19S", "GENE_OR_GENE_PRODUCT", 60, 63], ["caspase 3", "PROTEIN", 10, 19], ["Rpt5", "PROTEIN", 31, 35], ["Rpn2", "PROTEIN", 37, 41], ["Rpn10", "PROTEIN", 47, 52], ["19S proteasome", "PROTEIN", 60, 74], ["Activated caspase", "TREATMENT", 0, 17], ["Rpn2", "TREATMENT", 37, 41], ["Rpn10", "TREATMENT", 47, 52], ["the 19S proteasome", "TREATMENT", 56, 74]]], ["Indeed, hepatocyte apoptosis was immediately increased upon the depletion of Csn8 protein in the HS-Csn8KO livers and remained significantly increased during the first 6 weeks of age that were examined ( Figure 6 ) and we have previous reported that activated (the cleaved form) caspase 3 was significantly increased in Csn8 deficient livers [19] .", [["hepatocyte", "ANATOMY", 8, 18], ["HS-Csn8KO livers", "ANATOMY", 97, 113], ["livers", "ANATOMY", 335, 341], ["hepatocyte", "CELL", 8, 18], ["Csn8", "GENE_OR_GENE_PRODUCT", 77, 81], ["livers", "ORGAN", 107, 113], ["caspase 3", "GENE_OR_GENE_PRODUCT", 279, 288], ["Csn8", "GENE_OR_GENE_PRODUCT", 320, 324], ["Csn8 protein", "PROTEIN", 77, 89], ["caspase 3", "PROTEIN", 279, 288], ["Csn8", "PROTEIN", 320, 324], ["hepatocyte apoptosis", "PROBLEM", 8, 28], ["caspase", "TEST", 279, 286], ["hepatocyte", "ANATOMY", 8, 18], ["apoptosis", "OBSERVATION", 19, 28], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["livers", "ANATOMY", 107, 113], ["significantly", "OBSERVATION_MODIFIER", 127, 140], ["increased", "OBSERVATION", 141, 150], ["increased", "OBSERVATION_MODIFIER", 307, 316], ["livers", "ANATOMY", 335, 341]]], ["However, no discernible decreases of Rpn2 and Rpn10 were evidenced in the same HS-Csn8KO livers where Rpt5 decreases were observed, which stands against caspase activation as the main cause of Rpt5 down-regulation.", [["livers", "ANATOMY", 89, 95], ["Rpn2", "GENE_OR_GENE_PRODUCT", 37, 41], ["Rpn10", "GENE_OR_GENE_PRODUCT", 46, 51], ["livers", "ORGAN", 89, 95], ["Rpt5", "GENE_OR_GENE_PRODUCT", 102, 106], ["caspase", "GENE_OR_GENE_PRODUCT", 153, 160], ["Rpt5", "GENE_OR_GENE_PRODUCT", 193, 197], ["Rpn2", "PROTEIN", 37, 41], ["Rpn10", "PROTEIN", 46, 51], ["Rpt5", "PROTEIN", 102, 106], ["caspase", "PROTEIN", 153, 160], ["Rpt5", "PROTEIN", 193, 197], ["discernible decreases of Rpn2", "PROBLEM", 12, 41], ["Rpn10", "TEST", 46, 51], ["Rpt5 decreases", "PROBLEM", 102, 116], ["Rpt5", "TEST", 193, 197], ["no", "UNCERTAINTY", 9, 11], ["discernible", "OBSERVATION_MODIFIER", 12, 23], ["decreases", "OBSERVATION_MODIFIER", 24, 33], ["livers", "ANATOMY", 89, 95]]], ["Regardless of the cause of Rpt5 downregulation, the depletion of this key component of the19S proteasome is at least in part responsible for the impaired proteasomal function in HS-Csn8KO livers.", [["proteasomal", "ANATOMY", 154, 165], ["HS-Csn8KO livers", "ANATOMY", 178, 194], ["Rpt5", "GENE_OR_GENE_PRODUCT", 27, 31], ["19S", "GENE_OR_GENE_PRODUCT", 90, 93], ["livers", "ORGAN", 188, 194], ["Rpt5", "PROTEIN", 27, 31], ["19S proteasome", "PROTEIN", 90, 104], ["Rpt5 downregulation", "PROBLEM", 27, 46], ["the19S proteasome", "TREATMENT", 87, 104], ["the impaired proteasomal function", "PROBLEM", 141, 174], ["19S proteasome", "OBSERVATION", 90, 104], ["proteasomal function", "OBSERVATION", 154, 174], ["livers", "ANATOMY", 188, 194]]], ["Supporting this postulate, it has been reported that myocardial ischemic preconditioning preserves UPS function in ischemic myocardium via diminishing oxidative damage to Rpt5 [51] .Csn8 deficiency causes UPS derangementThe CSN has been proposed by some as an alternative and competing \"lid\" for the 19S proteasome [33, 52] ; however, as described above, none of the examined 19S lid subunits (Rpn2, Rpn8) or linker subunit (Rpn10) showed discernible changes in protein abundance upon Csn8 deficiency ( Figure 2A) .", [["myocardial", "ANATOMY", 53, 63], ["myocardium", "ANATOMY", 124, 134], ["Csn8", "CHEMICAL", 182, 186], ["UPS derangement", "DISEASE", 205, 220], ["myocardial", "MULTI-TISSUE_STRUCTURE", 53, 63], ["UPS", "GENE_OR_GENE_PRODUCT", 99, 102], ["myocardium", "ORGAN", 124, 134], ["Csn8", "GENE_OR_GENE_PRODUCT", 182, 186], ["CSN", "GENE_OR_GENE_PRODUCT", 224, 227], ["19S lid subunits", "GENE_OR_GENE_PRODUCT", 376, 392], ["Rpn2", "GENE_OR_GENE_PRODUCT", 394, 398], ["Rpn8", "GENE_OR_GENE_PRODUCT", 400, 404], ["Rpn10", "GENE_OR_GENE_PRODUCT", 425, 430], ["Csn8", "GENE_OR_GENE_PRODUCT", 485, 489], ["UPS", "PROTEIN", 99, 102], ["Csn8", "PROTEIN", 182, 186], ["CSN", "PROTEIN", 224, 227], ["19S proteasome", "PROTEIN", 300, 314], ["19S lid subunits", "PROTEIN", 376, 392], ["Rpn2", "PROTEIN", 394, 398], ["Rpn8", "PROTEIN", 400, 404], ["linker subunit", "PROTEIN", 409, 423], ["Rpn10", "PROTEIN", 425, 430], ["Csn8", "PROTEIN", 485, 489], ["myocardial ischemic preconditioning", "PROBLEM", 53, 88], ["ischemic myocardium", "PROBLEM", 115, 134], ["diminishing oxidative damage", "PROBLEM", 139, 167], ["Rpt5", "TEST", 171, 175], ["Csn8 deficiency", "PROBLEM", 182, 197], ["UPS derangement", "PROBLEM", 205, 220], ["Rpn8", "TREATMENT", 400, 404], ["linker subunit", "TREATMENT", 409, 423], ["discernible changes in protein abundance", "PROBLEM", 439, 479], ["Csn8 deficiency", "PROBLEM", 485, 500], ["myocardial", "ANATOMY", 53, 63], ["ischemic", "OBSERVATION", 64, 72], ["ischemic", "OBSERVATION_MODIFIER", 115, 123], ["myocardium", "ANATOMY", 124, 134], ["diminishing", "OBSERVATION_MODIFIER", 139, 150], ["oxidative damage", "OBSERVATION", 151, 167], ["protein abundance", "OBSERVATION", 462, 479]]], ["Interestingly, the expression of all three 11S proteasome subunits (PA28\u03b1, \u03b2, \u03b3) was significantly increased in HS-Csn8KO livers ( Figure 2C, 2D) .", [["HS-Csn8KO livers", "ANATOMY", 112, 128], ["PA28\u03b1", "GENE_OR_GENE_PRODUCT", 68, 73], ["\u03b2", "GENE_OR_GENE_PRODUCT", 75, 76], ["\u03b3", "GENE_OR_GENE_PRODUCT", 78, 79], ["11S proteasome subunits", "PROTEIN", 43, 66], ["PA28\u03b1", "PROTEIN", 68, 73], ["\u03b2", "PROTEIN", 75, 76], ["\u03b3", "PROTEIN", 78, 79], ["PA28", "TEST", 68, 72], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["livers", "ANATOMY", 122, 128]]], ["This is likely a compensatory response to proteasome functional impairment because upregulation of 11S proteasomes by PA28\u03b1 overexpression has been demonstrated to enhance proteasome-mediated degradation of misfolded proteins [4, 5] .", [["11S proteasomes", "GENE_OR_GENE_PRODUCT", 99, 114], ["PA28\u03b1", "GENE_OR_GENE_PRODUCT", 118, 123], ["proteasome", "PROTEIN", 42, 52], ["11S proteasomes", "PROTEIN", 99, 114], ["PA28\u03b1", "PROTEIN", 118, 123], ["proteasome", "PROTEIN", 172, 182], ["misfolded proteins", "PROTEIN", 207, 225], ["a compensatory response", "PROBLEM", 15, 38], ["proteasome functional impairment", "PROBLEM", 42, 74], ["upregulation of 11S proteasomes", "PROBLEM", 83, 114], ["PA28", "TEST", 118, 122], ["misfolded proteins", "PROBLEM", 207, 225], ["likely", "UNCERTAINTY", 8, 14], ["compensatory response", "OBSERVATION", 17, 38]]], ["Apparently, as revealed by the increases in GFPdgn proteins, this compensatory response was inadequate.", [["GFPdgn", "GENE_OR_GENE_PRODUCT", 44, 50], ["GFPdgn proteins", "PROTEIN", 44, 59], ["the increases in GFPdgn proteins", "PROBLEM", 27, 59], ["increases", "OBSERVATION_MODIFIER", 31, 40]]], ["Consistent with impairment of UPSmediated protein degradation, striking accumulation of IBL structures and increases in the nuclear and cell size of hepatocytes as shown by histological characterizations are prominent morphological features (Figures 4, 5) accompanying severe liver malfunction that was previous described for liver with HS-Csn8KO [19] .Increased Bim expression may mediate hepatocyte apoptosis by binding Bcl2 in HS-Csn8KO liversBlocking neddylation (including cullin neddylation) by, for example, a Nedd8 activating enzyme (NAE) inhibitor (e.g., MLN4924) can effectively induce cell death in cancer cells and is being clinically tested for treating malignancy [47] .", [["IBL structures", "ANATOMY", 88, 102], ["nuclear", "ANATOMY", 124, 131], ["cell", "ANATOMY", 136, 140], ["hepatocytes", "ANATOMY", 149, 160], ["liver", "ANATOMY", 276, 281], ["liver", "ANATOMY", 326, 331], ["hepatocyte", "ANATOMY", 390, 400], ["HS-Csn8KO livers", "ANATOMY", 430, 446], ["cell", "ANATOMY", 596, 600], ["cancer cells", "ANATOMY", 610, 622], ["liver malfunction", "DISEASE", 276, 293], ["MLN4924", "CHEMICAL", 564, 571], ["death", "DISEASE", 601, 606], ["cancer", "DISEASE", 610, 616], ["malignancy", "DISEASE", 667, 677], ["MLN4924", "CHEMICAL", 564, 571], ["IBL", "GENE_OR_GENE_PRODUCT", 88, 91], ["nuclear", "CELLULAR_COMPONENT", 124, 131], ["cell", "CELL", 136, 140], ["hepatocytes", "CELL", 149, 160], ["liver", "ORGAN", 276, 281], ["liver", "ORGAN", 326, 331], ["Bim", "GENE_OR_GENE_PRODUCT", 363, 366], ["hepatocyte", "CELL", 390, 400], ["Bcl2", "GENE_OR_GENE_PRODUCT", 422, 426], ["cullin", "GENE_OR_GENE_PRODUCT", 478, 484], ["Nedd8 activating enzyme", "GENE_OR_GENE_PRODUCT", 517, 540], ["NAE", "SIMPLE_CHEMICAL", 542, 545], ["MLN4924", "SIMPLE_CHEMICAL", 564, 571], ["cell", "CELL", 596, 600], ["cancer cells", "CELL", 610, 622], ["UPSmediated protein", "PROTEIN", 30, 49], ["IBL", "PROTEIN", 88, 91], ["hepatocytes", "CELL_TYPE", 149, 160], ["Bim", "PROTEIN", 363, 366], ["Bcl2", "PROTEIN", 422, 426], ["cullin", "PROTEIN", 478, 484], ["Nedd8 activating enzyme", "PROTEIN", 517, 540], ["cancer cells", "CELL_TYPE", 610, 622], ["UPSmediated protein degradation", "PROBLEM", 30, 61], ["striking accumulation of IBL structures", "PROBLEM", 63, 102], ["increases in the nuclear and cell size of hepatocytes", "PROBLEM", 107, 160], ["histological characterizations", "TEST", 173, 203], ["severe liver malfunction", "PROBLEM", 269, 293], ["Increased Bim expression", "PROBLEM", 353, 377], ["hepatocyte apoptosis", "PROBLEM", 390, 410], ["HS", "TEST", 430, 432], ["Blocking neddylation (including cullin neddylation", "TREATMENT", 446, 496], ["a Nedd8 activating enzyme (NAE) inhibitor", "TREATMENT", 515, 556], ["cell death in cancer cells", "PROBLEM", 596, 622], ["treating malignancy", "PROBLEM", 658, 677], ["protein degradation", "OBSERVATION", 42, 61], ["accumulation of", "OBSERVATION", 72, 87], ["IBL structures", "OBSERVATION", 88, 102], ["increases", "OBSERVATION_MODIFIER", 107, 116], ["cell", "OBSERVATION", 136, 140], ["size", "OBSERVATION_MODIFIER", 141, 145], ["hepatocytes", "ANATOMY", 149, 160], ["prominent", "OBSERVATION_MODIFIER", 208, 217], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["liver", "ANATOMY", 276, 281], ["malfunction", "OBSERVATION", 282, 293], ["liver", "ANATOMY", 326, 331], ["Bim expression", "OBSERVATION", 363, 377], ["hepatocyte apoptosis", "OBSERVATION", 390, 410], ["livers", "ANATOMY", 440, 446], ["cancer cells", "OBSERVATION", 610, 622]]], ["Here we show that blocking cullin deneddylation by HS-Csn8KO can also cause massive apoptosis in the liver ( Figure 6) .", [["liver", "ANATOMY", 101, 106], ["cullin", "GENE_OR_GENE_PRODUCT", 27, 33], ["HS-Csn8KO", "SIMPLE_CHEMICAL", 51, 60], ["liver", "ORGAN", 101, 106], ["cullin", "PROTEIN", 27, 33], ["blocking cullin deneddylation", "TREATMENT", 18, 47], ["massive apoptosis in the liver", "PROBLEM", 76, 106], ["massive", "OBSERVATION_MODIFIER", 76, 83], ["apoptosis", "OBSERVATION", 84, 93], ["liver", "ANATOMY", 101, 106]]], ["A common mediating mechanism for the two opposing approaches to cause apoptosis resides likely in the inhibition of CRLs and the resultant defects in the degradation of critical regulators of cell cycle and cell death.", [["cell", "ANATOMY", 192, 196], ["cell", "ANATOMY", 207, 211], ["death", "DISEASE", 212, 217], ["CRLs", "GENE_OR_GENE_PRODUCT", 116, 120], ["cell", "CELL", 192, 196], ["cell", "CELL", 207, 211], ["CRLs", "PROTEIN", 116, 120], ["apoptosis", "PROBLEM", 70, 79], ["the resultant defects", "PROBLEM", 125, 146], ["cell death", "PROBLEM", 207, 217], ["apoptosis", "OBSERVATION", 70, 79], ["resultant", "OBSERVATION_MODIFIER", 129, 138], ["defects", "OBSERVATION", 139, 146], ["cell cycle", "OBSERVATION", 192, 202], ["cell death", "OBSERVATION", 207, 217]]], ["It is in active investigation regarding how inhibition of CRLs causes apoptosis.", [["CRLs", "DISEASE", 58, 62], ["CRLs", "GENE_OR_GENE_PRODUCT", 58, 62], ["CRLs", "PROTEIN", 58, 62], ["apoptosis", "PROBLEM", 70, 79], ["active", "OBSERVATION_MODIFIER", 9, 15]]], ["Inactivation of cullin neddylation by MLN4924 in cancer cells can accumulate multiple CRL substrates, including (1) cell cycle inhibitors such as p21, p27, and Wee1, resulting in cell cycle arrest [53] ; (2) DNA replication licensing factors CDT1 and ORC1, leading to DNA re-replication stress and the DNA damage response [47, 54] ; and (3) I\u03baB\u03b1, inhibiting NF\u03baB activity [55] .", [["cancer cells", "ANATOMY", 49, 61], ["cell", "ANATOMY", 116, 120], ["cell", "ANATOMY", 179, 183], ["MLN4924", "CHEMICAL", 38, 45], ["cancer", "DISEASE", 49, 55], ["cullin", "GENE_OR_GENE_PRODUCT", 16, 22], ["MLN4924", "SIMPLE_CHEMICAL", 38, 45], ["cancer cells", "CELL", 49, 61], ["CRL", "GENE_OR_GENE_PRODUCT", 86, 89], ["cell", "CELL", 116, 120], ["p21", "GENE_OR_GENE_PRODUCT", 146, 149], ["p27", "GENE_OR_GENE_PRODUCT", 151, 154], ["Wee1", "GENE_OR_GENE_PRODUCT", 160, 164], ["cell", "CELL", 179, 183], ["DNA", "CELLULAR_COMPONENT", 208, 211], ["CDT1", "GENE_OR_GENE_PRODUCT", 242, 246], ["ORC1", "GENE_OR_GENE_PRODUCT", 251, 255], ["DNA", "CELLULAR_COMPONENT", 268, 271], ["DNA", "CELLULAR_COMPONENT", 302, 305], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 341, 345], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 358, 362], ["cullin", "PROTEIN", 16, 22], ["MLN4924", "PROTEIN", 38, 45], ["cancer cells", "CELL_TYPE", 49, 61], ["p21", "PROTEIN", 146, 149], ["p27", "PROTEIN", 151, 154], ["Wee1", "PROTEIN", 160, 164], ["DNA replication licensing factors", "PROTEIN", 208, 241], ["CDT1", "PROTEIN", 242, 246], ["ORC1", "PROTEIN", 251, 255], ["I\u03baB\u03b1", "PROTEIN", 341, 345], ["NF\u03baB", "PROTEIN", 358, 362], ["Inactivation of cullin neddylation", "TREATMENT", 0, 34], ["cancer cells", "PROBLEM", 49, 61], ["multiple CRL substrates", "TREATMENT", 77, 100], ["cell cycle inhibitors", "TREATMENT", 116, 137], ["p21", "TEST", 146, 149], ["p27", "TEST", 151, 154], ["Wee1", "TREATMENT", 160, 164], ["cell cycle arrest", "PROBLEM", 179, 196], ["CDT1", "PROBLEM", 242, 246], ["ORC1", "TREATMENT", 251, 255], ["DNA re-replication stress", "PROBLEM", 268, 293], ["the DNA damage response", "TEST", 298, 321], ["I\u03baB\u03b1", "TEST", 341, 345], ["cullin neddylation", "OBSERVATION", 16, 34]]], ["These factors may all contribute to apoptosis induced by NAE inhibition.", [["NAE", "CHEMICAL", 57, 60], ["NAE", "CHEMICAL", 57, 60], ["NAE", "SIMPLE_CHEMICAL", 57, 60], ["apoptosis", "PROBLEM", 36, 45], ["NAE inhibition", "OBSERVATION", 57, 71]]], ["In the present study, we collected compelling evidence that Csn8 deficiency reduces a CRL substrate receptor protein CIS and increases its substrate Bim (Figures 1, 7) .", [["Csn8", "CHEMICAL", 60, 64], ["Csn8", "GENE_OR_GENE_PRODUCT", 60, 64], ["Bim", "GENE_OR_GENE_PRODUCT", 149, 152], ["Csn8", "PROTEIN", 60, 64], ["CRL substrate receptor protein", "PROTEIN", 86, 116], ["CIS", "PROTEIN", 117, 120], ["Bim", "PROTEIN", 149, 152], ["the present study", "TEST", 3, 20], ["Csn8 deficiency", "PROBLEM", 60, 75], ["a CRL substrate receptor protein CIS", "PROBLEM", 84, 120]]], ["Bim is a pro-apoptotic BH3-only protein of the Bcl2 family, acting in the upstream of mitochondria-mediated apoptosis [22] [23] [24] 56] .", [["mitochondria", "ANATOMY", 86, 98], ["Bim", "GENE_OR_GENE_PRODUCT", 0, 3], ["Bcl2", "GENE_OR_GENE_PRODUCT", 47, 51], ["mitochondria", "CELLULAR_COMPONENT", 86, 98], ["Bim", "PROTEIN", 0, 3], ["BH3", "PROTEIN", 23, 26], ["Bcl2 family", "PROTEIN", 47, 58], ["a pro-apoptotic BH3", "TEST", 7, 26]]], ["Bim has at least 18 different splicing variants, among which BimEL (extra-long), BimL (long), and BimS (short) are the three major isoforms.", [["Bim", "GENE_OR_GENE_PRODUCT", 0, 3], ["BimEL", "GENE_OR_GENE_PRODUCT", 61, 66], ["extra-long)", "GENE_OR_GENE_PRODUCT", 68, 79], ["BimL (long)", "GENE_OR_GENE_PRODUCT", 81, 92], ["BimS (short)", "GENE_OR_GENE_PRODUCT", 98, 110], ["Bim", "PROTEIN", 0, 3], ["BimEL", "PROTEIN", 61, 66], ["BimL", "PROTEIN", 81, 85], ["BimS", "DNA", 98, 102], ["18 different", "OBSERVATION_MODIFIER", 17, 29], ["splicing variants", "OBSERVATION", 30, 47]]], ["BimEL and BimL expression are tightly regulated at both the transcriptional and posttranslational levels [29] .", [["BimEL", "GENE_OR_GENE_PRODUCT", 0, 5], ["BimL", "GENE_OR_GENE_PRODUCT", 10, 14], ["BimEL", "PROTEIN", 0, 5], ["BimL", "PROTEIN", 10, 14]]], ["In healthy cells, Bim is sequestered to the microtubule-associated dynein motor complex by binding to dynein light chain LC8, and is thereby unable to promote cell death.", [["cells", "ANATOMY", 11, 16], ["microtubule", "ANATOMY", 44, 55], ["cell", "ANATOMY", 159, 163], ["death", "DISEASE", 164, 169], ["cells", "CELL", 11, 16], ["Bim", "GENE_OR_GENE_PRODUCT", 18, 21], ["microtubule", "CELLULAR_COMPONENT", 44, 55], ["dynein", "CELLULAR_COMPONENT", 67, 73], ["dynein light chain LC8", "GENE_OR_GENE_PRODUCT", 102, 124], ["cell", "CELL", 159, 163], ["Bim", "PROTEIN", 18, 21], ["microtubule", "PROTEIN", 44, 55], ["dynein motor complex", "PROTEIN", 67, 87], ["dynein light chain", "PROTEIN", 102, 120], ["LC8", "PROTEIN", 121, 124], ["healthy cells", "OBSERVATION", 3, 16]]], ["Upon death stimulation, Bim is released from the microtubules, promoting Bax activation and apoptosis [57, 58] .Increased Bim expression may mediate hepatocyte apoptosis by binding Bcl2 in HS-Csn8KO liversIn HR-Csn8KO mouse livers, both the pro-apoptotic members (Bim, Bax) and the anti-apoptotic members (Bcl2 and Bcl-XL) of the Bcl2 family were significantly increased ( Figure 7) , suggesting that the intrinsic apoptotic pathway has likely mediated the increased hepatocyte apoptosis induced by Csn8 deficiency.", [["microtubules", "ANATOMY", 49, 61], ["hepatocyte", "ANATOMY", 149, 159], ["livers", "ANATOMY", 224, 230], ["hepatocyte", "ANATOMY", 467, 477], ["death", "DISEASE", 5, 10], ["Csn8", "CHEMICAL", 499, 503], ["Bim", "GENE_OR_GENE_PRODUCT", 24, 27], ["microtubules", "CELLULAR_COMPONENT", 49, 61], ["Bax", "GENE_OR_GENE_PRODUCT", 73, 76], ["Bim", "GENE_OR_GENE_PRODUCT", 122, 125], ["hepatocyte", "CELL", 149, 159], ["Bcl2", "GENE_OR_GENE_PRODUCT", 181, 185], ["HS-Csn8KO", "GENE_OR_GENE_PRODUCT", 189, 198], ["mouse", "ORGANISM", 218, 223], ["livers", "ORGAN", 224, 230], ["Bim", "GENE_OR_GENE_PRODUCT", 264, 267], ["Bax", "GENE_OR_GENE_PRODUCT", 269, 272], ["Bcl2", "GENE_OR_GENE_PRODUCT", 306, 310], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 315, 321], ["Bcl2", "GENE_OR_GENE_PRODUCT", 330, 334], ["hepatocyte", "CELL", 467, 477], ["Csn8", "GENE_OR_GENE_PRODUCT", 499, 503], ["Bim", "PROTEIN", 24, 27], ["Bax", "PROTEIN", 73, 76], ["Bim", "PROTEIN", 122, 125], ["Bcl2", "PROTEIN", 181, 185], ["pro-apoptotic members", "PROTEIN", 241, 262], ["Bim", "PROTEIN", 264, 267], ["Bax", "PROTEIN", 269, 272], ["anti-apoptotic members", "PROTEIN", 282, 304], ["Bcl2", "PROTEIN", 306, 310], ["Bcl", "PROTEIN", 315, 318], ["Bcl2 family", "PROTEIN", 330, 341], ["Csn8", "PROTEIN", 499, 503], ["mouse", "SPECIES", 218, 223], ["mouse", "SPECIES", 218, 223], ["Increased Bim expression", "PROBLEM", 112, 136], ["hepatocyte apoptosis", "PROBLEM", 149, 169], ["Bcl2", "TEST", 181, 185], ["HS", "TEST", 189, 191], ["Bcl2", "TEST", 306, 310], ["Bcl", "TEST", 315, 318], ["the intrinsic apoptotic pathway", "PROBLEM", 401, 432], ["the increased hepatocyte apoptosis", "PROBLEM", 453, 487], ["Csn8 deficiency", "PROBLEM", 499, 514], ["Bax activation", "OBSERVATION", 73, 87], ["Bim expression", "OBSERVATION", 122, 136], ["hepatocyte apoptosis", "OBSERVATION", 149, 169], ["livers", "ANATOMY", 224, 230], ["increased", "OBSERVATION_MODIFIER", 457, 466], ["hepatocyte apoptosis", "OBSERVATION", 467, 487], ["Csn8 deficiency", "OBSERVATION", 499, 514]]], ["The interaction and the functional balance between pro-apoptotic and anti-apoptotic Bcl2 family proteins in a cell determine the fate of the cell [21] .", [["cell", "ANATOMY", 110, 114], ["cell", "ANATOMY", 141, 145], ["Bcl2", "GENE_OR_GENE_PRODUCT", 84, 88], ["cell", "CELL", 110, 114], ["cell", "CELL", 141, 145], ["pro-apoptotic and anti-apoptotic Bcl2 family proteins", "PROTEIN", 51, 104], ["pro-apoptotic", "TREATMENT", 51, 64], ["anti-apoptotic Bcl2 family proteins", "TREATMENT", 69, 104]]], ["Anti-apoptotic Bcl2 family members usually inhibit the pro-apoptotic activity of Bax in healthy cells.", [["cells", "ANATOMY", 96, 101], ["Bcl2", "GENE_OR_GENE_PRODUCT", 15, 19], ["Bax", "GENE_OR_GENE_PRODUCT", 81, 84], ["cells", "CELL", 96, 101], ["Anti-apoptotic Bcl2 family members", "PROTEIN", 0, 34], ["Bax", "PROTEIN", 81, 84], ["healthy cells", "CELL_TYPE", 88, 101], ["healthy cells", "OBSERVATION", 88, 101]]], ["There are two competing theories for the mechanism by which the pro-apoptotic BH3-only proteins, such as Bim, promote the activation of Bax: one proposes that Bim binds to Bax and thereby activates Bax directly [26, 59] ; the other postulates that Bim binds and sequesters the antiapoptotic Bcl2 family proteins, which relieves Bax from being bound by Bcl2 and allows polymerization and activation of Bax [24] .", [["Bim", "GENE_OR_GENE_PRODUCT", 105, 108], ["Bax", "GENE_OR_GENE_PRODUCT", 136, 139], ["Bim", "GENE_OR_GENE_PRODUCT", 159, 162], ["Bax", "GENE_OR_GENE_PRODUCT", 172, 175], ["Bax", "GENE_OR_GENE_PRODUCT", 198, 201], ["Bim", "GENE_OR_GENE_PRODUCT", 248, 251], ["Bcl2", "GENE_OR_GENE_PRODUCT", 291, 295], ["Bax", "GENE_OR_GENE_PRODUCT", 328, 331], ["Bcl2", "GENE_OR_GENE_PRODUCT", 352, 356], ["Bax", "GENE_OR_GENE_PRODUCT", 401, 404], ["BH3", "PROTEIN", 78, 81], ["Bim", "PROTEIN", 105, 108], ["Bax", "PROTEIN", 136, 139], ["Bim", "PROTEIN", 159, 162], ["Bax", "PROTEIN", 172, 175], ["Bax", "PROTEIN", 198, 201], ["Bim", "PROTEIN", 248, 251], ["antiapoptotic Bcl2 family proteins", "PROTEIN", 277, 311], ["Bax", "PROTEIN", 328, 331], ["Bcl2", "PROTEIN", 352, 356], ["Bax", "PROTEIN", 401, 404], ["the pro-apoptotic BH3", "TREATMENT", 60, 81], ["Bim binds", "PROBLEM", 248, 257], ["Bax", "PROBLEM", 328, 331], ["polymerization", "TREATMENT", 368, 382], ["activation of Bax", "TREATMENT", 387, 404]]], ["Our data favor the latter as the mechanism taken by the increased Bim to promote hepatocyte apoptosis in HS-Csn8KO mouse livers.", [["hepatocyte", "ANATOMY", 81, 91], ["livers", "ANATOMY", 121, 127], ["Bim", "GENE_OR_GENE_PRODUCT", 66, 69], ["hepatocyte", "CELL", 81, 91], ["mouse", "ORGANISM", 115, 120], ["livers", "ORGAN", 121, 127], ["Bim", "PROTEIN", 66, 69], ["mouse", "SPECIES", 115, 120], ["mouse", "SPECIES", 115, 120], ["Our data", "TEST", 0, 8], ["the increased Bim", "PROBLEM", 52, 69], ["hepatocyte apoptosis", "PROBLEM", 81, 101], ["hepatocyte", "ANATOMY", 81, 91], ["apoptosis", "OBSERVATION", 92, 101], ["livers", "ANATOMY", 121, 127]]], ["This is because our co-immunoprecipitation reveals that increased BimEL and Bcl2 existed in the same complex, while increased Bim did not interact with Bax and the increased Bcl2 did not appear to interact with the increased Bax in HS-Csn8KO livers (Figure 8 ).ConclusionsThe present study demonstrates that Csn8 deficiency compromises protein deneddylation, differentially downregulates substrate receptor proteins of CRLs, and selectively accumulates CRL substrates such as pro-apoptotic protein Bim, and reduces 19S proteasome subunit Rpt5, leading to severe UPS functional impairment and massive apoptosis in hepatocytes of intact mice.", [["HS-Csn8KO livers", "ANATOMY", 232, 248], ["hepatocytes", "ANATOMY", 613, 624], ["Csn8", "CHEMICAL", 308, 312], ["functional impairment", "DISEASE", 566, 587], ["BimEL", "GENE_OR_GENE_PRODUCT", 66, 71], ["Bcl2", "GENE_OR_GENE_PRODUCT", 76, 80], ["Bim", "GENE_OR_GENE_PRODUCT", 126, 129], ["Bax", "GENE_OR_GENE_PRODUCT", 152, 155], ["Bcl2", "GENE_OR_GENE_PRODUCT", 174, 178], ["Bax", "GENE_OR_GENE_PRODUCT", 225, 228], ["Csn8", "GENE_OR_GENE_PRODUCT", 308, 312], ["CRLs", "GENE_OR_GENE_PRODUCT", 419, 423], ["CRL", "GENE_OR_GENE_PRODUCT", 453, 456], ["Bim", "GENE_OR_GENE_PRODUCT", 498, 501], ["19S proteasome", "GENE_OR_GENE_PRODUCT", 515, 529], ["Rpt5", "GENE_OR_GENE_PRODUCT", 538, 542], ["hepatocytes", "CELL", 613, 624], ["mice", "ORGANISM", 635, 639], ["BimEL", "PROTEIN", 66, 71], ["Bcl2", "PROTEIN", 76, 80], ["Bim", "PROTEIN", 126, 129], ["Bax", "PROTEIN", 152, 155], ["Bcl2", "PROTEIN", 174, 178], ["Bax", "PROTEIN", 225, 228], ["Csn8", "PROTEIN", 308, 312], ["substrate receptor proteins", "PROTEIN", 388, 415], ["CRLs", "PROTEIN", 419, 423], ["CRL substrates", "PROTEIN", 453, 467], ["pro-apoptotic protein", "PROTEIN", 476, 497], ["Bim", "PROTEIN", 498, 501], ["19S proteasome subunit", "PROTEIN", 515, 537], ["Rpt5", "PROTEIN", 538, 542], ["UPS", "PROTEIN", 562, 565], ["hepatocytes", "CELL_TYPE", 613, 624], ["mice", "SPECIES", 635, 639], ["mice", "SPECIES", 635, 639], ["our co-immunoprecipitation", "TEST", 16, 42], ["increased BimEL and Bcl2", "PROBLEM", 56, 80], ["Bax", "TREATMENT", 152, 155], ["the increased Bcl2", "PROBLEM", 160, 178], ["The present study", "TEST", 272, 289], ["Csn8 deficiency", "PROBLEM", 308, 323], ["protein deneddylation", "PROBLEM", 336, 357], ["selectively accumulates CRL substrates", "PROBLEM", 429, 467], ["pro-apoptotic protein Bim", "PROBLEM", 476, 501], ["19S proteasome subunit Rpt5", "TREATMENT", 515, 542], ["severe UPS functional impairment", "PROBLEM", 555, 587], ["massive apoptosis in hepatocytes", "PROBLEM", 592, 624], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["Bcl2", "OBSERVATION", 76, 80], ["increased", "OBSERVATION_MODIFIER", 164, 173], ["Bcl2", "OBSERVATION", 174, 178], ["livers", "ANATOMY", 242, 248], ["pro-apoptotic protein Bim", "OBSERVATION", 476, 501], ["19S proteasome", "OBSERVATION", 515, 529], ["severe", "OBSERVATION_MODIFIER", 555, 561], ["functional impairment", "OBSERVATION", 566, 587], ["massive", "OBSERVATION_MODIFIER", 592, 599], ["apoptosis", "OBSERVATION", 600, 609], ["hepatocytes", "ANATOMY", 613, 624], ["intact mice", "OBSERVATION", 628, 639]]], ["Increased Bim expression and its interaction with Bcl2 may play an important role in mediating hepatocyte apoptosis in HS-Csn8KO mice.", [["hepatocyte", "ANATOMY", 95, 105], ["Bim", "GENE_OR_GENE_PRODUCT", 10, 13], ["Bcl2", "GENE_OR_GENE_PRODUCT", 50, 54], ["hepatocyte", "CELL", 95, 105], ["HS-Csn8KO mice", "ORGANISM", 119, 133], ["Bim", "PROTEIN", 10, 13], ["Bcl2", "PROTEIN", 50, 54], ["mice", "SPECIES", 129, 133], ["Increased Bim expression", "PROBLEM", 0, 24], ["Bcl2", "TREATMENT", 50, 54], ["Bim expression", "OBSERVATION", 10, 24], ["hepatocyte", "ANATOMY", 95, 105], ["apoptosis", "OBSERVATION", 106, 115]]]], "f773f52694070066ff3186168efaf850dd6c8fae": [["RationaleTo reduce general anesthetic related maternal and neonatal morbidity and mortality To identify and give evidence based anesthetic services for pregnant mothers coming for cesarean deliveryRationaleTo have best possible maternal and neonatal outcome.", [["general anesthetic", "TREATMENT", 19, 37], ["maternal and neonatal morbidity", "PROBLEM", 46, 77], ["cesarean delivery", "TREATMENT", 180, 197], ["maternal and neonatal outcome", "PROBLEM", 228, 257]]], ["Internationally, obstetric anesthesia guidelines recommend spinal and epidural over general anesthesia (GA) for most caesarean sections (CSs).", [["spinal", "ANATOMY", 59, 65], ["epidural", "ANATOMY", 70, 78], ["sections", "ANATOMY", 127, 135], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 78], ["obstetric anesthesia guidelines", "TREATMENT", 17, 48], ["spinal and epidural over general anesthesia", "TREATMENT", 59, 102], ["most caesarean sections", "TREATMENT", 112, 135], ["spinal", "ANATOMY", 59, 65], ["epidural", "ANATOMY", 70, 78]]], ["The primary reason for recommending regional blocks is the risk of failed endotracheal intubation and aspiration of gastric contents.RationaleGeneral anesthesia is the fastest method for anesthetizing a category 1 cs associated with increased maternal mortality and morbidity and Spinal anesthesia is the preferred regional technique for cs but failure sometimes occurs.", [["endotracheal", "ANATOMY", 74, 86], ["gastric", "ANATOMY", 116, 123], ["Spinal", "ANATOMY", 280, 286], ["gastric", "ORGAN", 116, 123], ["regional blocks", "TREATMENT", 36, 51], ["failed endotracheal intubation", "TREATMENT", 67, 97], ["aspiration of gastric contents", "PROBLEM", 102, 132], ["RationaleGeneral anesthesia", "TREATMENT", 133, 160], ["increased maternal mortality", "PROBLEM", 233, 261], ["morbidity", "PROBLEM", 266, 275], ["Spinal anesthesia", "TREATMENT", 280, 297], ["cs", "PROBLEM", 338, 340], ["failure", "PROBLEM", 345, 352], ["endotracheal intubation", "OBSERVATION", 74, 97], ["gastric", "ANATOMY", 116, 123], ["Spinal", "ANATOMY", 280, 286], ["failure", "OBSERVATION", 345, 352]]], ["While regional anesthesia or general anesthesia are both acceptable for cesarean delivery, the use of general anesthesia has become less common in the past few decades.", [["regional anesthesia", "TREATMENT", 6, 25], ["general anesthesia", "TREATMENT", 29, 47], ["cesarean delivery", "TREATMENT", 72, 89], ["general anesthesia", "TREATMENT", 102, 120]]], ["While most cesarean sections are performed under regional anesthesia, general anesthesia should always be considered as it is occasionally necessary(1, 2).RationaleTo minimize the time factor of spinal anesthesia as well as to avoid the side effects of general anesthesia 'rapid sequence spinal '(RSS) has developed as a novel approach in cases of category one cesarean sections. neuraxial anesthetic techniques have several advantages which include low risk of aspiration and failed intubation, avoidance of central nervous system and respiratory depressant drugs, the ability to maintain a wakeful state of mother enjoying the experience of delivery of baby, lower incidence of blood loss, early ambulation and low risk of DVT, early return of gastrointestinal function and short hospital stay length.", [["cesarean sections", "ANATOMY", 11, 28], ["spinal", "ANATOMY", 195, 201], ["spinal", "ANATOMY", 288, 294], ["sections", "ANATOMY", 370, 378], ["central nervous system", "ANATOMY", 509, 531], ["respiratory", "ANATOMY", 536, 547], ["blood", "ANATOMY", 680, 685], ["gastrointestinal", "ANATOMY", 746, 762], ["blood loss", "DISEASE", 680, 690], ["DVT", "DISEASE", 725, 728], ["cesarean sections", "MULTI-TISSUE_STRUCTURE", 11, 28], ["central nervous system", "ANATOMICAL_SYSTEM", 509, 531], ["baby", "ORGANISM_SUBDIVISION", 655, 659], ["blood", "ORGANISM_SUBSTANCE", 680, 685], ["gastrointestinal", "ORGAN", 746, 762], ["most cesarean sections", "TREATMENT", 6, 28], ["regional anesthesia", "TREATMENT", 49, 68], ["general anesthesia", "TREATMENT", 70, 88], ["RationaleTo", "TREATMENT", 155, 166], ["spinal anesthesia", "TREATMENT", 195, 212], ["general anesthesia", "TREATMENT", 253, 271], ["rapid sequence spinal '(RSS", "TREATMENT", 273, 300], ["category one cesarean sections", "TREATMENT", 348, 378], ["neuraxial anesthetic techniques", "TREATMENT", 380, 411], ["aspiration", "PROBLEM", 462, 472], ["failed intubation", "TREATMENT", 477, 494], ["central nervous system", "PROBLEM", 509, 531], ["respiratory depressant drugs", "TREATMENT", 536, 564], ["delivery", "TREATMENT", 643, 651], ["blood loss", "PROBLEM", 680, 690], ["early ambulation", "PROBLEM", 692, 708], ["DVT", "PROBLEM", 725, 728], ["spinal", "ANATOMY", 195, 201], ["aspiration", "OBSERVATION", 462, 472], ["central", "ANATOMY_MODIFIER", 509, 516], ["nervous system", "ANATOMY", 517, 531], ["respiratory depressant", "OBSERVATION", 536, 558], ["blood loss", "OBSERVATION", 680, 690], ["DVT", "OBSERVATION", 725, 728], ["gastrointestinal", "ANATOMY", 746, 762]]], ["Amongst the various neuraxial techniques, spinal anesthesia has been popular for cesarean delivery because of ease of administration, effectiveness and faster onset providing dense motor block with minimal drug toxicity to mother and to fetus due to limited placental transfer(1, 2).RationaleThe rapid sequence spinal (RSS), first described in 2003, consists of measures aimed at reducing the time to establish spinal anesthesia in urgent obstetric cases and We all know that category-1 caesarean sections are a challenge and the anesthetic we provide has to be safe, effective and fast.", [["spinal", "ANATOMY", 42, 48], ["fetus", "ANATOMY", 237, 242], ["placental", "ANATOMY", 258, 267], ["spinal", "ANATOMY", 311, 317], ["spinal", "ANATOMY", 411, 417], ["sections", "ANATOMY", 497, 505], ["toxicity", "DISEASE", 211, 219], ["fetus", "ORGAN", 237, 242], ["placental", "ORGAN", 258, 267], ["the various neuraxial techniques", "TREATMENT", 8, 40], ["spinal anesthesia", "TREATMENT", 42, 59], ["cesarean delivery", "TREATMENT", 81, 98], ["dense motor block", "PROBLEM", 175, 192], ["minimal drug toxicity", "PROBLEM", 198, 219], ["spinal anesthesia", "TREATMENT", 411, 428], ["urgent obstetric cases", "TREATMENT", 432, 454], ["1 caesarean sections", "TREATMENT", 485, 505], ["the anesthetic", "TREATMENT", 526, 540], ["spinal", "ANATOMY", 42, 48], ["dense", "OBSERVATION_MODIFIER", 175, 180], ["motor block", "OBSERVATION", 181, 192], ["spinal", "ANATOMY", 311, 317], ["spinal", "ANATOMY", 411, 417], ["anesthesia", "OBSERVATION", 418, 428]]], ["The concept of rapid sequence spinal (RSS) evolved as an alternative to both emergency general anesthesia, which carries risks of several fatal complications and also the conventional spinal anesthesia, which is time consuming.", [["spinal", "ANATOMY", 30, 36], ["spinal", "ANATOMY", 184, 190], ["spinal", "MULTI-TISSUE_STRUCTURE", 30, 36], ["emergency general anesthesia", "TREATMENT", 77, 105], ["several fatal complications", "PROBLEM", 130, 157], ["the conventional spinal anesthesia", "TREATMENT", 167, 201], ["spinal", "ANATOMY", 30, 36], ["spinal", "ANATOMY", 184, 190], ["anesthesia", "OBSERVATION", 191, 201]]], ["It is actually a conjugation of the two which is based on the principles of performing as fast as possible carrying out only the absolute essential steps thereby cutting the permissible time and on the other hand, limiting the attempts of administering J o u r n a l P r e -p r o o f 4 the block or even abandoning it in favor of other alternative techniques as is done during rapid sequence induction including multiple drug exposure during general anesthesia(3, 4).JustificationsThe choice of anesthetic in Cesarean section has long been recognized as one of prime importance, because there are two lives to safeguard instead of one.", [["a l P r e -p r o o f", "TREATMENT", 263, 283], ["the block", "TREATMENT", 286, 295], ["rapid sequence induction", "TREATMENT", 377, 401], ["multiple drug exposure", "TREATMENT", 412, 434], ["general anesthesia", "TREATMENT", 442, 460], ["anesthetic", "TREATMENT", 495, 505], ["Cesarean section", "TREATMENT", 509, 525]]], ["A balance must be struck between the anesthetic dictated by the general condition of the mother and that suited to the needs of the fetal respiratory system because fetal distress is one of the indications to fasten the delivery process and the diagnosis of fetal distress is based on the fetal heart beats, whether they are fast, slow, irregular and whether there is meconium present during delivery.", [["fetal respiratory system", "ANATOMY", 132, 156], ["fetal", "ANATOMY", 165, 170], ["fetal", "ANATOMY", 258, 263], ["fetal heart", "ANATOMY", 289, 300], ["meconium", "ANATOMY", 368, 376], ["fetal distress", "DISEASE", 165, 179], ["fetal distress", "DISEASE", 258, 272], ["fetal respiratory", "ORGANISM_SUBDIVISION", 132, 149], ["system", "ANATOMICAL_SYSTEM", 150, 156], ["fetal", "ANATOMICAL_SYSTEM", 165, 170], ["fetal", "ANATOMICAL_SYSTEM", 258, 263], ["fetal", "MULTI-TISSUE_STRUCTURE", 289, 294], ["heart", "ORGAN", 295, 300], ["meconium", "ORGANISM_SUBSTANCE", 368, 376], ["the fetal respiratory system", "TEST", 128, 156], ["fetal distress", "PROBLEM", 165, 179], ["the delivery process", "TREATMENT", 216, 236], ["fetal distress", "PROBLEM", 258, 272], ["the fetal heart beats", "PROBLEM", 285, 306], ["meconium", "PROBLEM", 368, 376], ["delivery", "TREATMENT", 392, 400], ["balance", "OBSERVATION", 2, 9], ["fetal distress", "OBSERVATION", 258, 272], ["heart beats", "ANATOMY", 295, 306], ["irregular", "OBSERVATION_MODIFIER", 337, 346], ["meconium", "OBSERVATION", 368, 376]]], ["There have been many reasons to develop and adopt rapid sequence spinal anesthesia for category 1 cesarean section and this can be generally justified by weighing risk and benefits of general and spinal anesthesia.", [["spinal", "ANATOMY", 65, 71], ["spinal", "ANATOMY", 196, 202], ["spinal", "ORGANISM_SUBDIVISION", 196, 202], ["rapid sequence spinal anesthesia", "TREATMENT", 50, 82], ["category 1 cesarean section", "TREATMENT", 87, 114], ["general and spinal anesthesia", "TREATMENT", 184, 213], ["spinal", "ANATOMY", 65, 71], ["spinal", "ANATOMY", 196, 202], ["anesthesia", "OBSERVATION", 203, 213]]], ["Clinical investigations and reviews done in different countries with time period showed, the death due to g anesthesia related death is high even though spinal anesthesia related deaths decreased (5-7),.", [["spinal", "ANATOMY", 153, 159], ["death", "DISEASE", 93, 98], ["death", "DISEASE", 127, 132], ["deaths", "DISEASE", 179, 185], ["Clinical investigations", "TEST", 0, 23], ["the death", "PROBLEM", 89, 98], ["g anesthesia", "TREATMENT", 106, 118], ["death", "PROBLEM", 127, 132], ["spinal anesthesia", "TREATMENT", 153, 170], ["spinal", "ANATOMY", 153, 159]]], ["The risk is high in pregnancy because of pregnancy related physiologic and anatomic changes such as large breast, edematous air way and frequent hypoxia, which is due to limited diaphragmatic excursion due to gravid uterus, high oxygen consumption and high risk of aspiration to have standard laryngoscopy by repeated attempts.", [["breast", "ANATOMY", 106, 112], ["diaphragmatic", "ANATOMY", 178, 191], ["uterus", "ANATOMY", 216, 222], ["hypoxia", "DISEASE", 145, 152], ["oxygen", "CHEMICAL", 229, 235], ["oxygen", "CHEMICAL", 229, 235], ["breast", "ORGANISM_SUBDIVISION", 106, 112], ["diaphragmatic", "ORGAN", 178, 191], ["uterus", "ORGAN", 216, 222], ["oxygen", "SIMPLE_CHEMICAL", 229, 235], ["pregnancy related physiologic", "PROBLEM", 41, 70], ["anatomic changes", "PROBLEM", 75, 91], ["large breast, edematous air way", "PROBLEM", 100, 131], ["frequent hypoxia", "PROBLEM", 136, 152], ["limited diaphragmatic excursion", "PROBLEM", 170, 201], ["gravid uterus", "PROBLEM", 209, 222], ["high oxygen consumption", "PROBLEM", 224, 247], ["aspiration", "PROBLEM", 265, 275], ["standard laryngoscopy", "TEST", 284, 305], ["large", "OBSERVATION_MODIFIER", 100, 105], ["breast", "ANATOMY", 106, 112], ["edematous", "OBSERVATION_MODIFIER", 114, 123], ["air", "OBSERVATION", 124, 127], ["frequent", "OBSERVATION_MODIFIER", 136, 144], ["hypoxia", "OBSERVATION", 145, 152], ["uterus", "ANATOMY", 216, 222], ["high", "OBSERVATION_MODIFIER", 224, 228], ["oxygen consumption", "OBSERVATION", 229, 247], ["aspiration", "OBSERVATION", 265, 275]]], ["As this was supported by many evidences previously that here are still risk of difficult intubation, difficult laryngoscopy, failed intubation, regurgitation during intubation trials and aspiration of gastric contents during emergency cesarean section under general anesthesia(11).", [["gastric", "ANATOMY", 201, 208], ["gastric", "ORGAN", 201, 208], ["difficult intubation", "PROBLEM", 79, 99], ["difficult laryngoscopy", "TEST", 101, 123], ["failed intubation", "TREATMENT", 125, 142], ["regurgitation", "PROBLEM", 144, 157], ["intubation trials", "TREATMENT", 165, 182], ["aspiration", "TREATMENT", 187, 197], ["gastric contents", "PROBLEM", 201, 217], ["emergency cesarean section", "TREATMENT", 225, 251], ["general anesthesia", "TREATMENT", 258, 276], ["regurgitation", "OBSERVATION", 144, 157], ["gastric", "ANATOMY", 201, 208]]], ["Poor airway assessment contributed to poor airway outcomes because of omission, incomplete assessment or a failure to alter the airway management technique in response to findings at assessment.", [["airway", "ANATOMY", 5, 11], ["airway", "ANATOMY", 43, 49], ["airway", "ANATOMY", 128, 134], ["airway", "MULTI-TISSUE_STRUCTURE", 5, 11], ["airway", "MULTI-TISSUE_STRUCTURE", 43, 49], ["airway", "MULTI-TISSUE_STRUCTURE", 128, 134], ["Poor airway assessment", "TEST", 0, 22], ["poor airway outcomes", "PROBLEM", 38, 58], ["incomplete assessment", "TEST", 80, 101], ["a failure", "PROBLEM", 105, 114], ["the airway management technique", "TREATMENT", 124, 155], ["findings at assessment", "TEST", 171, 193], ["airway", "ANATOMY", 5, 11], ["airway", "ANATOMY", 128, 134]]], ["Studies from difficult air way society of united kingdom recommended that ,assessment to predict both potential airway difficulty and aspiration risk were equally important and this all were due to in adequate time during category 1 emergency cesarean section cases (14, 15) ,.Discussion22 studies from Cochrane review showed that there was significant decrement of blood loss and post-operative pain relief during regional anesthesia than general anesthesia even though other parameters such as recovery times, effects on breastfeeding, effects on the mother-child relationship and length of time before mother feels well enough to care for her baby are not It is known that spinal anesthesia is not without risk eventhough it has been considered for urgent cesarean section and failed block was found to be 6%(28)*.DiscussionNowadays we are suffering with corona virus (covid- 19) pandemic.", [["airway", "ANATOMY", 112, 118], ["blood", "ANATOMY", 366, 371], ["spinal", "ANATOMY", 676, 682], ["blood loss", "DISEASE", 366, 376], ["pain", "DISEASE", 396, 400], ["airway", "MULTI-TISSUE_STRUCTURE", 112, 118], ["blood", "ORGANISM_SUBSTANCE", 366, 371], ["spinal", "ORGANISM_SUBDIVISION", 676, 682], ["corona virus", "ORGANISM", 858, 870], ["covid- 19", "ORGANISM", 872, 881], ["Studies", "TEST", 0, 7], ["assessment", "TEST", 75, 85], ["potential airway difficulty", "PROBLEM", 102, 129], ["aspiration risk", "PROBLEM", 134, 149], ["category 1 emergency cesarean section", "TREATMENT", 222, 259], ["Cochrane review", "TEST", 303, 318], ["blood loss", "PROBLEM", 366, 376], ["post-operative pain relief", "PROBLEM", 381, 407], ["regional anesthesia", "TREATMENT", 415, 434], ["general anesthesia", "TREATMENT", 440, 458], ["spinal anesthesia", "TREATMENT", 676, 693], ["urgent cesarean section", "TREATMENT", 752, 775], ["failed block", "PROBLEM", 780, 792], ["corona virus", "PROBLEM", 858, 870], ["pandemic", "PROBLEM", 883, 891], ["airway", "ANATOMY", 112, 118], ["difficulty", "OBSERVATION", 119, 129], ["significant", "OBSERVATION_MODIFIER", 341, 352], ["decrement", "OBSERVATION", 353, 362], ["blood loss", "OBSERVATION", 366, 376], ["spinal", "ANATOMY", 676, 682], ["anesthesia", "OBSERVATION", 683, 693], ["not without", "UNCERTAINTY", 697, 708]]], ["In addition to limited time to assess the airways of pregnant mothers decided for emergent cesarean section with corona virus confirmed, the is risk of disease transmission to so.", [["airways", "ANATOMY", 42, 49], ["airways", "MULTI-TISSUE_STRUCTURE", 42, 49], ["emergent cesarean section", "TREATMENT", 82, 107], ["corona virus", "PROBLEM", 113, 125], ["disease transmission", "PROBLEM", 152, 172], ["airways", "ANATOMY", 42, 49], ["disease", "OBSERVATION", 152, 159]]], ["As it has been mentioned about higher rates of difficult airway during general anesthesia for cesarean section, the corona virus transmission is very high during any aerosol transmission and the rapid sequence spinal anesthesia is becoming new and novel approach for those patients indicated for cesarean section with category1 indication (30)**.", [["airway", "ANATOMY", 57, 63], ["spinal", "ANATOMY", 210, 216], ["airway", "MULTI-TISSUE_STRUCTURE", 57, 63], ["corona virus", "ORGANISM", 116, 128], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 273, 281], ["difficult airway", "PROBLEM", 47, 63], ["general anesthesia", "TREATMENT", 71, 89], ["cesarean section", "TREATMENT", 94, 110], ["the corona virus transmission", "TEST", 112, 141], ["any aerosol transmission", "TREATMENT", 162, 186], ["the rapid sequence spinal anesthesia", "TREATMENT", 191, 227], ["cesarean section", "TREATMENT", 296, 312], ["airway", "ANATOMY", 57, 63], ["spinal", "ANATOMY", 210, 216]]], ["This disease is associated with wide ranges of respiratory compromization which could potentially be affected or aggravated by the drugs during general anesthesia and it is recommended to proceed with rapid sequence spinal anesthesia to prevent the mentioned problems (31)*.Areas of controversyGreat controversy is timing to attain rapid sequence spinal anesthesia when compared with rapid sequence general anesthesia because of there are some factors for inability to attain rapidConclusionNeuraxial anesthetic techniques have several advantages which include low risk of aspiration and failed intubation, avoidance of central nervous system (CNS) and respiratory depressant drugs, the ability to maintain a wakeful state of mother enjoying the experience of delivery of baby and also lower incidence of blood loss.", [["respiratory", "ANATOMY", 47, 58], ["spinal", "ANATOMY", 216, 222], ["spinal", "ANATOMY", 347, 353], ["central nervous system", "ANATOMY", 620, 642], ["CNS", "ANATOMY", 644, 647], ["respiratory", "ANATOMY", 653, 664], ["blood", "ANATOMY", 805, 810], ["respiratory compromization", "DISEASE", 47, 73], ["avoidance of central nervous system", "DISEASE", 607, 642], ["blood loss", "DISEASE", 805, 815], ["central nervous system", "ANATOMICAL_SYSTEM", 620, 642], ["CNS", "ANATOMICAL_SYSTEM", 644, 647], ["baby", "ORGANISM", 772, 776], ["blood", "ORGANISM_SUBSTANCE", 805, 810], ["This disease", "PROBLEM", 0, 12], ["respiratory compromization", "PROBLEM", 47, 73], ["general anesthesia", "TREATMENT", 144, 162], ["rapid sequence spinal anesthesia", "TREATMENT", 201, 233], ["rapid sequence spinal anesthesia", "TREATMENT", 332, 364], ["rapid sequence general anesthesia", "TREATMENT", 384, 417], ["some factors", "PROBLEM", 439, 451], ["Neuraxial anesthetic techniques", "TREATMENT", 491, 522], ["aspiration", "PROBLEM", 573, 583], ["failed intubation", "TREATMENT", 588, 605], ["respiratory depressant drugs", "TREATMENT", 653, 681], ["delivery", "TREATMENT", 760, 768], ["blood loss", "PROBLEM", 805, 815], ["disease", "OBSERVATION", 5, 12], ["respiratory compromization", "OBSERVATION", 47, 73], ["controversy", "OBSERVATION", 283, 294], ["aspiration", "OBSERVATION", 573, 583], ["central", "ANATOMY_MODIFIER", 620, 627], ["nervous system", "ANATOMY", 628, 642], ["respiratory depressant", "OBSERVATION", 653, 675], ["blood loss", "OBSERVATION", 805, 815]]], ["'Rapid sequence spinal' described to minimize anesthetic time.", [["spinal", "ANATOMY", 16, 22], ["Rapid sequence spinal'", "TREATMENT", 1, 23], ["spinal", "ANATOMY", 16, 22]]], ["This consists of a no-touch spinal technique, consideration of omission of the spinal opioid, limiting spinal attempts, allowing the start of surgery before full establishment of the spinal block, and being prepared for conversion to general anesthesia if there are delays or problems.ConclusionTo do rapid sequence spinal anesthesia safely and timely, cooperative work is mandatory with good team relation for those simultaneous and necessary tasks.", [["spinal", "ANATOMY", 28, 34], ["spinal", "ANATOMY", 79, 85], ["spinal", "ANATOMY", 103, 109], ["spinal", "ANATOMY", 183, 189], ["spinal", "ANATOMY", 316, 322], ["a no-touch spinal technique", "TREATMENT", 17, 44], ["the spinal opioid", "PROBLEM", 75, 92], ["surgery", "TREATMENT", 142, 149], ["the spinal block", "TREATMENT", 179, 195], ["general anesthesia", "TREATMENT", 234, 252], ["problems", "PROBLEM", 276, 284], ["rapid sequence spinal anesthesia", "TREATMENT", 301, 333], ["spinal opioid", "ANATOMY", 79, 92], ["spinal", "ANATOMY", 103, 109], ["spinal", "ANATOMY", 183, 189], ["spinal", "ANATOMY", 316, 322]]], ["The task of IV cannulation most of the time is experienced midwife but anybody from the team members can do so to avoid unnecessary delay.", [["IV cannulation", "TREATMENT", 12, 26], ["unnecessary delay", "PROBLEM", 120, 137]]], ["Regarding with dose of local anesthetics, it is recommended that better to use slightly higher doses than usual which is 3ml of 0.5% hyperbaric bupivacaine or 2.5 ml of 0.5% hyperbaric bupivacaine with 25microgram fentanyl if it readily available.", [["bupivacaine", "CHEMICAL", 144, 155], ["bupivacaine", "CHEMICAL", 185, 196], ["fentanyl", "CHEMICAL", 214, 222], ["bupivacaine", "CHEMICAL", 144, 155], ["bupivacaine", "CHEMICAL", 185, 196], ["fentanyl", "CHEMICAL", 214, 222], ["bupivacaine", "SIMPLE_CHEMICAL", 144, 155], ["bupivacaine", "SIMPLE_CHEMICAL", 185, 196], ["fentanyl", "SIMPLE_CHEMICAL", 214, 222], ["local anesthetics", "TREATMENT", 23, 40], ["slightly higher doses", "TREATMENT", 79, 100], ["0.5% hyperbaric bupivacaine", "TREATMENT", 128, 155], ["0.5% hyperbaric bupivacaine", "TREATMENT", 169, 196], ["25microgram fentanyl", "TREATMENT", 202, 222]]], ["Finally it is possible to convert to general anesthesia if spinal block fails without taking additional time for preoxygenation and general anesthetic preparation because the client was on 100% oxygen as it is shown on flow diagram of the tasks and procedures of it and the drugs were already prepared.RecommendationAwareness should be created among the team members i.e. obstetric residents, obstetricians, midwifes and assistants in addition to Anesthetists' should be training about its essential steps and overall objectives J o u r n a l P r e -p r o o fFlow diagram, Rapid sequence Spinal AnesthesiaBe prepared to convert to general anesthesia -keep mother informed.Deploy other staff for intravenous cannulation and monitoringNo touch' technique -gloves only with glove packet as sterile surface for equipment.", [["spinal", "ANATOMY", 59, 65], ["intravenous", "ANATOMY", 695, 706], ["surface", "ANATOMY", 795, 802], ["oxygen", "CHEMICAL", 194, 200], ["oxygen", "CHEMICAL", 194, 200], ["oxygen", "SIMPLE_CHEMICAL", 194, 200], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 695, 706], ["general anesthesia", "TREATMENT", 37, 55], ["spinal block", "PROBLEM", 59, 71], ["preoxygenation", "TREATMENT", 113, 127], ["general anesthetic preparation", "TREATMENT", 132, 162], ["100% oxygen", "TREATMENT", 189, 200], ["procedures", "TREATMENT", 249, 259], ["the drugs", "TREATMENT", 270, 279], ["a l P r e -p r o o fFlow diagram", "TEST", 539, 571], ["general anesthesia", "TREATMENT", 631, 649], ["intravenous cannulation", "TREATMENT", 695, 718], ["touch' technique", "TREATMENT", 736, 752], ["gloves", "TREATMENT", 754, 760], ["glove packet", "TREATMENT", 771, 783], ["Spinal", "ANATOMY", 588, 594]]], ["Prepare skin with alcoholic providone iodine.Deploy other staff for intravenous cannulation and monitoringConsider increased dose of hyperbaric bupivacaine 0.5% (up to 2.5-3 ml) Add fentanyl 25 micg if procuring it does not produce unacceptable delay Local infiltration not mandatory.", [["skin", "ANATOMY", 8, 12], ["intravenous", "ANATOMY", 68, 79], ["providone iodine", "CHEMICAL", 28, 44], ["bupivacaine", "CHEMICAL", 144, 155], ["fentanyl", "CHEMICAL", 182, 190], ["iodine", "CHEMICAL", 38, 44], ["bupivacaine", "CHEMICAL", 144, 155], ["fentanyl", "CHEMICAL", 182, 190], ["skin", "ORGAN", 8, 12], ["providone iodine", "SIMPLE_CHEMICAL", 28, 44], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 79], ["fentanyl", "SIMPLE_CHEMICAL", 182, 190], ["alcoholic providone iodine", "TREATMENT", 18, 44], ["intravenous cannulation", "TREATMENT", 68, 91], ["increased dose of hyperbaric bupivacaine", "TREATMENT", 115, 155], ["fentanyl", "TREATMENT", 182, 190], ["unacceptable delay Local infiltration", "PROBLEM", 232, 269], ["skin", "ANATOMY", 8, 12], ["infiltration", "OBSERVATION", 257, 269]]], ["One attempt at spinal unless obvious correction allows a second Preoxygenate during procedures all the time", [["spinal", "ANATOMY", 15, 21], ["a second Preoxygenate during procedures", "TREATMENT", 55, 94], ["spinal", "ANATOMY", 15, 21]]]], "c72ea8846db0028599a07e8eefd087ede77f6dad": [["Sampling was performed in COVID-19 isolation units in two hospitals and one quarantine 78 facility.", [["Sampling", "TEST", 0, 8]]], ["Hospital-A isolation unit is a 28-bed ward, comprised of secluded rooms occupied by 1- unit is a 40-bed ward, comprised of secluded rooms occupied by 1-6 patients each.", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162]]], ["Staff used 84 coveralls, masks, shoe covers and face shields.", [["masks", "TREATMENT", 25, 30], ["face shields", "TREATMENT", 48, 60]]], ["SOP was the use of two pairs of gloves at a time.85The outer pair was not consistently changed during patient care.", [["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109]]], ["At the time of sampling, the unit 86 contained patients with mild-to-severe disease, including seven ventilated patients.", [["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 112, 120], ["mild-to-severe disease", "PROBLEM", 61, 83], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["disease", "OBSERVATION", 76, 83]]], ["In both 87 hospitals, patients were free to ambulate in the unit if they were fit to walk.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["In addition, routine 88 cleaning and decontamination was done twice a day using 1000ppm bleach solution in both 89 wards.", [["routine 88 cleaning", "TREATMENT", 13, 32], ["decontamination", "TREATMENT", 37, 52], ["1000ppm bleach solution", "TREATMENT", 80, 103]]], ["The quarantine facility was a hotel repurposed for the isolation of patients with 90 asymptomatic to mild disease until becoming negative for viral nasopharyngeal PCR.", [["nasopharyngeal", "ANATOMY", 148, 162], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["mild disease", "PROBLEM", 101, 113], ["viral nasopharyngeal PCR", "PROBLEM", 142, 166], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["disease", "OBSERVATION", 106, 113]]], ["Sampling 91 J o u r n a l P r e -p r o o f was conducted at main public areas and in hotel rooms.", [["Sampling", "TEST", 0, 8], ["a l P r e -p r o o f", "TEST", 22, 42]]], ["Patients stayed in private rooms either 92 alone or as a family but were free to move around the hotel and socialize in public spaces.93Routine cleaning and decontamination was done once daily at best only on communal areas. was tested by seeding quadruplets of 200 \u00b5l on VERO E6 cells for CPE assay as described 115 above.", [["VERO E6 cells", "ANATOMY", 272, 285], ["Patients", "ORGANISM", 0, 8], ["VERO E6 cells", "CELL", 272, 285], ["VERO E6 cells", "CELL_LINE", 272, 285], ["Patients", "SPECIES", 0, 8], ["Routine cleaning", "TREATMENT", 136, 152], ["decontamination", "TREATMENT", 157, 172], ["VERO E6 cells", "TREATMENT", 272, 285], ["CPE assay", "TEST", 290, 299]]], ["CPE assay limit of detection has been determined to be 10PFU/ml.", [["CPE assay", "TEST", 0, 9]]], ["Finally, we mapped the contamination in a quarantine hotel for asymptomatic (patients found to 155 be infected during contact testing but had no symptoms) and very mild COVID-19 patients.156Sampling was performed at the hotel communal areas and at three hotel rooms that had been 157 J o u r n a l P r e -p r o o f recently (2-4 days) occupied by newly diagnosed patients.", [["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 178, 186], ["patients", "ORGANISM", 363, 371], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 363, 371], ["contact testing", "TEST", 118, 133], ["symptoms", "PROBLEM", 145, 153], ["very mild COVID", "PROBLEM", 159, 174], ["Sampling", "TEST", 190, 198]]], ["We found that 16/42 (38%) samples 158 were positive for viral RNA (Table 2) .", [["samples", "ANATOMY", 26, 33], ["samples", "CANCER", 26, 33], ["viral RNA", "RNA", 56, 65], ["samples", "TEST", 26, 33], ["viral RNA", "PROBLEM", 56, 65]]], ["At the communal areas we found viral RNA 159 contamination on a water cooler, chairs, most elevator buttons, a kettle and a used cup.199In this study, viral RNA contamination was found in 46% of the surface and air samples.216Our study has some limitations.", [["cup", "ANATOMY", 129, 132], ["surface", "ANATOMY", 199, 206], ["air samples", "ANATOMY", 211, 222], ["surface", "CELLULAR_COMPONENT", 199, 206], ["air samples", "CANCER", 211, 222], ["viral RNA", "PROBLEM", 31, 40], ["a water cooler", "TREATMENT", 62, 76], ["this study", "TEST", 139, 149], ["viral RNA contamination", "PROBLEM", 151, 174], ["air samples", "TEST", 211, 222], ["Our study", "TEST", 226, 235], ["viral RNA", "OBSERVATION", 31, 40], ["159 contamination", "OBSERVATION_MODIFIER", 41, 58], ["air samples", "OBSERVATION", 211, 222]]], ["There was a delay between onset of symptoms and the actual 217 sampling in patients' rooms.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["symptoms", "PROBLEM", 35, 43]]], ["Therefore, at the time of sampling these patients might not have 218 shed viable virus as suggested by studies that showed culturable viruses in respiratory samples 219 up to 8 th -9 th day of illness (18, 24) .", [["respiratory samples", "ANATOMY", 145, 164], ["illness", "DISEASE", 193, 200], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["viable virus", "PROBLEM", 74, 86], ["culturable viruses", "PROBLEM", 123, 141], ["respiratory samples", "TEST", 145, 164], ["illness", "PROBLEM", 193, 200]]], ["For that reason, we have noted new patients with recent 220 disease onset in hospital A and the quarantine hotel and sampled around them.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["The CPE assay 221 has a 10pfu/ml limit of detection that is comparable to CT value of 34, therefore a very low level J o u r n a l P r e -p r o o f", [["The CPE assay", "TEST", 0, 13], ["CT value", "TEST", 74, 82]]]], "PMC7315964": [["IntroductionThe coronavirus disease 2019 (COVID-19) has evolved as a global public health emergency affecting 212 countries and territories around the world as of May 12, 2020 [30].", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["coronavirus", "ORGANISM", 16, 27], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["coronavirus disease", "OBSERVATION", 16, 35]]], ["COVID-19 is one kind of respiratory disease by the novel coronavirus (SARS-CoV-2) that was first spotted around late December 2019, in Wuhan, Hubei province, China [3], [7].", [["respiratory", "ANATOMY", 24, 35], ["COVID-19", "CHEMICAL", 0, 8], ["respiratory disease", "DISEASE", 24, 43], ["coronavirus", "ORGANISM", 57, 68], ["SARS-CoV-2", "ORGANISM", 70, 80], ["COVID", "TEST", 0, 5], ["respiratory disease", "PROBLEM", 24, 43], ["the novel coronavirus", "PROBLEM", 47, 68], ["one kind", "OBSERVATION_MODIFIER", 12, 20], ["respiratory disease", "OBSERVATION", 24, 43]]], ["This novel virus started transmitting around the world rapidly, and on 30 January, WHO declared the outbreak as a Public Health Emergency of International Concern (PHEIC).", [["This novel virus", "PROBLEM", 0, 16], ["virus", "OBSERVATION", 11, 16]]], ["Later, WHO Director-General announced COVID-19 as a global pandemic.", [["pandemic", "OBSERVATION", 59, 67]]], ["As of May 11, 2020, an outbreak of COVID-19 has resulted in 4,271,689 confirmed cumulative cases with reported deaths of 287,613 worldwide [30].", [["COVID-19", "CHEMICAL", 35, 43], ["deaths", "DISEASE", 111, 117], ["COVID", "TEST", 35, 40]]], ["In most of the countries, infected patients are struggling to get the proper treatment due to highly transmissible and virulent nature of the virus.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["the proper treatment", "TREATMENT", 66, 86], ["the virus", "PROBLEM", 138, 147], ["infected", "OBSERVATION", 26, 34], ["virus", "OBSERVATION", 142, 147]]], ["Nevertheless, numerous COVID-19 mitigation strategies has been adapted so far such as quarantine, isolation, promoting the wearing of face masks, travel restrictions, and lockdowns with a view to reducing community transmission of the disease.IntroductionIn the absence of either established effective treatment or a vaccine, the already fragile health care systems of different developed and developing countries can be overburdened due to the overwhelming surge of infections in in the coming months provided that the spread is not controlled.", [["infections", "DISEASE", 467, 477], ["numerous COVID-19 mitigation strategies", "TREATMENT", 14, 53], ["quarantine", "TREATMENT", 86, 96], ["isolation", "TREATMENT", 98, 107], ["face masks", "TREATMENT", 134, 144], ["the disease", "PROBLEM", 231, 242], ["effective treatment", "TREATMENT", 292, 311], ["a vaccine", "TREATMENT", 315, 324], ["infections", "PROBLEM", 467, 477], ["disease", "OBSERVATION", 235, 242], ["infections", "OBSERVATION", 467, 477]]], ["This pandemic is giving an upsurge to multifarious noteworthy socio-economic and public health impacts and has highlighted the significance of detecting the evolution of the disease and prediction of disease future dynamics for designing infectious disease prevention and control strategies, effective public health policies and economical activity guidelines.", [["infectious disease", "DISEASE", 238, 256], ["the disease", "PROBLEM", 170, 181], ["disease future dynamics", "PROBLEM", 200, 223], ["infectious disease prevention", "TREATMENT", 238, 267], ["economical activity guidelines", "TREATMENT", 329, 359], ["disease", "OBSERVATION", 174, 181]]], ["Different mathematical paradigms have always played a notable role in providing deeper understanding of the transmission mechanisms of a disease outbreak, contributing considerable insights for controlling the disease outbreak.", [["a disease outbreak", "PROBLEM", 135, 153], ["the disease outbreak", "PROBLEM", 206, 226], ["disease", "OBSERVATION", 210, 217]]], ["One of the familiar models for human-to-human transmission which is reasonably predictive is Susceptible-Infectious-Removed (SIR) epidemic model proposed by Kermack-Mckendrick in 1927 [10], [14].", [["Infectious-Removed (SIR) epidemic", "DISEASE", 105, 138], ["human", "ORGANISM", 31, 36], ["human", "ORGANISM", 40, 45], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 40, 45], ["Infectious", "OBSERVATION", 105, 115]]], ["After that, the SIR epidemic model has been extended to Susceptible-Exposed-Infectious-Removed (SEIR) model and many of its variants to explore the risk factors of a disease or predict the dynamics of a disease outbreak [9], [11], [13], [10], [12], [14].", [["[11]", "SIMPLE_CHEMICAL", 225, 229], ["[13]", "SIMPLE_CHEMICAL", 231, 235], ["[10]", "SIMPLE_CHEMICAL", 237, 241], ["[12]", "SIMPLE_CHEMICAL", 243, 247], ["[14]", "SIMPLE_CHEMICAL", 249, 253], ["Removed (SEIR) model", "TREATMENT", 87, 107], ["a disease", "PROBLEM", 164, 173], ["a disease outbreak", "PROBLEM", 201, 219], ["Infectious", "OBSERVATION", 76, 86]]], ["In fact, analysis and prediction could go wrong in the absence of adequate historical real data.", [["analysis", "TEST", 9, 17]]], ["On the other hand, various agent-based often stochastic models where individuals interact on a network structure and get infected stochastically, have been treated as useful tools for tracing fine-grained effects of heterogeneous intervention policies in diverse disease outbreaks [4], [15], [16], [17].", [["[15]", "SIMPLE_CHEMICAL", 286, 290], ["[16]", "SIMPLE_CHEMICAL", 292, 296], ["[17]", "SIMPLE_CHEMICAL", 298, 302], ["heterogeneous intervention policies", "TREATMENT", 216, 251], ["diverse disease outbreaks", "PROBLEM", 255, 280], ["heterogeneous", "OBSERVATION_MODIFIER", 216, 229], ["diverse", "OBSERVATION_MODIFIER", 255, 262], ["disease", "OBSERVATION", 263, 270]]], ["However, accuracy of this approach can be a vital issue due to the time-varying nature of network-structure.IntroductionSince the outbreak of the virus, incorporating travel between major cities in China, [3] proposed an SEIR-model incorporating a metapopulation structure for both reported and unreported infections.", [["infections", "DISEASE", 306, 316], ["network", "MULTI-TISSUE_STRUCTURE", 90, 97], ["the virus", "PROBLEM", 142, 151], ["an SEIR-model", "TREATMENT", 218, 231], ["unreported infections", "PROBLEM", 295, 316], ["metapopulation structure", "OBSERVATION", 248, 272], ["infections", "OBSERVATION", 306, 316]]], ["According to their estimation, on an individual basis, around 55% asymptomatic spreaders were contagious who were responsible for 79% of new infected cases.", [["new infected cases", "PROBLEM", 137, 155], ["new", "OBSERVATION_MODIFIER", 137, 140], ["infected", "OBSERVATION", 141, 149]]], ["Other studies [19], [4] solidified the significance of incorporating asymptomatic carriers with a view to understanding COVID-19 future dynamics appropriately.", [["[4]", "SIMPLE_CHEMICAL", 20, 23], ["Other studies", "TEST", 0, 13], ["incorporating asymptomatic carriers", "PROBLEM", 55, 90], ["COVID", "TEST", 120, 125]]], ["[13] apply the SIRD model to Chinese official statistics, estimating parameters using linear regression and predict the COVID-19 pandemic in Hubei province by using these models and parameters.", [["the COVID", "TEST", 116, 125]]], ["Nonetheless, long-term forecasting is debatable while using a simple mathematical model.", [["a simple mathematical model", "TREATMENT", 60, 87], ["long-term", "OBSERVATION_MODIFIER", 13, 22]]], ["[20] and [21] independently apply modified SIRD models, in which parameters change overtime following specific function forms.", [["modified SIRD models", "TREATMENT", 34, 54]]], ["Moreover, fitting the SIRD model in the early stage of infection is questionable as well.IntroductionIn the light of above shortcomings of several established mathematical models, a more refined deterministic system of nonlinear differential equations, considering all possible interactions, a Susceptible-Exposed-Symptomatic Infectious-Asymptomatic Infectious-Quarantined-Hospitalized-Recovered-Dead (SEIDIUQHRD) model has been proposed, which can give more accurate and robust short-term as well as long-term predictions of COVID-19 future dynamics.", [["infection", "DISEASE", 55, 64], ["fitting the SIRD model", "PROBLEM", 10, 32], ["infection", "PROBLEM", 55, 64], ["nonlinear differential equations", "PROBLEM", 219, 251], ["COVID", "TREATMENT", 526, 531], ["early stage", "OBSERVATION_MODIFIER", 40, 51], ["infection", "OBSERVATION", 55, 64], ["Symptomatic", "OBSERVATION_MODIFIER", 314, 325], ["Infectious", "OBSERVATION", 326, 336]]], ["This model could be considered as a generalization of SEIR, which is based on the introduction of asymptomatic infectious state, quarantined state in order to understand the effect of preventive actions and hospitalized (isolated) state.", [["asymptomatic infectious state", "PROBLEM", 98, 127], ["preventive actions", "TREATMENT", 184, 202], ["could be considered", "UNCERTAINTY", 11, 30], ["asymptomatic", "OBSERVATION_MODIFIER", 98, 110], ["infectious", "OBSERVATION", 111, 121]]], ["Based on similar studies performed over SEIR dynamical systems some assumptions are taken into account [9], [13], [10].", [["[13]", "SIMPLE_CHEMICAL", 108, 112], ["similar studies", "TEST", 9, 24]]], ["As of May 11, it is evident that how the early stage mathematical model parameters have changed drastically as detection rate was really low until middle of February, however the outbreak situation has improved comprehensively in several countries due to massive scale testing [31].", [["detection rate", "TEST", 111, 125], ["the outbreak situation", "PROBLEM", 175, 197], ["massive scale testing", "TEST", 255, 276]]], ["We have considered the nominal values of the model parameters understanding the characteristics of the coronavirus infection, quantitatively estimated in the literature or published by health organizations [3], [9], [19], [2].", [["coronavirus infection", "DISEASE", 103, 124], ["coronavirus", "ORGANISM", 103, 114], ["the coronavirus infection", "PROBLEM", 99, 124], ["coronavirus", "OBSERVATION_MODIFIER", 103, 114], ["infection", "OBSERVATION", 115, 124]]], ["In sequence, a rigorous process of model calibration which is known as Trust-region-reflective algorithm is applied to determine the best-fitted parameter values of the model.", [["model calibration", "PROBLEM", 35, 52], ["reflective algorithm", "TEST", 84, 104], ["model calibration", "OBSERVATION", 35, 52]]], ["Our analysis was based on the publicly available data of the new confirmed daily cases reported for the future probable COVID-19 hotspots which are Russia, Brazil, India and Bangladesh from late January until May 09, 2020 [18].", [["Our analysis", "TEST", 0, 12]]], ["Based on the released data, we attempted to estimate the mean values of the crucial epidemiological parameters for COVID-19, such as the infectiousness factor for asymptotic carriers, isolation period, the estimation of the inflection point with probable date, recovery period for both symptomatic and asymptomatic individuals, case-fatality ratio and mortality rate in those potential hotspots.", [["COVID", "TEST", 115, 120], ["the infectiousness factor", "PROBLEM", 133, 158], ["asymptotic carriers", "PROBLEM", 163, 182], ["both symptomatic and asymptomatic individuals", "PROBLEM", 281, 326], ["fatality ratio", "TEST", 333, 347], ["mortality rate", "TEST", 352, 366]]], ["Perfect data-driven and curve-fitting methods for the prediction of any disease outbreak have always been question of interest in epidemiological research.", [["any disease outbreak", "PROBLEM", 68, 88]]], ["Trust-region-reflect algorithm is one of the robust least-square data-fitting techniques that can promote a fine relation between the model driving mechanisms and model responses.", [["fitting techniques", "TREATMENT", 70, 88]]], ["This real-time data fitting approach could be efficient providing considerable insights on disease outbreak dynamics in different countries and designing worthwhile public health policies in curtailing the disease burden.", [["disease outbreak dynamics", "PROBLEM", 91, 116], ["the disease burden", "PROBLEM", 202, 220], ["disease", "OBSERVATION", 206, 213]]], ["Calibrating our model parameters by using the above algorithm, we have provided probable forecasts for the newly evolving COVID-19 hotspots.IntroductionThis paper is organized as follows.", [["COVID-19 hotspots", "DNA", 122, 139], ["the above algorithm", "TEST", 42, 61], ["the newly evolving COVID", "PROBLEM", 103, 127]]], ["In section 3 and 4, the model has been analysed and model calibration technique has been discussed respectively.", [["model calibration technique", "TREATMENT", 52, 79]]], ["In section 5, model prediction accuracy has been illustrated by representing a graphical comparison between model responses and real-time data.", [["model prediction accuracy", "TEST", 14, 39]]], ["In section 6, one of the robust global sensitivity analysis techniques is used to quantify the most influential mechanisms in our model.", [["the robust global sensitivity analysis techniques", "TEST", 21, 70]]], ["This paper ends with some qualitative and quantitative observations and discussions.Baseline epidemiological parameters ::: Formulation of the Mathematical ModelIn the study of [5], the average incubation period of COVID-19 was calculate to be 5.1 days and similar model-based studies also justified the above finding [3], [6], [4].", [["COVID", "TEST", 215, 220]]], ["Moreover, within 11.5 days (i.e. \u03ba=1/11.5day\u22121) of infection, the individuals who were exposed to the virus started developing symptoms [5], [19] and 20.0 days was the mean duration of viral shedding observed in COVID-19 survivors [7].", [["infection", "DISEASE", 51, 60], ["individuals", "ORGANISM", 66, 77], ["infection", "PROBLEM", 51, 60], ["the virus", "PROBLEM", 98, 107], ["symptoms", "PROBLEM", 127, 135], ["viral shedding", "PROBLEM", 185, 199], ["COVID", "TEST", 212, 217], ["infection", "OBSERVATION", 51, 60]]], ["The time duration from symptoms onset to recovery was estimated to be 24.7 days, whereas from onset of symptoms to death,the average mean duration was estimated to be 178 days [19].", [["death", "DISEASE", 115, 120], ["symptoms", "PROBLEM", 23, 31], ["symptoms", "PROBLEM", 103, 111], ["death", "PROBLEM", 115, 120]]], ["In previous modeling studies,[3], [1], [2], the novel coronavirus effective transmission rate, \u03b2 ranges from around 0.25\u22121.5day\u22121, which gradually follows a downward trend with time [6].", [["[3]", "SIMPLE_CHEMICAL", 29, 32], ["[1]", "SIMPLE_CHEMICAL", 34, 37], ["[2]", "SIMPLE_CHEMICAL", 39, 42], ["coronavirus", "ORGANISM", 54, 65], ["previous modeling studies", "TEST", 3, 28], ["the novel coronavirus", "TEST", 44, 65], ["transmission rate", "TEST", 76, 93]]], ["In sequence, we have considered this parameter as a time-varying parameter in our fits.", [["this parameter", "TREATMENT", 32, 46]]], ["Table 1illustrates the list of baseline model parameters with brief description, probable ranges presented on clinical studies and calibration, and default base value selected for our study.Dataset ::: Formulation of the Mathematical ModelThe recent epidemic data of five different countries which are Russia, Brazil, India, Bangladesh and the United Kingdom is accumulated from authoritative and genuine sources which are Center of Disease Control and Prevention (CDC) and the COVID Tracking Project (testing and hospitalizations).", [["clinical studies", "TEST", 110, 126], ["calibration", "TEST", 131, 142], ["default base value", "TEST", 148, 166], ["our study", "TEST", 180, 189], ["Disease Control", "TREATMENT", 433, 448]]], ["The data repository is handled by the Johns Hopkins University Center for Systems Science and Engineering (JHU CSSE) and supported by ESRI Living Atlas Team and the Johns Hopkins University Applied Physics Lab (JHU APL).", [["APL", "DISEASE", 215, 218]]], ["The repository is publicly available and easy to compile [18].Disease Free Equilibrium (DFE) ::: Analysis of the ModelThe disease-free equilibrium (DFE) of (1) can be obtained easily by setting S=E=ID=IU=Q=H=R=D=0.", [["E", "TEST", 196, 197], ["ID", "TEST", 198, 200], ["disease", "OBSERVATION", 122, 129]]], ["Therefore the DFE of (1) is :E0=(S0,ID0,Q0,R0)=(0,0,0,0,0)", [["the DFE", "TEST", 10, 17], ["ID0", "TEST", 36, 39]]]], "PMC7429129": [["Main textNon-invasive ventilation (NIV) delivered by a helmet interface in acute respiratory distress syndrome (ARDS) has been associated with a lower rate of intubation, and mortality, compared to face mask NIV [1].", [["respiratory", "ANATOMY", 81, 92], ["acute respiratory distress syndrome", "DISEASE", 75, 110], ["ARDS", "DISEASE", 112, 116], ["Main textNon-invasive ventilation", "TREATMENT", 0, 33], ["a helmet interface", "TREATMENT", 53, 71], ["acute respiratory distress syndrome", "PROBLEM", 75, 110], ["ARDS", "PROBLEM", 112, 116], ["face mask NIV", "TREATMENT", 198, 211], ["textNon-invasive ventilation", "OBSERVATION", 5, 33], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory distress", "OBSERVATION", 81, 101], ["intubation", "OBSERVATION", 159, 169]]], ["The mechanism accounting for this apparent benefit is uncertain; postulated mechanisms include more effective delivery of airway pressure due to better sealing of the interface and/or higher inspiratory flows.Main textDuring routine care of two patients with acute hypoxemic respiratory failure, we used electrical impedance tomography (\u2018EIT\u2019, Draeger Pulmovista 500) to monitor ventilation while transitioning from face mask to helmet NIV.", [["airway", "ANATOMY", 122, 128], ["respiratory", "ANATOMY", 275, 286], ["hypoxemic respiratory failure", "DISEASE", 265, 294], ["airway", "MULTI-TISSUE_STRUCTURE", 122, 128], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["airway pressure", "TREATMENT", 122, 137], ["acute hypoxemic respiratory failure", "PROBLEM", 259, 294], ["electrical impedance tomography", "TEST", 304, 335], ["ventilation", "TREATMENT", 379, 390], ["face mask", "TREATMENT", 416, 425], ["helmet NIV", "TREATMENT", 429, 439], ["airway pressure", "OBSERVATION", 122, 137], ["sealing", "OBSERVATION_MODIFIER", 152, 159], ["higher", "OBSERVATION_MODIFIER", 184, 190], ["inspiratory flows", "OBSERVATION", 191, 208], ["acute", "OBSERVATION_MODIFIER", 259, 264], ["hypoxemic", "OBSERVATION_MODIFIER", 265, 274], ["respiratory failure", "OBSERVATION", 275, 294]]], ["The transition to helmet NIV was a clinical decision prompted by worsening respiratory failure on face mask NIV, with the goal of avoiding intubation.", [["respiratory", "ANATOMY", 75, 86], ["respiratory failure", "DISEASE", 75, 94], ["helmet NIV", "TREATMENT", 18, 28], ["worsening respiratory failure", "PROBLEM", 65, 94], ["face mask NIV", "TREATMENT", 98, 111], ["intubation", "TREATMENT", 139, 149], ["worsening", "OBSERVATION_MODIFIER", 65, 74], ["respiratory failure", "OBSERVATION", 75, 94]]], ["EIT is a non-invasive imaging technique that permits visualization of lung volumes and the distribution of ventilation.", [["lung", "ANATOMY", 70, 74], ["lung", "ORGAN", 70, 74], ["a non-invasive imaging technique", "TEST", 7, 39], ["visualization of lung volumes", "TEST", 53, 82], ["ventilation", "TREATMENT", 107, 118], ["lung", "ANATOMY", 70, 74], ["volumes", "ANATOMY_MODIFIER", 75, 82], ["distribution", "OBSERVATION_MODIFIER", 91, 103], ["ventilation", "OBSERVATION", 107, 118]]], ["Its high temporal resolution can detect rapid changes in lung volume during tidal ventilation and during adjustments to ventilator settings [2].", [["lung", "ANATOMY", 57, 61], ["lung", "ORGAN", 57, 61], ["rapid changes in lung volume", "PROBLEM", 40, 68], ["tidal ventilation", "TREATMENT", 76, 93], ["ventilator settings", "TREATMENT", 120, 139], ["high", "OBSERVATION_MODIFIER", 4, 8], ["temporal", "OBSERVATION_MODIFIER", 9, 17], ["rapid", "OBSERVATION_MODIFIER", 40, 45], ["lung", "ANATOMY", 57, 61], ["volume", "OBSERVATION", 62, 68], ["tidal ventilation", "OBSERVATION", 76, 93]]], ["After calibration, EIT signals were recorded while the patients were ventilated on face mask NIV (Draeger V500 or BiPAP-Vision).", [["NIV", "CHEMICAL", 93, 96], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["EIT signals", "TEST", 19, 30], ["face mask NIV", "TREATMENT", 83, 96], ["BiPAP", "TREATMENT", 114, 119]]], ["We then exchanged the mask interface for a helmet interface (StarMed CaStar-R, Intersurgical), resuming ventilation at the same inspiratory and expiratory positive airway pressure (IPAP, EPAP) settings.", [["airway", "ANATOMY", 164, 170], ["airway", "MULTI-TISSUE_STRUCTURE", 164, 170], ["the mask interface", "TREATMENT", 18, 36], ["a helmet interface", "TREATMENT", 41, 59], ["resuming ventilation", "TREATMENT", 95, 115], ["expiratory positive airway pressure", "TREATMENT", 144, 179], ["IPAP", "TREATMENT", 181, 185], ["EPAP) settings", "TREATMENT", 187, 201], ["airway pressure", "OBSERVATION", 164, 179]]], ["During the transition, patients breathed without support at functional residual capacity.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["support", "TREATMENT", 49, 56], ["residual capacity", "OBSERVATION", 71, 88]]], ["Global and regional end-expiratory lung impedance (EELI) and tidal impedance variation (TIV) were recorded throughout (Fig. 1).", [["lung", "ANATOMY", 35, 39], ["lung", "ORGAN", 35, 39], ["Global and regional end-expiratory lung impedance", "PROBLEM", 0, 49], ["tidal impedance variation (TIV", "TREATMENT", 61, 91], ["regional", "OBSERVATION_MODIFIER", 11, 19], ["end", "OBSERVATION_MODIFIER", 20, 23], ["expiratory", "ANATOMY_MODIFIER", 24, 34], ["lung", "ANATOMY", 35, 39], ["impedance", "ANATOMY_MODIFIER", 40, 49], ["tidal impedance", "OBSERVATION", 61, 76]]], ["Changes in end-expiratory lung volume were computed from changes in end-expiratory lung impedance by normalizing changes in lung impedance during tidal breathing to tidal volume measured by the ventilator [3].", [["lung", "ANATOMY", 26, 30], ["lung", "ANATOMY", 83, 87], ["lung", "ANATOMY", 124, 128], ["lung", "ORGAN", 26, 30], ["lung", "ORGAN", 83, 87], ["lung", "ORGAN", 124, 128], ["Changes in end-expiratory lung volume", "PROBLEM", 0, 37], ["end-expiratory lung impedance", "TREATMENT", 68, 97], ["normalizing changes in lung impedance", "PROBLEM", 101, 138], ["tidal breathing", "TREATMENT", 146, 161], ["tidal volume", "TEST", 165, 177], ["expiratory", "ANATOMY_MODIFIER", 15, 25], ["lung", "ANATOMY", 26, 30], ["volume", "OBSERVATION", 31, 37], ["expiratory lung impedance", "OBSERVATION", 72, 97], ["lung", "ANATOMY", 124, 128], ["impedance", "OBSERVATION", 129, 138], ["tidal breathing", "OBSERVATION", 146, 161]]], ["Consent was obtained from the patients/legal representatives.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]]], "PMC7430260": [["IntroductionThe current COVID-19 pandemic has once again reminded us that international travel plays a central role in the rapid spread of epidemics around the world [[1], [2], [3], [4]].", [["[2]", "SIMPLE_CHEMICAL", 172, 175], ["[3], [4]", "SIMPLE_CHEMICAL", 177, 185]]], ["It is therefore of utmost importance that, before international air travel gradually returns to normal, measures are taken to mitigate the risks of spreading infections associated with such travel, especially since COVID-19 is unlikely to be globally eradicated before travel increases.", [["infections", "DISEASE", 158, 168], ["international air travel", "PROBLEM", 50, 74], ["spreading infections", "PROBLEM", 148, 168], ["COVID", "TEST", 215, 220], ["spreading", "OBSERVATION_MODIFIER", 148, 157], ["infections", "OBSERVATION", 158, 168], ["unlikely to be", "UNCERTAINTY", 227, 241], ["globally", "OBSERVATION_MODIFIER", 242, 250], ["eradicated", "OBSERVATION", 251, 261]]], ["Furthermore, border control measures such as screening for symptoms in travellers are unlikely to be effective for infections like COVID-19 [5], where there is a high likelihood of asymptomatic transmission [6, 7].", [["infections", "DISEASE", 115, 125], ["border control measures", "TREATMENT", 13, 36], ["screening", "TEST", 45, 54], ["symptoms", "PROBLEM", 59, 67], ["infections", "PROBLEM", 115, 125], ["COVID", "TEST", 131, 136], ["asymptomatic transmission", "PROBLEM", 181, 206], ["high", "OBSERVATION_MODIFIER", 162, 166]]], ["Hence, there is an important role in ensuring that travellers take adequate precautions during their travel, to reduce the risk that they will be infected during their travel, and also potentially facilitate the spread of the virus.IntroductionAdequate pre-travel preparations and suitable precautionary behaviour during travel can reduce the risk of acquiring infectious diseases during travel [8].", [["infectious diseases", "DISEASE", 361, 380], ["adequate precautions", "TREATMENT", 67, 87], ["the virus", "PROBLEM", 222, 231], ["Adequate pre-travel preparations", "TREATMENT", 244, 276], ["acquiring infectious diseases", "PROBLEM", 351, 380]]], ["A study found that only a minority of Australian GPs were aware that VFR travellers are a high risk group [9].", [["A study", "TEST", 0, 7]]], ["It is known that VFR travellers in general often do not undertake adequate pre-travel preparations [[10], [11], [12], [13]].", [["[11], [12], [13]]", "SIMPLE_CHEMICAL", 106, 123]]], ["Furthermore, VFR travellers also often reside in local family settings during travel, have prolonged close contact with the local population, have a prolonged duration of travel, and have eating habits similar to the local population [[17], [18], [19]].", [["[17], [18], [19]]", "SIMPLE_CHEMICAL", 235, 252]]], ["All these factors place them at increased risk of acquiring infectious diseases during travel [18, 20, 21] which can in turn facilitate the global spread of infections [22, 23].IntroductionWhile some aspects of VFR traveller behaviour have been found to be generalisable to VFR travellers of multiple ethnicities, each ethnic group also has culture-specific health behaviours, for example, the use of Chinese medicine among ethnic Chinese.", [["infectious diseases", "DISEASE", 60, 79], ["infections", "DISEASE", 157, 167], ["acquiring infectious diseases", "PROBLEM", 50, 79], ["infections", "PROBLEM", 157, 167], ["culture", "TEST", 341, 348], ["Chinese medicine", "TREATMENT", 401, 417], ["infectious", "OBSERVATION_MODIFIER", 60, 70], ["global", "OBSERVATION_MODIFIER", 140, 146], ["spread", "OBSERVATION_MODIFIER", 147, 153], ["infections", "OBSERVATION", 157, 167]]], ["Ethnic Chinese are one of the largest cultural groups in many Western countries, including Australia, and account for a substantial proportion of VFR travel in these countries [24].", [["largest", "OBSERVATION_MODIFIER", 30, 37]]], ["Therefore, we sought to better understand Australian Chinese VFR travellers and their travel health-related behaviours.IntroductionThis article presents findings from a qualitative study of Australian Chinese VFR travellers, aiming to inform future educational interventions for this population.", [["a qualitative study", "TEST", 167, 186], ["educational interventions", "TREATMENT", 249, 274]]], ["Although the study was not conducted specifically regarding a global pandemic context like COVID-19, many of its findings and their implications are highly relevant for informing the development of risk communication and educational interventions for this population in the context of the current pandemic.MethodologyFive focus groups, with a total of 51 participants, were conducted among Chinese VFR travellers in Sydney, Australia, in June 2013.", [["participants", "SPECIES", 355, 367], ["the study", "TEST", 9, 18], ["COVID", "TEST", 91, 96], ["educational interventions", "TREATMENT", 221, 246], ["this population", "PROBLEM", 251, 266], ["pandemic", "OBSERVATION", 297, 305]]], ["Eligible participants were ethnic Chinese Australians living in Sydney, aged 18 years or older, who had travelled to mainland China or Hong Kong for the purpose of visiting friends or relatives in the previous 18 months.", [["participants", "SPECIES", 9, 21]]], ["A standard focus group guide, which was also used for another related study [25], was used for all groups.", [["another related study", "TEST", 54, 75]]], ["The focus group guide has been included in the appendix.", [["appendix", "ORGAN", 47, 55], ["appendix", "ANATOMY", 47, 55]]], ["Prior to transcription, each participant was assigned a number, and participants were referred to only by their number throughout transcription and data analysis.", [["participant", "SPECIES", 29, 40], ["participants", "SPECIES", 68, 80], ["data analysis", "TEST", 148, 161]]], ["Random sections of the transcripts were checked for accuracy by a third transcriber.", [["sections", "ANATOMY", 7, 15], ["accuracy", "TEST", 52, 60]]], ["The transcripts were then analysed using a thematic analysis approach.", [["a thematic analysis approach", "TEST", 41, 69]]], ["The codes were derived through content analysis of the data; no pre-determined codes were used.", [["content analysis", "TEST", 31, 47], ["the data", "TEST", 51, 59]]], ["Coded data were then analysed and summarised.Participant characteristics ::: ResultsA total of 51 respondents participated in five focus groups.", [["Coded data", "TEST", 0, 10]]], ["Participants had undertaken an average of 5.5 trips to China since migrating to Australia.", [["Participants", "SPECIES", 0, 12]]], ["The demographic characteristics of the focus group participants are presented in Table 1.Risk perception and awareness of travel-associated infectious diseases ::: ResultsParticipants generally believed that China was a low-risk destination for travel-associated infectious diseases and a number of reasons were given for this perception.", [["infectious diseases", "DISEASE", 140, 159], ["infectious diseases", "DISEASE", 263, 282], ["participants", "SPECIES", 51, 63], ["associated infectious diseases", "PROBLEM", 252, 282], ["infectious", "OBSERVATION", 140, 150], ["infectious", "OBSERVATION", 263, 273]]], ["Familiarity with the destination, including spending their childhood in China, was commonly perceived by participants.I was born and grew up there, what is there to be scared about? \u2026 There are 1.3 billion people in China, so it\u2019s not that bad a place that you can\u2019t have people living there.", [["people", "ORGANISM", 206, 212], ["people", "ORGANISM", 272, 278], ["participants", "SPECIES", 105, 117], ["people", "SPECIES", 206, 212], ["people", "SPECIES", 272, 278], ["1.3 billion", "OBSERVATION_MODIFIER", 194, 205]]]], "PMC7287752": [], "3838bdddcd0cfff2e8c711da8bb3fcb1d17eaaa6": [["Contents lists available at ScienceDirectOral Oncology journal homepage: www.elsevier.com/locate/oraloncology Letter to the editor An oncologist perspective on COVID 19: A mysterious cryptic virus An uncharted journey with the Coronavirus has begun world over as the mundane rules of many of the common viruses have been wrecked by the coronavirus.", [["Coronavirus", "CHEMICAL", 227, 238], ["coronavirus", "ORGANISM", 336, 347], ["A mysterious cryptic virus", "PROBLEM", 170, 196], ["the Coronavirus", "PROBLEM", 223, 238], ["the common viruses", "PROBLEM", 292, 310], ["the coronavirus", "PROBLEM", 332, 347], ["cryptic virus", "OBSERVATION", 183, 196], ["Coronavirus", "OBSERVATION", 227, 238], ["common", "OBSERVATION_MODIFIER", 296, 302], ["viruses", "OBSERVATION", 303, 310]]], ["The potential sauce for its disruption is the locomotion of individuals that propels the transmission of this immobile virus.", [["its disruption", "PROBLEM", 24, 38], ["this immobile virus", "PROBLEM", 105, 124]]], ["The emergence, re-emergence and the advantageous mutations from the animal kingdom of this mysterious and cryptic virus is indeed an imperceptible foe to the humankind.", [["the advantageous mutations", "PROBLEM", 32, 58], ["this mysterious and cryptic virus", "PROBLEM", 86, 119], ["cryptic virus", "OBSERVATION", 106, 119]]], ["There has been a rising infodemic and researchers who are yet to weather the storm are at their best in studying the trajectory of the virus and dissecting the information.", [["rising", "OBSERVATION_MODIFIER", 17, 23]]], ["The host inflammatory response and the cytokine storm-generated reflects its curious manifold attack on the lungs, heart and liver and kidney [1, 2] .", [["lungs", "ANATOMY", 108, 113], ["heart", "ANATOMY", 115, 120], ["liver", "ANATOMY", 125, 130], ["kidney", "ANATOMY", 135, 141], ["lungs", "ORGAN", 108, 113], ["heart", "ORGAN", 115, 120], ["liver", "ORGAN", 125, 130], ["kidney", "ORGAN", 135, 141], ["cytokine", "PROTEIN", 39, 47], ["The host inflammatory response", "PROBLEM", 0, 30], ["the cytokine storm", "TEST", 35, 53], ["its curious manifold attack on the lungs, heart and liver and kidney", "PROBLEM", 73, 141], ["host", "OBSERVATION_MODIFIER", 4, 8], ["inflammatory", "OBSERVATION_MODIFIER", 9, 21], ["lungs", "ANATOMY", 108, 113], ["heart", "ANATOMY", 115, 120], ["liver", "ANATOMY", 125, 130], ["kidney", "ANATOMY", 135, 141]]], ["It is also prudent to understand the \"patient zero\" that would help in the containment of viruses and unfold some of the mysteries such as its high transmissibility.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["viruses", "PROBLEM", 90, 97], ["viruses", "OBSERVATION", 90, 97]]], ["The increased infectivity of the virus and the viral shedding during the asymptomatic phase explains its high reproduction number and the need for social distancing.", [["The increased infectivity of the virus", "PROBLEM", 0, 38], ["the viral shedding", "PROBLEM", 43, 61], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["infectivity", "OBSERVATION_MODIFIER", 14, 25], ["virus", "OBSERVATION", 33, 38], ["viral", "OBSERVATION_MODIFIER", 47, 52]]], ["The dictum that the virus has specificity for a particular species and cell type has been overcome by the coronavirus known for its Spillover.", [["cell", "ANATOMY", 71, 75], ["cell type", "CELL", 71, 80], ["coronavirus", "ORGANISM", 106, 117], ["the virus", "PROBLEM", 16, 25], ["a particular species", "PROBLEM", 46, 66], ["cell type", "PROBLEM", 71, 80], ["virus", "OBSERVATION", 20, 25]]], ["To keep the virus at bay a noble vaccine that can kick-start the immune system is at its infancy.", [["immune system", "ANATOMY", 65, 78], ["immune system", "ANATOMICAL_SYSTEM", 65, 78], ["the virus", "PROBLEM", 8, 17], ["a noble vaccine", "TREATMENT", 25, 40]]], ["Also, the ever-changing and evolving virus can sometimes make vaccines obsolete and ineffective.", [["evolving virus", "PROBLEM", 28, 42], ["vaccines", "TREATMENT", 62, 70], ["virus", "OBSERVATION", 37, 42]]], ["A cocktail of medications from the drug pipeline including off-label drugs [3] has been shadow boxing due to the lack of vaccines that can hit this pandemic hard.Contents lists available at ScienceDirectHead and neck cancers are commonly seen in elderly individuals and substance abusers.", [["neck cancers", "ANATOMY", 212, 224], ["neck cancers", "DISEASE", 212, 224], ["neck cancers", "CANCER", 212, 224], ["A cocktail of medications", "TREATMENT", 0, 25], ["the drug pipeline", "TREATMENT", 31, 48], ["label drugs", "TREATMENT", 63, 74], ["vaccines", "TREATMENT", 121, 129], ["neck cancers", "PROBLEM", 212, 224], ["neck", "ANATOMY", 212, 216], ["cancers", "OBSERVATION", 217, 224]]], ["Tobacco use is the leading cause of COPD: an independent risk factor in severe COVID-19.", [["COPD", "DISEASE", 36, 40], ["Tobacco", "ORGANISM", 0, 7], ["COPD", "PROBLEM", 36, 40], ["severe COVID", "PROBLEM", 72, 84], ["COPD", "OBSERVATION", 36, 40]]], ["Besides, Tobacco increases the gene expression of angiotensin-converting enzyme 2, the binding receptor for severe acute respiratory syndrome coronavirus 2 [4, 5] .Contents lists available at ScienceDirectThe immune system declines with age increasing the susceptibility of elderly individuals to viral infections.", [["immune system", "ANATOMY", 209, 222], ["angiotensin", "CHEMICAL", 50, 61], ["acute respiratory syndrome coronavirus", "DISEASE", 115, 153], ["viral infections", "DISEASE", 297, 313], ["Tobacco", "ORGANISM", 9, 16], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 50, 81], ["angiotensin-converting enzyme 2", "PROTEIN", 50, 81], ["binding receptor", "PROTEIN", 87, 103], ["severe acute respiratory syndrome coronavirus", "SPECIES", 108, 153], ["angiotensin-converting enzyme", "TREATMENT", 50, 79], ["the binding receptor", "TREATMENT", 83, 103], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 108, 153], ["viral infections", "PROBLEM", 297, 313], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["respiratory syndrome", "OBSERVATION", 121, 141], ["immune system", "OBSERVATION", 209, 222], ["viral infections", "OBSERVATION", 297, 313]]], ["Production of innate interferons constitutes the most prompt and dominant innate immune response to counter viral infections.", [["viral infections", "DISEASE", 108, 124], ["innate interferons", "PROTEIN", 14, 32], ["innate interferons", "TREATMENT", 14, 32], ["counter viral infections", "PROBLEM", 100, 124], ["innate interferons", "OBSERVATION", 14, 32]]], ["The decline in the Plasmacytoid dendritic cells in the elderly and a further decline in the frail elderly population with comorbidities depletes the immune envelop.", [["Plasmacytoid dendritic cells", "ANATOMY", 19, 47], ["Plasmacytoid dendritic cells", "CELL", 19, 47], ["Plasmacytoid dendritic cells", "CELL_TYPE", 19, 47], ["The decline", "PROBLEM", 0, 11], ["the Plasmacytoid dendritic cells", "PROBLEM", 15, 47], ["a further decline", "PROBLEM", 67, 84], ["comorbidities depletes", "PROBLEM", 122, 144], ["the immune envelop", "PROBLEM", 145, 163], ["decline", "OBSERVATION_MODIFIER", 4, 11], ["Plasmacytoid dendritic cells", "OBSERVATION", 19, 47], ["immune envelop", "OBSERVATION", 149, 163]]], ["Elderly individuals are unable to mount a stable immune response against all types of viral infections due to the decreased interferon production or its inhibition through viral non-structural protein 1 (NS1) which in turn increases the relentlessness of viral infection [6] [7] [8] .Contents lists available at ScienceDirectGiven the pandemic and global lockdown COVID-19 patients are currently prioritized and there can be an increase in the risk of interruption in the drug supply chain.", [["viral infections", "DISEASE", 86, 102], ["viral infection", "DISEASE", 255, 270], ["individuals", "ORGANISM", 8, 19], ["interferon", "GENE_OR_GENE_PRODUCT", 124, 134], ["viral non-structural protein 1", "GENE_OR_GENE_PRODUCT", 172, 202], ["NS1", "GENE_OR_GENE_PRODUCT", 204, 207], ["patients", "ORGANISM", 373, 381], ["interferon", "PROTEIN", 124, 134], ["viral non-structural protein 1", "PROTEIN", 172, 202], ["NS1", "PROTEIN", 204, 207], ["patients", "SPECIES", 373, 381], ["viral infections", "PROBLEM", 86, 102], ["the decreased interferon production", "PROBLEM", 110, 145], ["viral non-structural protein", "TREATMENT", 172, 200], ["viral infection", "PROBLEM", 255, 270], ["viral infections", "OBSERVATION", 86, 102], ["decreased", "OBSERVATION_MODIFIER", 114, 123], ["interferon", "OBSERVATION", 124, 134], ["viral infection", "OBSERVATION", 255, 270], ["increase", "OBSERVATION_MODIFIER", 428, 436]]], ["Lifesaving therapy for cancer in contrast to the life-threatening infectious COVID 19 has instilled a lot of agony amongst the cancer patients.", [["cancer", "ANATOMY", 23, 29], ["cancer", "ANATOMY", 127, 133], ["cancer", "DISEASE", 23, 29], ["COVID", "DISEASE", 77, 82], ["cancer", "DISEASE", 127, 133], ["cancer", "CANCER", 23, 29], ["cancer", "CANCER", 127, 133], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["Lifesaving therapy", "TREATMENT", 0, 18], ["cancer", "PROBLEM", 23, 29], ["cancer", "OBSERVATION", 23, 29], ["cancer", "OBSERVATION", 127, 133]]], ["An oncologist should forge a strategy to ensure a continuum of care considering the tumor doubling and increase in the total treatment time that can have an impact on the treatment outcome.", [["tumor", "ANATOMY", 84, 89], ["tumor", "DISEASE", 84, 89], ["tumor", "CANCER", 84, 89], ["a strategy", "TREATMENT", 27, 37], ["the tumor doubling", "PROBLEM", 80, 98], ["the treatment outcome", "TREATMENT", 167, 188], ["tumor", "OBSERVATION", 84, 89]]], ["Oncological screening for normal patients can be rescheduled because of the contagion nature of the virus.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Oncological screening", "TEST", 0, 21], ["the virus", "PROBLEM", 96, 105]]], ["The risk of COVID19 in cancer patients is yet to be ascertained however the severity of the disease may be higher as Cancer and its treatment knocks down the immune system.", [["cancer", "ANATOMY", 23, 29], ["Cancer", "ANATOMY", 117, 123], ["immune system", "ANATOMY", 158, 171], ["COVID19", "CHEMICAL", 12, 19], ["cancer", "DISEASE", 23, 29], ["Cancer", "DISEASE", 117, 123], ["COVID19", "GENE_OR_GENE_PRODUCT", 12, 19], ["cancer", "CANCER", 23, 29], ["patients", "ORGANISM", 30, 38], ["Cancer", "CANCER", 117, 123], ["COVID19", "PROTEIN", 12, 19], ["patients", "SPECIES", 30, 38], ["COVID19 in cancer", "PROBLEM", 12, 29], ["the disease", "PROBLEM", 88, 99], ["Cancer", "PROBLEM", 117, 123], ["its treatment knocks", "TREATMENT", 128, 148], ["cancer", "OBSERVATION", 23, 29], ["disease", "OBSERVATION", 92, 99], ["may be", "UNCERTAINTY", 100, 106], ["higher", "OBSERVATION_MODIFIER", 107, 113], ["Cancer", "OBSERVATION", 117, 123]]], ["Head and neck surgeries harbor a high viral load, have a high risk of exposure and infection from aerosol and droplet contamination.", [["Head", "ANATOMY", 0, 4], ["neck", "ANATOMY", 9, 13], ["infection", "DISEASE", 83, 92], ["neck", "ORGAN", 9, 13], ["Head and neck surgeries", "TREATMENT", 0, 23], ["a high viral load", "PROBLEM", 31, 48], ["infection", "PROBLEM", 83, 92], ["aerosol", "TREATMENT", 98, 105], ["droplet contamination", "PROBLEM", 110, 131], ["neck", "ANATOMY", 9, 13], ["surgeries", "OBSERVATION", 14, 23], ["high viral load", "OBSERVATION", 33, 48], ["infection", "OBSERVATION", 83, 92], ["droplet contamination", "OBSERVATION", 110, 131]]], ["Patients under palliative care or in case of emergency: airway obstruction cannot be denied of treatment or can be postponed.", [["airway", "ANATOMY", 56, 62], ["airway obstruction", "DISEASE", 56, 74], ["Patients", "ORGANISM", 0, 8], ["airway", "MULTI-TISSUE_STRUCTURE", 56, 62], ["Patients", "SPECIES", 0, 8], ["palliative care", "TREATMENT", 15, 30], ["airway obstruction", "PROBLEM", 56, 74], ["treatment", "TREATMENT", 95, 104], ["airway", "ANATOMY", 56, 62], ["obstruction", "OBSERVATION", 63, 74]]], ["The patient's medical need who are in the different phases of cancer treatment and the logistical competence of the individual hospital to meet those needs in real-time should be assessed on a case to case basis.Contents lists available at ScienceDirectOncologists have to get prepared for a new routine and protect themselves and their patients.Contents lists available at ScienceDirectThe highly skilled and limited health workforce work in a vulnerable environment and hence should be shielded physically with the personal protective equipment, financially and mentally during this unprecedented crisis.", [["cancer", "ANATOMY", 62, 68], ["cancer", "DISEASE", 62, 68], ["patient", "ORGANISM", 4, 11], ["cancer", "CANCER", 62, 68], ["patients", "ORGANISM", 337, 345], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 337, 345], ["cancer treatment", "TREATMENT", 62, 78], ["this unprecedented crisis", "PROBLEM", 580, 605], ["cancer", "OBSERVATION", 62, 68]]], ["Tracheostomy should be done with utmost diligence with ample sedation and muscle relaxants to avoid the risk of coughing and preferably a percutaneous dilatational tracheostomy should be considered.Contents lists available at ScienceDirectPrioritise newly diagnosed malignant cases and close surveillance of follow up and palliative care patients using telemedicine.", [["muscle", "ANATOMY", 74, 80], ["percutaneous", "ANATOMY", 138, 150], ["coughing", "DISEASE", 112, 120], ["muscle", "ORGAN", 74, 80], ["patients", "ORGANISM", 338, 346], ["patients", "SPECIES", 338, 346], ["Tracheostomy", "TREATMENT", 0, 12], ["ample sedation", "TREATMENT", 55, 69], ["muscle relaxants", "TREATMENT", 74, 90], ["coughing", "PROBLEM", 112, 120], ["a percutaneous dilatational tracheostomy", "TREATMENT", 136, 176], ["palliative care", "TREATMENT", 322, 337], ["coughing", "OBSERVATION", 112, 120], ["tracheostomy", "OBSERVATION", 164, 176]]], ["A switch over to metronomic chemotherapy can also be considered during the acute phase of the pandemic to halt tumor growth.Contents lists available at ScienceDirect*Revamp the immune system by cyclic meditation and deep breathing exercises.Contents lists available at ScienceDirectA word of caution, concern and preventive measures would be a more fruitful and appropriate response to the virus than a panic state that can paralyze the health care system and derange the economy and social fabric of the community.", [["tumor", "ANATOMY", 111, 116], ["tumor", "DISEASE", 111, 116], ["panic", "DISEASE", 403, 408], ["tumor", "CANCER", 111, 116], ["A switch", "TREATMENT", 0, 8], ["metronomic chemotherapy", "TREATMENT", 17, 40], ["halt tumor growth", "PROBLEM", 106, 123], ["the immune system", "TREATMENT", 173, 190], ["cyclic meditation", "TREATMENT", 194, 211], ["deep breathing exercises", "TREATMENT", 216, 240], ["preventive measures", "TREATMENT", 313, 332], ["the virus", "PROBLEM", 386, 395], ["a panic state", "PROBLEM", 401, 414], ["deep breathing", "OBSERVATION", 216, 230]]]], "19a2b476bded9c2fbb3c16c000510fc9de8c8d53": [["a1111111111 a1111111111 a1111111111 a1111111111 a1111111111IntroductionSince December 2019, several cases of coronavirus disease (COVID-19) emerged in Wuhan, Hubei Province, China [1] [2] [3] .", [["coronavirus disease", "DISEASE", 109, 128], ["coronavirus", "ORGANISM", 109, 120], ["coronavirus disease", "PROBLEM", 109, 128], ["COVID", "TEST", 130, 135], ["coronavirus disease", "OBSERVATION", 109, 128]]], ["SARS-Cov-2 is transmitted by respiratory droplets and aerosols, direct contact, and stool [8, 9] .", [["respiratory droplets", "ANATOMY", 29, 49], ["SARS", "DISEASE", 0, 4], ["respiratory droplets", "OBSERVATION", 29, 49]]], ["COVID-19 is very contagious, and the general population is highly susceptible to infection.", [["COVID-19", "CHEMICAL", 0, 8], ["infection", "DISEASE", 81, 90], ["COVID", "TEST", 0, 5], ["very contagious", "PROBLEM", 12, 27], ["infection", "PROBLEM", 81, 90], ["very", "OBSERVATION_MODIFIER", 12, 16], ["contagious", "OBSERVATION", 17, 27], ["infection", "OBSERVATION", 81, 90]]], ["The number of affected countries and number of deaths have increased dramatically since the beginning of the outbreak [4] .", [["deaths", "DISEASE", 47, 53], ["affected", "OBSERVATION_MODIFIER", 14, 22], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["dramatically", "OBSERVATION_MODIFIER", 69, 81]]], ["COVID-19 infection reached more than 130 countries.", [["infection", "DISEASE", 9, 18], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["infection", "OBSERVATION", 9, 18]]], ["According to the World Health Organization, as of April 17, 2020, more than 2,034,802 confirmed cases were reported worldwide, and more than 135,163 infected patients died [5] .", [["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166]]], ["Therefore, COVID-19 is a serious health problem worldwide.IntroductionCoronavirus can affect multiple organs, including the lungs [1] .", [["organs", "ANATOMY", 102, 108], ["lungs", "ANATOMY", 124, 129], ["COVID-19", "CHEMICAL", 11, 19], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 70, 81], ["organs", "ORGAN", 102, 108], ["lungs", "ORGAN", 124, 129], ["IntroductionCoronavirus", "PROBLEM", 58, 81], ["lungs", "ANATOMY", 124, 129]]], ["The main clinical presentation of COVID-19 is pneumonia.", [["pneumonia", "DISEASE", 46, 55], ["COVID", "TEST", 34, 39], ["pneumonia", "PROBLEM", 46, 55], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pneumonia", "OBSERVATION", 46, 55]]], ["Most patients have mild disease, with common respiratory symptoms and good prognosis [6] .", [["respiratory", "ANATOMY", 45, 56], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["mild disease", "PROBLEM", 19, 31], ["common respiratory symptoms", "PROBLEM", 38, 65], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["disease", "OBSERVATION", 24, 31]]], ["The most common clinical symptoms are fever and cough.", [["fever", "DISEASE", 38, 43], ["cough", "DISEASE", 48, 53], ["The most common clinical symptoms", "PROBLEM", 0, 33], ["fever", "PROBLEM", 38, 43], ["cough", "PROBLEM", 48, 53], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["fever", "OBSERVATION", 38, 43], ["cough", "OBSERVATION", 48, 53]]], ["However, it has been reported that only 43.8% of patients present with fever on admission.", [["fever", "DISEASE", 71, 76], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["fever", "PROBLEM", 71, 76], ["fever", "OBSERVATION", 71, 76]]], ["Radiologic abnormalities were not observed on initial presentation in approximately 20% of cases [7] .", [["Radiologic abnormalities", "PROBLEM", 0, 24]]], ["According to the sixth edition of the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan, severe cases should meet any of the following criteria: 1) shortness of breath (respiratory rate \ufffd30 breaths per min), 2) oxygen saturation \ufffd93% at rest, or 3) arterial partial pressure of oxygen/fraction of inspired oxygen \ufffd 300 mm Hg [8] .", [["arterial", "ANATOMY", 256, 264], ["Pneumonia", "DISEASE", 56, 65], ["shortness of breath", "DISEASE", 155, 174], ["oxygen", "CHEMICAL", 218, 224], ["oxygen", "CHEMICAL", 285, 291], ["oxygen", "CHEMICAL", 313, 319], ["oxygen", "CHEMICAL", 218, 224], ["oxygen", "CHEMICAL", 285, 291], ["oxygen", "CHEMICAL", 313, 319], ["Hg", "CHEMICAL", 329, 331], ["oxygen", "SIMPLE_CHEMICAL", 218, 224], ["arterial", "MULTI-TISSUE_STRUCTURE", 256, 264], ["oxygen", "SIMPLE_CHEMICAL", 285, 291], ["oxygen", "SIMPLE_CHEMICAL", 313, 319], ["the Novel Coronavirus Pneumonia", "PROBLEM", 34, 65], ["shortness of breath", "PROBLEM", 155, 174], ["respiratory rate", "TEST", 176, 192], ["oxygen saturation", "TEST", 218, 235], ["arterial partial pressure of oxygen/fraction", "TREATMENT", 256, 300], ["inspired oxygen", "TEST", 304, 319], ["Pneumonia", "OBSERVATION", 56, 65], ["pressure", "OBSERVATION_MODIFIER", 273, 281]]], ["A small percentage of patients present with severe disease before or during hospitalization, including severe pneumonia, adult respiratory distress syndrome, or multiple organ failure, which are associated with worse outcomes [9] [10] [11] .", [["respiratory", "ANATOMY", 127, 138], ["organ", "ANATOMY", 170, 175], ["pneumonia", "DISEASE", 110, 119], ["respiratory distress syndrome", "DISEASE", 127, 156], ["multiple organ failure", "DISEASE", 161, 183], ["patients", "ORGANISM", 22, 30], ["organ", "ORGAN", 170, 175], ["patients", "SPECIES", 22, 30], ["severe disease", "PROBLEM", 44, 58], ["severe pneumonia", "PROBLEM", 103, 119], ["adult respiratory distress syndrome", "PROBLEM", 121, 156], ["multiple organ failure", "PROBLEM", 161, 183], ["small", "OBSERVATION_MODIFIER", 2, 7], ["percentage", "OBSERVATION_MODIFIER", 8, 18], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["disease", "OBSERVATION", 51, 58], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["pneumonia", "OBSERVATION", 110, 119], ["respiratory distress syndrome", "OBSERVATION", 127, 156], ["multiple", "OBSERVATION_MODIFIER", 161, 169], ["organ", "ANATOMY", 170, 175], ["failure", "OBSERVATION", 176, 183]]], ["As of February 15, 2020, the mortality rate and percentage of severe cases in Hubei Province were 2.6% and 15.2%, respectively [11, 12] .", [["the mortality rate", "TEST", 25, 43], ["severe cases", "PROBLEM", 62, 74], ["severe", "OBSERVATION_MODIFIER", 62, 68]]], ["Therefore, specific predictive methods are urgently required to predict the risk of severe COVID-19 [9] .", [["COVID", "DISEASE", 91, 96], ["COVID-19", "CHEMICAL", 91, 99], ["severe COVID", "PROBLEM", 84, 96]]], ["Of all existing models, nomogram allows for individualized and evidence-based risk estimation, facilitating management-based decision-making [13, 14] .", [["nomogram", "TEST", 24, 32]]], ["To the best of our knowledge, no previous studies have evaluated early warning models for predicting the risk of severe COVID-19.IntroductionPrevious studies have shown that there are significant regional differences in the mortality rate and percentage of severe cases [12, 15] .", [["COVID", "DISEASE", 120, 125], ["COVID-19", "CHEMICAL", 120, 128], ["previous studies", "TEST", 33, 49], ["severe COVID", "PROBLEM", 113, 125], ["IntroductionPrevious studies", "TEST", 129, 157], ["significant regional differences", "PROBLEM", 184, 216], ["the mortality rate", "TEST", 220, 238], ["severe cases", "PROBLEM", 257, 269], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["significant", "OBSERVATION_MODIFIER", 184, 195], ["regional", "OBSERVATION_MODIFIER", 196, 204], ["differences", "OBSERVATION_MODIFIER", 205, 216], ["severe", "OBSERVATION_MODIFIER", 257, 263]]], ["The aim of this study is to describe the clinical characteristics of confirmed cases of COVID-19 in Sichuan, China, and construct an early warning prediction nomogram model incorporating clinical characteristics to identify the risk of developing severe COVID-19. respiratory tract [16] .", [["COVID-19", "CHEMICAL", 254, 262], ["this study", "TEST", 11, 21], ["COVID", "TEST", 88, 93], ["developing severe COVID", "PROBLEM", 236, 259], ["severe", "OBSERVATION_MODIFIER", 247, 253], ["tract", "OBSERVATION", 276, 281]]], ["All study patients were diagnosed with COVID-19 according to the WHO interim guidance [17] .", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["All study", "TEST", 0, 9], ["COVID", "TEST", 39, 44]]], ["The study was approved by the Research Ethics Committee of West China Hospital, and data were collected retrospectively after patients gave written informed consent.Demographical and risk variablesThe following data were obtained from electronic medical records: demographics (age and gender), clinical signs on admission, clinical symptoms, clinical risk factors, and exposure to infection.", [["infection", "DISEASE", 381, 390], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["The study", "TEST", 0, 9], ["clinical signs", "TEST", 294, 308], ["clinical symptoms", "PROBLEM", 323, 340], ["clinical risk factors", "PROBLEM", 342, 363], ["infection", "PROBLEM", 381, 390], ["infection", "OBSERVATION", 381, 390]]], ["Clinical symptoms were defined as the interval between the onset of clinical symptoms and the data of admission.", [["Clinical symptoms", "PROBLEM", 0, 17], ["clinical symptoms", "PROBLEM", 68, 85]]], ["Exposure to infection was defined as contact with sources of infection in the past 14 days, including Wuhan or other COVID-19 affected areas, febrile patients, or COVID-19 patients, and the incidence had clustering phenomenon.", [["infection", "DISEASE", 12, 21], ["infection", "DISEASE", 61, 70], ["febrile", "DISEASE", 142, 149], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 172, 180], ["infection", "PROBLEM", 12, 21], ["infection", "PROBLEM", 61, 70], ["other COVID-19 affected areas", "PROBLEM", 111, 140], ["febrile", "PROBLEM", 142, 149], ["clustering phenomenon", "PROBLEM", 204, 225], ["infection", "OBSERVATION", 12, 21], ["infection", "OBSERVATION", 61, 70], ["clustering phenomenon", "OBSERVATION", 204, 225]]], ["The risk of exposure to infection changed as the relevant definitions in the COVID-19 guidelines of the National Health Commission of the People's Republic of China changed.", [["infection", "DISEASE", 24, 33], ["infection", "PROBLEM", 24, 33], ["infection", "OBSERVATION", 24, 33]]], ["All data were analyzed by two physicians (He YQ and Zhou YW), and a third researcher was consulted in cases of disagreement.", [["All data", "TEST", 0, 8]]], ["The clinical and demographic features in our cohort are summarized in Table 1 .Definition of outcomesThe primary outcome was severe COVID-19 during hospitalization according to the American Thoracic Society guidelines for community-acquired pneumonia [19] .", [["pneumonia", "DISEASE", 241, 250], ["severe COVID", "PROBLEM", 125, 137], ["community-acquired pneumonia", "PROBLEM", 222, 250], ["Thoracic", "ANATOMY", 190, 198], ["pneumonia", "OBSERVATION", 241, 250]]], ["Severe cases should meet one major criterion (septic shock with need for vasopressors or respiratory failure requiring mechanical ventilation) or at least three minor criteria (respiratory rate \ufffd30 breaths per min, arterial partial oxygen pressure/fraction of inspired oxygen \ufffd250 mmHg, multilobar infiltrates, confusion/disorientation, uremia (blood urea nitrogen level \ufffd20 mg/dL), leukopenia (white blood cell count <400 cells/\u03bcL), thrombocytopenia (platelet count <100,000/\u03bcL), hypothermia (core temperature <36\u02daC), and hypotension requiring aggressive fluid resuscitation [19] .Statistical analysisStatistical analyses were performed using R software version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS version 25.0 (IBM Corporation, Armonk, NY).", [["respiratory", "ANATOMY", 89, 100], ["respiratory", "ANATOMY", 177, 188], ["arterial", "ANATOMY", 215, 223], ["multilobar infiltrates", "ANATOMY", 287, 309], ["blood", "ANATOMY", 345, 350], ["white blood cell", "ANATOMY", 395, 411], ["cells", "ANATOMY", 423, 428], ["platelet", "ANATOMY", 452, 460], ["fluid", "ANATOMY", 556, 561], ["septic shock", "DISEASE", 46, 58], ["respiratory failure", "DISEASE", 89, 108], ["oxygen", "CHEMICAL", 232, 238], ["oxygen", "CHEMICAL", 269, 275], ["confusion", "DISEASE", 311, 320], ["disorientation", "DISEASE", 321, 335], ["uremia", "DISEASE", 337, 343], ["blood urea nitrogen", "CHEMICAL", 345, 364], ["leukopenia", "DISEASE", 383, 393], ["thrombocytopenia", "DISEASE", 434, 450], ["hypothermia", "DISEASE", 481, 492], ["hypotension", "DISEASE", 523, 534], ["oxygen", "CHEMICAL", 232, 238], ["oxygen", "CHEMICAL", 269, 275], ["urea", "CHEMICAL", 351, 355], ["nitrogen", "CHEMICAL", 356, 364], ["arterial", "MULTI-TISSUE_STRUCTURE", 215, 223], ["oxygen", "SIMPLE_CHEMICAL", 232, 238], ["oxygen", "SIMPLE_CHEMICAL", 269, 275], ["blood", "ORGANISM_SUBSTANCE", 345, 350], ["urea", "SIMPLE_CHEMICAL", 351, 355], ["blood cell", "CELL", 401, 411], ["platelet", "CELL", 452, 460], ["Severe cases", "PROBLEM", 0, 12], ["septic shock", "PROBLEM", 46, 58], ["vasopressors", "TREATMENT", 73, 85], ["respiratory failure", "PROBLEM", 89, 108], ["mechanical ventilation", "TREATMENT", 119, 141], ["respiratory rate", "TEST", 177, 193], ["arterial partial oxygen pressure", "TEST", 215, 247], ["inspired oxygen", "TREATMENT", 260, 275], ["multilobar infiltrates", "PROBLEM", 287, 309], ["confusion", "PROBLEM", 311, 320], ["disorientation", "PROBLEM", 321, 335], ["uremia", "PROBLEM", 337, 343], ["blood urea nitrogen level", "TEST", 345, 370], ["leukopenia", "PROBLEM", 383, 393], ["white blood cell count", "TEST", 395, 417], ["cells", "TEST", 423, 428], ["\u03bcL", "TEST", 429, 431], ["thrombocytopenia", "PROBLEM", 434, 450], ["platelet count", "TEST", 452, 466], ["hypothermia", "PROBLEM", 481, 492], ["core temperature", "TEST", 494, 510], ["hypotension", "PROBLEM", 523, 534], ["aggressive fluid resuscitation", "TREATMENT", 545, 575], ["Statistical analysisStatistical analyses", "TEST", 582, 622], ["R software version", "TEST", 644, 662], ["SPSS version", "TEST", 731, 743], ["septic", "OBSERVATION", 46, 52], ["respiratory failure", "OBSERVATION", 89, 108], ["oxygen pressure", "OBSERVATION", 232, 247], ["multilobar", "OBSERVATION_MODIFIER", 287, 297], ["infiltrates", "OBSERVATION", 298, 309], ["leukopenia", "OBSERVATION", 383, 393], ["thrombocytopenia", "OBSERVATION", 434, 450], ["hypothermia", "OBSERVATION", 481, 492], ["hypotension", "OBSERVATION", 523, 534]]], ["Categorical variables were expressed as absolute values and percentages.", [["Categorical variables", "TEST", 0, 21], ["percentages", "TEST", 60, 71]]], ["The means of continuous variables were compared using independent group t-tests for normally distributed data and the Mann-Whitney test for non-normally distributed data.", [["independent group t-tests", "TEST", 54, 79]]], ["The \u03c7 2 or Fisher's exact test was used to compare proportions.Statistical analysisThe least absolute shrinkage and selection operator (LASSO) method, which is suitable for analyzing high-dimensional data, was used to select the most significant predictive features [20, 21] .", [["Fisher's exact test", "TEST", 11, 30], ["Statistical analysis", "TEST", 63, 83], ["least", "OBSERVATION_MODIFIER", 87, 92], ["absolute", "OBSERVATION_MODIFIER", 93, 101], ["shrinkage", "OBSERVATION_MODIFIER", 102, 111]]], ["Features with non-zero coefficients in the LASSO regression model were selected in the forward stepwise logistic regression model [22] .", [["non-zero coefficients", "PROBLEM", 14, 35], ["non-zero coefficients", "OBSERVATION", 14, 35]]], ["Variables with p-values smaller than 0.1 in the univariate analysis and potentially significant in the multivariate analysis were included in the logistic regression analysis, and the forward selection procedure was used to develop a parsimonious model for predicting severe COVID-19 in our cohort.PLOS ONENomogram is a statistical model useful for risk assessment.", [["p-values", "TEST", 15, 23], ["the univariate analysis", "TEST", 44, 67], ["the multivariate analysis", "TEST", 99, 124], ["the forward selection procedure", "TREATMENT", 180, 211], ["predicting severe COVID", "PROBLEM", 257, 280], ["risk assessment", "TEST", 349, 364], ["potentially", "UNCERTAINTY", 72, 83], ["significant", "OBSERVATION_MODIFIER", 84, 95]]], ["A predictive nomogram was developed using the independent factors selected by LASSO to generate a combined indicator for estimating the severity of COVID-19, and provided a quantitative tool for physicians to assess the individual probability of disease severity.", [["A predictive nomogram", "TEST", 0, 21], ["COVID", "TEST", 148, 153], ["disease severity", "PROBLEM", 246, 262], ["disease", "OBSERVATION", 246, 253]]], ["The created nomogram was used for internal validation, and the total score for each nodule was calculated.", [["nodule", "ANATOMY", 84, 90], ["nodule", "CANCER", 84, 90], ["The created nomogram", "TEST", 0, 20], ["internal validation", "TEST", 34, 53], ["the total score", "TEST", 59, 74], ["each nodule", "PROBLEM", 79, 90], ["nodule", "OBSERVATION", 84, 90]]], ["The nomogram was constructed using the total score as a factor.", [["The nomogram", "TEST", 0, 12]]], ["Adequate discrimination and calibration were performed to test and validate the prognostic accuracy of the nomogram model [24] .", [["test", "TEST", 58, 62], ["the nomogram model", "TEST", 103, 121]]], ["Discrimination was quantified using Harrell's concordance index (C-index), in which an absolute value close to 1 indicated that the model had strong predictive ability.", [["Harrell's concordance index", "TEST", 36, 63], ["an absolute value", "TEST", 84, 101]]], ["The nomogram was further validated by bootstrapping (1000 bootstrap replicates) to calculate the corrected C-index.", [["The nomogram", "TEST", 0, 12], ["the corrected C-index", "PROBLEM", 93, 114]]], ["Calibration plots were developed to assess the predictive accuracy and agreement between predicted and observed severity.", [["Calibration plots", "TEST", 0, 17], ["the predictive accuracy", "TEST", 43, 66]]], ["Decision curve analyses (DCAs) were performed to assess the clinical usefulness of the nomogram.", [["Decision curve analyses (DCAs)", "TEST", 0, 30], ["the nomogram", "TEST", 83, 95]]], ["The net benefit was calculated by subtracting the proportion of patients with false-positive results from the proportion of patients with true-positive results and by weighing the relative risk of an intervention compared with the adverse effects of an unnecessary intervention.", [["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 124, 132], ["an intervention", "TREATMENT", 197, 212], ["an unnecessary intervention", "TREATMENT", 250, 277]]], ["Two-sided p-values of less than 0.05 were considered to indicate a statistically significant difference.Clinical characteristics of patientsA total of 366 patients with COVID-19 who had been hospitalized in 47 regions of Sichuan were enrolled until January 20, 2020.", [["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 155, 163], ["Two-sided p-values", "TEST", 0, 18], ["a statistically significant difference", "PROBLEM", 65, 103], ["sided", "ANATOMY_MODIFIER", 4, 9], ["p-values", "OBSERVATION", 10, 18], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["difference", "OBSERVATION", 93, 103]]], ["Most patients were admitted to a public health clinical center located in Chengdu.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["The median age was 43 years (interquartile range, 31.8-51.0), and 56.6% were male.", [["interquartile range", "TEST", 29, 48]]], ["Fever occurred in 42.9% of patients from the earliest onset of symptom and in 29.5% on admission.", [["Fever", "DISEASE", 0, 5], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["Fever", "PROBLEM", 0, 5], ["symptom", "PROBLEM", 63, 70]]], ["The second most common symptom was cough (31.4%).", [["cough", "DISEASE", 35, 40], ["cough", "PROBLEM", 35, 40], ["cough", "OBSERVATION", 35, 40]]], ["Digestive symptoms, including vomiting and diarrhea, were present in 7.4% of cases.", [["Digestive", "ANATOMY", 0, 9], ["Digestive symptoms", "DISEASE", 0, 18], ["vomiting", "DISEASE", 30, 38], ["diarrhea", "DISEASE", 43, 51], ["Digestive", "ORGAN", 0, 9], ["Digestive symptoms", "PROBLEM", 0, 18], ["vomiting", "PROBLEM", 30, 38], ["diarrhea", "PROBLEM", 43, 51], ["symptoms", "OBSERVATION", 10, 18], ["diarrhea", "OBSERVATION", 43, 51]]], ["In our cohort, 25.9% had at least one coexisting disease (hypertension, diabetes, or chronic obstructive pulmonary disease).Clinical characteristics of patientsDisease severity was considered mild in 323 patients and severe in 43 patients.", [["pulmonary", "ANATOMY", 105, 114], ["hypertension", "DISEASE", 58, 70], ["diabetes", "DISEASE", 72, 80], ["chronic obstructive pulmonary disease", "DISEASE", 85, 122], ["pulmonary", "ORGAN", 105, 114], ["patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 204, 212], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 204, 212], ["patients", "SPECIES", 230, 238], ["coexisting disease", "PROBLEM", 38, 56], ["hypertension", "PROBLEM", 58, 70], ["diabetes", "PROBLEM", 72, 80], ["chronic obstructive pulmonary disease)", "PROBLEM", 85, 123], ["Disease severity", "PROBLEM", 160, 176], ["coexisting", "OBSERVATION_MODIFIER", 38, 48], ["disease", "OBSERVATION", 49, 56], ["hypertension", "OBSERVATION", 58, 70], ["diabetes", "OBSERVATION", 72, 80], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["obstructive", "OBSERVATION_MODIFIER", 93, 104], ["pulmonary", "ANATOMY", 105, 114], ["disease", "OBSERVATION", 115, 122], ["mild", "OBSERVATION_MODIFIER", 192, 196], ["severe", "OBSERVATION_MODIFIER", 217, 223]]], ["Patients with severe disease were older than those with mild disease by a median of 6 years.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["severe disease", "PROBLEM", 14, 28], ["mild disease", "PROBLEM", 56, 68], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["disease", "OBSERVATION", 21, 28], ["mild", "OBSERVATION_MODIFIER", 56, 60], ["disease", "OBSERVATION", 61, 68]]], ["More than 50% of severe patients had systolic blood pressure greater than 110 mmHg.", [["blood", "ANATOMY", 46, 51], ["patients", "ORGANISM", 24, 32], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["patients", "SPECIES", 24, 32], ["systolic blood pressure", "TEST", 37, 60]]], ["Moreover, fever, cough, and dyspnea were more common in patients with severe disease than those with mild disease (58.1% vs. 40.9, 69.8% vs. 26.3, and 27.9% vs. 3.4%, respectively).", [["fever", "DISEASE", 10, 15], ["cough", "DISEASE", 17, 22], ["dyspnea", "DISEASE", 28, 35], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["fever", "PROBLEM", 10, 15], ["cough", "PROBLEM", 17, 22], ["dyspnea", "PROBLEM", 28, 35], ["severe disease", "PROBLEM", 70, 84], ["mild disease", "PROBLEM", 101, 113], ["fever", "OBSERVATION", 10, 15], ["cough", "OBSERVATION", 17, 22], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["disease", "OBSERVATION", 77, 84], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["disease", "OBSERVATION", 106, 113]]], ["Comorbidities were more prevalent in severe patients than mild patients, including hypertension (32.6% vs. 7.4%), cardiovascular disease (16.3% vs. 0.6%), diabetes (14.0% vs. 4.6%), chronic liver disease (9.3% vs. 1.2%), and chronic kidney disease (7.0% vs. 0.3%).", [["cardiovascular", "ANATOMY", 114, 128], ["liver", "ANATOMY", 190, 195], ["kidney", "ANATOMY", 233, 239], ["hypertension", "DISEASE", 83, 95], ["cardiovascular disease", "DISEASE", 114, 136], ["diabetes", "DISEASE", 155, 163], ["chronic liver disease", "DISEASE", 182, 203], ["chronic kidney disease", "DISEASE", 225, 247], ["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 63, 71], ["liver", "ORGAN", 190, 195], ["kidney", "ORGAN", 233, 239], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 63, 71], ["Comorbidities", "PROBLEM", 0, 13], ["hypertension", "PROBLEM", 83, 95], ["cardiovascular disease", "PROBLEM", 114, 136], ["diabetes", "PROBLEM", 155, 163], ["chronic liver disease", "PROBLEM", 182, 203], ["chronic kidney disease", "PROBLEM", 225, 247], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["hypertension", "OBSERVATION", 83, 95], ["cardiovascular", "ANATOMY", 114, 128], ["disease", "OBSERVATION", 129, 136], ["chronic", "OBSERVATION_MODIFIER", 182, 189], ["liver", "ANATOMY", 190, 195], ["disease", "OBSERVATION", 196, 203], ["chronic", "OBSERVATION_MODIFIER", 225, 232], ["kidney", "ANATOMY", 233, 239], ["disease", "OBSERVATION", 240, 247]]], ["More than 37% of severe patients had visited Wuhan or other COVID-affected areas in the past 14 days.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["However, the history of contact with febrile or COVID-19 patients was similar between the two groups.Selection of independent predictive factorsBased on demographics, clinical signs on admission, clinical symptoms, clinical risk factors, and exposure to infection, seven potential predictors with non-zero coefficients were selected in the LASSO logistic regression model (Fig 1A and 1B) .Selection of independent predictive factorsThe selected predictors were body temperature on admission, cough, dyspnea, hypertension, cardiovascular disease, chronic liver disease, and chronic kidney disease.", [["body", "ANATOMY", 461, 465], ["cardiovascular", "ANATOMY", 522, 536], ["liver", "ANATOMY", 554, 559], ["kidney", "ANATOMY", 581, 587], ["febrile", "DISEASE", 37, 44], ["infection", "DISEASE", 254, 263], ["cough", "DISEASE", 492, 497], ["dyspnea", "DISEASE", 499, 506], ["hypertension", "DISEASE", 508, 520], ["cardiovascular disease", "DISEASE", 522, 544], ["chronic liver disease", "DISEASE", 546, 567], ["chronic kidney disease", "DISEASE", 573, 595], ["patients", "ORGANISM", 57, 65], ["body", "ORGANISM_SUBDIVISION", 461, 465], ["liver", "ORGAN", 554, 559], ["kidney", "ORGAN", 581, 587], ["predictive factors", "PROTEIN", 414, 432], ["patients", "SPECIES", 57, 65], ["febrile", "PROBLEM", 37, 44], ["clinical signs", "TEST", 167, 181], ["clinical symptoms", "PROBLEM", 196, 213], ["clinical risk factors", "PROBLEM", 215, 236], ["infection", "PROBLEM", 254, 263], ["non-zero coefficients", "PROBLEM", 297, 318], ["independent predictive factors", "PROBLEM", 402, 432], ["cough", "PROBLEM", 492, 497], ["dyspnea", "PROBLEM", 499, 506], ["hypertension", "PROBLEM", 508, 520], ["cardiovascular disease", "PROBLEM", 522, 544], ["chronic liver disease", "PROBLEM", 546, 567], ["chronic kidney disease", "PROBLEM", 573, 595], ["hypertension", "OBSERVATION", 508, 520], ["cardiovascular disease", "OBSERVATION", 522, 544], ["chronic", "OBSERVATION_MODIFIER", 546, 553], ["liver", "ANATOMY", 554, 559], ["disease", "OBSERVATION", 560, 567], ["chronic", "OBSERVATION_MODIFIER", 573, 580], ["kidney", "ANATOMY", 581, 587], ["disease", "OBSERVATION", 588, 595]]], ["The results of the logistic regression analysis are shown in Table 2 .Building and validating a prediction nomogram modelThe nomogram used for predicting severe COVID-19 was formulated using significant independent factors, including body temperature at admission, cough, dyspnea, hypertension, cardiovascular disease, chronic liver disease, and chronic kidney disease.", [["body", "ANATOMY", 234, 238], ["cardiovascular", "ANATOMY", 295, 309], ["liver", "ANATOMY", 327, 332], ["kidney", "ANATOMY", 354, 360], ["cough", "DISEASE", 265, 270], ["dyspnea", "DISEASE", 272, 279], ["hypertension", "DISEASE", 281, 293], ["cardiovascular disease", "DISEASE", 295, 317], ["chronic liver disease", "DISEASE", 319, 340], ["chronic kidney disease", "DISEASE", 346, 368], ["body", "ORGANISM_SUBDIVISION", 234, 238], ["liver", "ORGAN", 327, 332], ["kidney", "ORGAN", 354, 360], ["the logistic regression analysis", "TEST", 15, 47], ["a prediction nomogram model", "TEST", 94, 121], ["The nomogram", "TEST", 121, 133], ["predicting severe COVID", "PROBLEM", 143, 166], ["significant independent factors", "PROBLEM", 191, 222], ["body temperature", "PROBLEM", 234, 250], ["cough", "PROBLEM", 265, 270], ["dyspnea", "PROBLEM", 272, 279], ["hypertension", "PROBLEM", 281, 293], ["cardiovascular disease", "PROBLEM", 295, 317], ["chronic liver disease", "PROBLEM", 319, 340], ["chronic kidney disease", "PROBLEM", 346, 368], ["cough", "OBSERVATION", 265, 270], ["dyspnea", "OBSERVATION", 272, 279], ["hypertension", "OBSERVATION", 281, 293], ["cardiovascular disease", "OBSERVATION", 295, 317], ["chronic", "OBSERVATION_MODIFIER", 319, 326], ["liver", "ANATOMY", 327, 332], ["disease", "OBSERVATION", 333, 340], ["chronic", "OBSERVATION_MODIFIER", 346, 353], ["kidney", "ANATOMY", 354, 360], ["disease", "OBSERVATION", 361, 368]]], ["The nomogram showed that the best predictor of severity was comorbidity, including chronic kidney disease, cardiovascular disease, and chronic liver disease.", [["kidney", "ANATOMY", 91, 97], ["cardiovascular", "ANATOMY", 107, 121], ["liver", "ANATOMY", 143, 148], ["chronic kidney disease", "DISEASE", 83, 105], ["cardiovascular disease", "DISEASE", 107, 129], ["chronic liver disease", "DISEASE", 135, 156], ["kidney", "ORGAN", 91, 97], ["cardiovascular", "ANATOMICAL_SYSTEM", 107, 121], ["liver", "ORGAN", 143, 148], ["The nomogram", "TEST", 0, 12], ["comorbidity", "PROBLEM", 60, 71], ["chronic kidney disease", "PROBLEM", 83, 105], ["cardiovascular disease", "PROBLEM", 107, 129], ["chronic liver disease", "PROBLEM", 135, 156], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["kidney", "ANATOMY", 91, 97], ["disease", "OBSERVATION", 98, 105], ["cardiovascular disease", "OBSERVATION", 107, 129], ["chronic", "OBSERVATION_MODIFIER", 135, 142], ["liver", "ANATOMY", 143, 148], ["disease", "OBSERVATION", 149, 156]]], ["Each variable was assigned a score according to the demographic and clinical characteristics of each patient, and the total score was computed by summing individual scores.", [["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["the total score", "TEST", 114, 129]]], ["Patient severity probabilities were also obtained from the nomogram (Fig 2) .Building and validating a prediction nomogram modelThe C-index of the nomogram was 0.863 (95% CI, 0.801-0.925) in our model and 0.839 by bootstrapping analysis, suggesting that the model had good discriminative ability.", [["Patient", "SPECIES", 0, 7], ["Patient severity probabilities", "PROBLEM", 0, 30], ["the nomogram", "TEST", 55, 67], ["a prediction nomogram model", "TEST", 101, 128], ["The C", "TEST", 128, 133], ["the nomogram", "TEST", 143, 155], ["CI", "TEST", 171, 173], ["bootstrapping analysis", "TEST", 214, 236]]], ["The calibration plots of the nomogram showed that the agreement between predicted and observed severity was optimal (Fig 3A) .", [["The calibration plots", "TEST", 0, 21], ["the nomogram", "TEST", 25, 37]]], ["In addition, DCA showed that the predictive model had significant net benefits for almost all threshold probabilities at different time points, demonstrating the potential clinical benefit of the predictive model (Fig 3B) .", [["DCA", "CHEMICAL", 13, 16], ["DCA", "CHEMICAL", 13, 16], ["DCA", "SIMPLE_CHEMICAL", 13, 16], ["DCA", "TEST", 13, 16]]], ["The AUC of the nomogram was 0.862, indicating improved survival prediction compared with the nomogram model (Fig 3C) .DiscussionWe developed and validated a prediction nomogram based on clinical features to identify patients who might develop severe disease.", [["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["The AUC of the nomogram", "TEST", 0, 23], ["the nomogram model", "TEST", 89, 107], ["a prediction nomogram", "TEST", 155, 176], ["severe disease", "PROBLEM", 243, 257], ["severe", "OBSERVATION_MODIFIER", 243, 249], ["disease", "OBSERVATION", 250, 257]]], ["The nomogram included vital signs, symptoms, and comorbidities, and showed good discrimination and calibration.", [["The nomogram", "TEST", 0, 12], ["vital signs", "TEST", 22, 33], ["symptoms", "PROBLEM", 35, 43], ["comorbidities", "PROBLEM", 49, 62]]], ["Our model is useful to predict severe COVID-19.", [["COVID-19", "CHEMICAL", 38, 46], ["severe COVID", "PROBLEM", 31, 43]]], ["Traditional evaluation scoring tools, including NEWS, qSOFA, andPLOS ONECURB-65, are adopted to assess disease severity in emergency departments [23, 25, 26] .", [["Traditional evaluation", "TEST", 0, 22], ["scoring tools", "TEST", 23, 36], ["qSOFA", "TEST", 54, 59]]], ["However, there is no evidence that these tools are useful for the early assessment of COVID-19 severity.", [["the early assessment", "TEST", 62, 82], ["COVID", "TEST", 86, 91], ["no evidence", "UNCERTAINTY", 18, 29]]], ["Compared with other diseases, COVID-19 progresses faster, and severity cannot be identified promptly.", [["COVID", "TEST", 30, 35], ["cannot be identified", "UNCERTAINTY", 71, 91]]], ["The early symptoms of COVID-19 are more insidious, the disease progresses faster, and early detection is challenging.", [["The early symptoms", "PROBLEM", 0, 18], ["COVID", "TEST", 22, 27], ["the disease", "PROBLEM", 51, 62], ["early", "OBSERVATION_MODIFIER", 4, 9], ["insidious", "OBSERVATION_MODIFIER", 40, 49], ["disease", "OBSERVATION", 55, 62]]], ["Therefore, our nomogram is a convenient and valuable clinical tool for predicting severe COVID-19.PLOS ONEPrevious studies have shown that age is an important independent prognostic factor in patients with severe infection diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [20, 26] .", [["infection diseases", "DISEASE", 213, 231], ["acute respiratory syndrome", "DISEASE", 248, 274], ["SARS", "DISEASE", 276, 280], ["Middle East respiratory syndrome", "DISEASE", 286, 318], ["MERS", "DISEASE", 320, 324], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["Middle East respiratory syndrome (MERS)", "SPECIES", 286, 325], ["predicting severe COVID", "PROBLEM", 71, 94], ["PLOS ONEPrevious studies", "TEST", 98, 122], ["severe infection diseases", "PROBLEM", 206, 231], ["severe acute respiratory syndrome", "PROBLEM", 241, 274], ["SARS)", "PROBLEM", 276, 281], ["Middle East respiratory syndrome", "PROBLEM", 286, 318], ["severe", "OBSERVATION_MODIFIER", 206, 212], ["infection", "OBSERVATION", 213, 222], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["respiratory syndrome", "OBSERVATION", 254, 274], ["Middle", "ANATOMY_MODIFIER", 286, 292], ["respiratory syndrome", "OBSERVATION", 298, 318]]], ["It has been demonstrated that prognosis in older COVID-19 patients, especially those aged >65 years, was worse than in younger patients [1, 5] .", [["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 127, 135]]], ["In our study, the severe group was older than the non-severe group.", [["our study", "TEST", 3, 12], ["severe", "OBSERVATION_MODIFIER", 18, 24]]], ["However, age was not an independent predictive factor for severe disease.PLOS ONEUnderlying diseases are more prevalent in severe COVID-19 patients than in mild patients, and the most common comorbidities are hypertension, diabetes, and coronary heart disease [11, 27] .", [["coronary", "ANATOMY", 237, 245], ["heart", "ANATOMY", 246, 251], ["hypertension", "DISEASE", 209, 221], ["diabetes", "DISEASE", 223, 231], ["coronary heart disease", "DISEASE", 237, 259], ["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 161, 169], ["heart", "ORGAN", 246, 251], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 161, 169], ["severe disease", "PROBLEM", 58, 72], ["hypertension", "PROBLEM", 209, 221], ["diabetes", "PROBLEM", 223, 231], ["coronary heart disease", "PROBLEM", 237, 259], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["disease", "OBSERVATION", 65, 72], ["diseases", "OBSERVATION", 92, 100], ["more prevalent", "OBSERVATION_MODIFIER", 105, 119], ["mild", "OBSERVATION_MODIFIER", 156, 160], ["hypertension", "OBSERVATION", 209, 221], ["diabetes", "OBSERVATION", 223, 231], ["coronary heart", "ANATOMY", 237, 251], ["disease", "OBSERVATION", 252, 259]]], ["In the univariate analysis, hospital mortality was significantly higher in patients with underlying diseases (i.e., diabetes and coronary heart disease) than in patients without these comorbidities.", [["coronary", "ANATOMY", 129, 137], ["heart", "ANATOMY", 138, 143], ["diabetes", "DISEASE", 116, 124], ["coronary heart disease", "DISEASE", 129, 151], ["patients", "ORGANISM", 75, 83], ["heart", "ORGAN", 138, 143], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 161, 169], ["underlying diseases", "PROBLEM", 89, 108], ["diabetes", "PROBLEM", 116, 124], ["coronary heart disease)", "PROBLEM", 129, 152], ["these comorbidities", "PROBLEM", 178, 197], ["diseases", "OBSERVATION", 100, 108], ["coronary heart", "ANATOMY", 129, 143], ["disease", "OBSERVATION", 144, 151]]], ["To the best of our knowledge, no other studies have evaluated the relationship between underlying diseases and COVID-19 severity.", [["other studies", "TEST", 33, 46], ["underlying diseases", "PROBLEM", 87, 106], ["COVID", "TEST", 111, 116], ["diseases", "OBSERVATION", 98, 106]]], ["Our study found that chronicPLOS ONEcardiovascular disease, hypertension, kidney disease, and liver disease were risk factors for the development of severe illness.", [["kidney", "ANATOMY", 74, 80], ["liver", "ANATOMY", 94, 99], ["ONEcardiovascular disease", "DISEASE", 33, 58], ["hypertension", "DISEASE", 60, 72], ["kidney disease", "DISEASE", 74, 88], ["liver disease", "DISEASE", 94, 107], ["illness", "DISEASE", 156, 163], ["kidney", "ORGAN", 74, 80], ["liver", "ORGAN", 94, 99], ["Our study", "TEST", 0, 9], ["chronicPLOS ONEcardiovascular disease", "PROBLEM", 21, 58], ["hypertension", "PROBLEM", 60, 72], ["kidney disease", "PROBLEM", 74, 88], ["liver disease", "PROBLEM", 94, 107], ["severe illness", "PROBLEM", 149, 163], ["ONEcardiovascular disease", "OBSERVATION", 33, 58], ["hypertension", "OBSERVATION", 60, 72], ["kidney", "ANATOMY", 74, 80], ["disease", "OBSERVATION", 81, 88], ["liver", "ANATOMY", 94, 99], ["disease", "OBSERVATION", 100, 107], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["illness", "OBSERVATION", 156, 163]]], ["COVID-19 impairs the function of multiple organs, including the heart, liver, and kidneys.", [["organs", "ANATOMY", 42, 48], ["heart", "ANATOMY", 64, 69], ["liver", "ANATOMY", 71, 76], ["kidneys", "ANATOMY", 82, 89], ["COVID-19", "CHEMICAL", 0, 8], ["COVID-19", "CHEMICAL", 0, 8], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["organs", "ORGAN", 42, 48], ["heart", "ORGAN", 64, 69], ["liver", "ORGAN", 71, 76], ["kidneys", "ORGAN", 82, 89], ["COVID-19", "PROTEIN", 0, 8], ["COVID", "TEST", 0, 5], ["multiple", "ANATOMY_MODIFIER", 33, 41], ["organs", "ANATOMY", 42, 48], ["heart", "ANATOMY", 64, 69], ["liver", "ANATOMY", 71, 76], ["kidneys", "ANATOMY", 82, 89]]], ["Existing research suggests that angiotensin-converting enzyme 2 (ACE2) may be a functional receptor for SARS-CoV-2 entry into human cells, and the virus may increase pulmonary vascular permeability and induce acute lung injury by down-regulating ACE2 expression and increasing angiotensin II levels [28] [29] [30] .", [["cells", "ANATOMY", 132, 137], ["pulmonary vascular", "ANATOMY", 166, 184], ["lung", "ANATOMY", 215, 219], ["angiotensin", "CHEMICAL", 32, 43], ["lung injury", "DISEASE", 215, 226], ["angiotensin II", "CHEMICAL", 277, 291], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 32, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["human", "ORGANISM", 126, 131], ["cells", "CELL", 132, 137], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 166, 184], ["lung", "ORGAN", 215, 219], ["ACE2", "GENE_OR_GENE_PRODUCT", 246, 250], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 277, 291], ["[28] [29] [30]", "SIMPLE_CHEMICAL", 299, 313], ["angiotensin-converting enzyme 2", "PROTEIN", 32, 63], ["ACE2", "PROTEIN", 65, 69], ["human cells", "CELL_TYPE", 126, 137], ["ACE2", "PROTEIN", 246, 250], ["angiotensin II", "PROTEIN", 277, 291], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["angiotensin-converting enzyme", "TEST", 32, 61], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["the virus", "PROBLEM", 143, 152], ["pulmonary vascular permeability", "PROBLEM", 166, 197], ["acute lung injury", "PROBLEM", 209, 226], ["increasing angiotensin II levels", "PROBLEM", 266, 298], ["pulmonary vascular", "ANATOMY", 166, 184], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["lung", "ANATOMY", 215, 219], ["injury", "OBSERVATION", 220, 226]]], ["ACE2 receptors are highly expressed in cells of the bronchial epithelium, alveoli (type 2 cells), myocardium, renal proximal tubule epithelium, bladder epithelium, esophagus, and ileum, suggesting that SARS-Cov-2 infection not only affects the respiratory system, but may also affect the circulatory, urinary, and digestive systems [31] .", [["cells", "ANATOMY", 39, 44], ["bronchial epithelium", "ANATOMY", 52, 72], ["alveoli", "ANATOMY", 74, 81], ["type 2 cells", "ANATOMY", 83, 95], ["myocardium", "ANATOMY", 98, 108], ["renal proximal tubule epithelium", "ANATOMY", 110, 142], ["bladder epithelium", "ANATOMY", 144, 162], ["esophagus", "ANATOMY", 164, 173], ["ileum", "ANATOMY", 179, 184], ["respiratory system", "ANATOMY", 244, 262], ["circulatory", "ANATOMY", 288, 299], ["urinary", "ANATOMY", 301, 308], ["digestive", "ANATOMY", 314, 323], ["SARS", "DISEASE", 202, 206], ["infection", "DISEASE", 213, 222], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 39, 44], ["bronchial epithelium", "TISSUE", 52, 72], ["alveoli", "MULTI-TISSUE_STRUCTURE", 74, 81], ["type 2 cells", "CELL", 83, 95], ["myocardium", "TISSUE", 98, 108], ["renal proximal tubule epithelium", "TISSUE", 110, 142], ["bladder epithelium", "TISSUE", 144, 162], ["esophagus", "ORGAN", 164, 173], ["ileum", "ORGAN", 179, 184], ["Cov-2", "GENE_OR_GENE_PRODUCT", 207, 212], ["urinary", "ORGANISM_SUBDIVISION", 301, 308], ["digestive", "ORGAN", 314, 323], ["ACE2 receptors", "PROTEIN", 0, 14], ["ACE2 receptors", "TEST", 0, 14], ["the bronchial epithelium", "PROBLEM", 48, 72], ["alveoli (type 2 cells", "PROBLEM", 74, 95], ["myocardium, renal proximal tubule epithelium, bladder epithelium, esophagus, and ileum", "PROBLEM", 98, 184], ["SARS", "PROBLEM", 202, 206], ["Cov-2 infection", "PROBLEM", 207, 222], ["the circulatory, urinary, and digestive systems", "PROBLEM", 284, 331], ["bronchial", "ANATOMY", 52, 61], ["epithelium", "ANATOMY_MODIFIER", 62, 72], ["alveoli", "ANATOMY_MODIFIER", 74, 81], ["myocardium", "ANATOMY", 98, 108], ["renal", "ANATOMY", 110, 115], ["proximal", "ANATOMY_MODIFIER", 116, 124], ["tubule", "ANATOMY_MODIFIER", 125, 131], ["epithelium", "ANATOMY_MODIFIER", 132, 142], ["bladder epithelium", "ANATOMY", 144, 162], ["esophagus", "ANATOMY", 164, 173], ["ileum", "ANATOMY", 179, 184], ["SARS", "OBSERVATION", 202, 206], ["Cov", "OBSERVATION_MODIFIER", 207, 210], ["infection", "OBSERVATION", 213, 222], ["respiratory system", "ANATOMY", 244, 262], ["urinary", "ANATOMY", 301, 308]]], ["Severe patients have multiple organ damage, potentially leading to multiple organ failure.", [["organ", "ANATOMY", 30, 35], ["organ", "ANATOMY", 76, 81], ["organ damage", "DISEASE", 30, 42], ["organ failure", "DISEASE", 76, 89], ["patients", "ORGANISM", 7, 15], ["organ", "ORGAN", 30, 35], ["organ", "ORGAN", 76, 81], ["patients", "SPECIES", 7, 15], ["multiple organ damage", "PROBLEM", 21, 42], ["multiple organ failure", "PROBLEM", 67, 89], ["multiple", "OBSERVATION_MODIFIER", 21, 29], ["organ", "ANATOMY", 30, 35], ["damage", "OBSERVATION", 36, 42], ["potentially leading to", "UNCERTAINTY", 44, 66], ["multiple", "OBSERVATION_MODIFIER", 67, 75], ["organ", "ANATOMY", 76, 81], ["failure", "OBSERVATION", 82, 89]]], ["However, additional studies are needed to confirm that patients with underlying diseases (i.e., cardiovascular disease or kidney disease) infected with SARS-Cov-2 will accelerate this series of processes and their underlying mechanisms.PLOS ONEIn the early stages of COVID-19, the diversity of symptoms and imaging manifestations limit diagnosis [32] [33] [34] .", [["cardiovascular", "ANATOMY", 96, 110], ["kidney", "ANATOMY", 122, 128], ["cardiovascular disease or kidney disease", "DISEASE", 96, 136], ["SARS", "DISEASE", 152, 156], ["patients", "ORGANISM", 55, 63], ["cardiovascular", "ANATOMICAL_SYSTEM", 96, 110], ["kidney", "ORGAN", 122, 128], ["Cov-2", "GENE_OR_GENE_PRODUCT", 157, 162], ["patients", "SPECIES", 55, 63], ["additional studies", "TEST", 9, 27], ["underlying diseases", "PROBLEM", 69, 88], ["cardiovascular disease", "PROBLEM", 96, 118], ["kidney disease)", "PROBLEM", 122, 137], ["SARS", "PROBLEM", 152, 156], ["COVID", "TEST", 267, 272], ["symptoms", "PROBLEM", 294, 302], ["imaging manifestations", "TEST", 307, 329], ["diseases", "OBSERVATION", 80, 88], ["kidney", "ANATOMY", 122, 128], ["disease", "OBSERVATION", 129, 136]]], ["Fever and cough are common, and gastrointestinal symptoms are rare in COVID-19 [35] .", [["gastrointestinal", "ANATOMY", 32, 48], ["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 10, 15], ["gastrointestinal symptoms", "DISEASE", 32, 57], ["gastrointestinal", "ORGAN", 32, 48], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 10, 15], ["gastrointestinal symptoms", "PROBLEM", 32, 57], ["COVID", "TEST", 70, 75], ["cough", "OBSERVATION", 10, 15], ["gastrointestinal", "ANATOMY", 32, 48]]], ["No fever is more common than SARS and MERS in patients with early stage COVID-19 [11] .", [["fever", "DISEASE", 3, 8], ["SARS", "DISEASE", 29, 33], ["MERS", "DISEASE", 38, 42], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["fever", "PROBLEM", 3, 8], ["SARS", "PROBLEM", 29, 33], ["early stage COVID", "PROBLEM", 60, 77], ["fever", "OBSERVATION", 3, 8], ["more common", "OBSERVATION_MODIFIER", 12, 23]]], ["Therefore, patients without fever may be undiagnosed.", [["fever", "DISEASE", 28, 33], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["fever", "PROBLEM", 28, 33], ["undiagnosed", "PROBLEM", 41, 52]]], ["This study found that body temperature higher than 37.3\u02daC was not a risk factor in COVID-19, and patients without fever in the early stage of the disease had a higher risk of developing severe conditions.", [["body", "ANATOMY", 22, 26], ["fever", "DISEASE", 114, 119], ["body", "ORGANISM_SUBDIVISION", 22, 26], ["C", "GENE_OR_GENE_PRODUCT", 56, 57], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["This study", "TEST", 0, 10], ["body temperature", "TEST", 22, 38], ["a risk factor", "PROBLEM", 66, 79], ["COVID", "TEST", 83, 88], ["fever", "PROBLEM", 114, 119], ["the disease", "PROBLEM", 142, 153], ["developing severe conditions", "PROBLEM", 175, 203], ["disease", "OBSERVATION", 146, 153], ["severe", "OBSERVATION_MODIFIER", 186, 192], ["conditions", "OBSERVATION", 193, 203]]], ["The reason is that fever may encourage the patient to seek medical treatment promptly, allowing early disease detection and implementation of medical interventions.", [["fever", "DISEASE", 19, 24], ["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["fever", "PROBLEM", 19, 24], ["medical treatment", "TREATMENT", 59, 76], ["early disease detection", "PROBLEM", 96, 119], ["medical interventions", "TREATMENT", 142, 163]]], ["In addition, fever can inhibit the reproduction or growth of the virus; however, this process is complex, and the effect of fever on this parameter should be better investigated.PLOS ONEThe clinical data obtained on admission are included in the COVID-19 early warning system, which is simple, practical, reliable, and fast.", [["fever", "DISEASE", 13, 18], ["fever", "DISEASE", 124, 129], ["fever", "PROBLEM", 13, 18], ["the virus", "PROBLEM", 61, 70], ["fever", "PROBLEM", 124, 129], ["The clinical data", "TEST", 186, 203], ["fever", "OBSERVATION", 13, 18], ["virus", "OBSERVATION", 65, 70]]], ["This system was used to assess the risk of developing critical illness in the emergency department and allows medical staff to intervene at an early stage and determine their treatment location and the type of intervention.", [["critical illness", "DISEASE", 54, 70], ["intervention", "TREATMENT", 210, 222], ["critical", "OBSERVATION_MODIFIER", 54, 62], ["illness", "OBSERVATION", 63, 70]]], ["This system is more practical to evaluate COVID-19 patients than other scoring tools.PLOS ONEOur study has some limitations.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["COVID", "TEST", 42, 47], ["PLOS ONEOur study", "TEST", 85, 102]]], ["Second, some cases had incomplete data on symptoms, laboratory tests, and imaging examinations, given the variation in the structure of electronic databases across different participating hospitals and an urgent data extraction schedule.", [["incomplete data", "PROBLEM", 23, 38], ["symptoms", "PROBLEM", 42, 50], ["laboratory tests", "TEST", 52, 68], ["imaging examinations", "TEST", 74, 94], ["an urgent data extraction schedule", "TREATMENT", 202, 236]]], ["Third, some patients were not discharged during the study period, and final prognosis could not be determined.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["the study", "TEST", 48, 57]]], ["Fourth, the model verification method used internal random verification.", [["the model verification method", "TEST", 8, 37], ["internal random verification", "TEST", 43, 71]]], ["Fifth, although the AUC was high (0.863) and 95% CI was adequate (0.801-0.925), the number of severe cases was small; therefore, future studies with larger sample sizes are warranted to validate our results.", [["the AUC", "TEST", 16, 23], ["CI", "TEST", 49, 51], ["future studies", "TEST", 129, 143], ["larger sample sizes", "TREATMENT", 149, 168], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["cases", "OBSERVATION", 101, 106], ["small", "OBSERVATION_MODIFIER", 111, 116]]], ["Sixth, severe patients were older than nonsevere patients, and this difference in age may be a confounding factor.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 49, 57], ["a confounding factor", "PROBLEM", 93, 113], ["severe", "OBSERVATION_MODIFIER", 7, 13]]], ["Seventh, although the study is multicenter, the results cannot be generalized to other populations.ConclusionWe established an early warning model incorporating clinical characteristics that could be quickly obtained on hospital admission.", [["the study", "TEST", 18, 27]]], ["This model can be conveniently used to facilitate the predict the individual risk of severe COVID-19 and help identify patients who might develop severe disease at early stage with convenience.Author ContributionsConceptualization: Yiwu Zhou, Yanqi He, Rong Yao, Zongan Liang.", [["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["severe COVID", "PROBLEM", 85, 97], ["severe disease", "PROBLEM", 146, 160], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["disease", "OBSERVATION", 153, 160]]]]}